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ABSTRACT OF DISSERTATION

INVESTIGATING THE ROLE OF PRION PROTEIN POLYMORPHISMS
ON PRION PATHOGENESIS
Transmissible spongiform encephalopathies (TSEs), also known as prion
diseases, are lethal and infectious neurodegenerative diseases of humans and
animals. The misfolding of the normal, or cellular isoform of the prion protein
(PrPC) into the abnormal disease-associated isoform of PrP (PrPSc) could change
the properties of PrP, consequently, PrPSc has lethal infectivity to transmit
diseases. The proteinaceous infectious particle consisting mainly of PrPSc is
called prion. Transmissibility of prions is strongly influenced by multiple factors
including PrP polymorphisms, species barriers (PrP sequence specificity) and
prion strains (conformational specificity) by unknown mechanisms. Even though
the ability of prions to cross a species barrier has been recognized, the precise
mechanisms of interspecies prion transmission remain unclear.
This dissertation research was conducted in order to learn more about the
molecular mechanisms of conversion, propagation and transmission of PrPSc;
about determinants of genetic susceptibility to infection in prion diseases; and
about understanding those mechanisms, which might govern the zoonotic
potential of prion diseases.
First, we investigated the transmissibility risk of multiple strains of Chronic
Wasting Disease, which is a cervid TSE, with humanized transgenic mice and
showed that the transmission barriers between cervid and the humanized mice
are high. Next, the structural factors underlying the species barrier of prion
diseases were studied using cell culture systems by systematically introducing
amino acid substitutions in the regions of PrP, where the most divergences of
different PrP species are recognized. Thirdly, we investigated the effects of the
genetic susceptibility to prions as well as conversion kinetics and properties of
PrPSc using Tg mice expressing ovine PrP polymorphism (OvPrP) at codon 136
either alanine (A) or valine (V). The templating characteristics of OvPrPSc-V136
were dominant over OvPrPSc-A136 under co-expressions of OvPrPC-A136 and

OvPrPC-V136. Finally, the function of PrP was studied in relation to the
pathogenesis of Alzheimer’s disease.
These studies demonstrated that the conformational compatibility between
PrPC and PrPSc contributed to the conversion kinetics and species barrier. We
concluded that the conformational compatibility of PrPC to PrPSc is controlled not
only by the PrP sequence specificity but also by the tertiary structure of PrPC.
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PrP Polymorphisms, Zoonotic Potential
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Chapter 1
Introduction to prion biology
Transmissible spongiform encephalopathies (TSEs), or prion diseases, are a
group of fatal and transmissible neurodegenerative diseases affecting the central
nervous system (CNS) of humans and animals (Prusiner, 1998). Currently, no
cure is known for any prion disease. A typical clinical sign of patients with prion
disease is a progressive dementia, while sheep, cattle and cervid generally
present ataxic illness (Parry, 1962; Wells et al., 1987; Williams & Young, 1980).
In about the last decade, the view has acquired wide acceptance that TSEs are
caused by the misfolding of the normal, or cellular, form of the prion protein
(commonly designated PrPC) into infectious disease-causing PrP (PrPSc) in the
brain (Prusiner, 1998). Prions are infectious protein consisting of pathogenic
PrPSc and defined as a “proteinaceous infectious particle that lacks nucleic acid”
(Prusiner, 1982). The underlying mechanisms of conversion and propagation of
PrPSc as well as transmission of prions are still under investigation.

TSEs in humans
Human prion diseases occur in various forms, including genetic, sporadic and
infectious disorders. Inherited forms of human prion diseases are GerstmannSträussler-Scheinker (GSS), Fatal Familial Insomnia (FFI) and familial
Creutzfeldt-Jakob disease (CJD). Germ-line mutations in the PrP gene (PRNP)
are the cause of all of the inheritable prion diseases (Colby & Prusiner, 2011). In
1

contrast, somatic mutations in PRNP, or spontaneous conformation conversion
of PrPC to PrPSc, are the most likely cause of such prion diseases as, sporadic
CJD and sporadic Fatal Insomnia (Colby & Prusiner, 2011). Sporadic CJD is the
most common form of human prion diseases accounting for approximately 85%
of prion disease patients (Colby & Prusiner, 2011). Infectious prion disease forms
include Kuru and variant or iatrogenic CJDs. Kuru was found in a Fore linguistic
group residing in the highlands of Papua, New Guinea, and person-to-person
transmission occurred through the tribe practice of ritual cannibalism (Klitzman et
al., 1984). Variant CJD (vCJD) is that form of human prion disease best known
among the general public. Epidemiological and experimental studies have
provided good evidence that vCJD might be caused by the consumption of
bovine spongiform encephalopathy (BSE)-contaminated products (Asante et al.,
2002; Bruce et al., 1997; Collinge et al., 1996; Scott et al., 1999; Will et al.,
1996). Iatrogenic CJD is most likely induced by the accidental use of prioncontaminated surgical tools (Davanipour et al., 1984; Kondo & Kuroiwa, 1982;
Masters & Richardson, 1978; Will & Matthews, 1982), as well as by transmission
from human growth hormone and gonadotropin, dura matter grafts, and
transplants of corneas harvested from individuals who died from CJD (Duffy et
al., 1974; Koch et al., 1985).

TSEs in animals
TSEs in animals include chronic wasting disease (CWD) of deer, elk and moose,
scrapie of sheep, goat and moufflon, transmissible mink encephalopathy, BSE,

2

feline spongiform encephalopathy (FSE) and exotic ungulate encephalopathy
(EUE). FSEs affect domestic cats (Leggett et al., 1990; Wyatt et al., 1991) and
captive wild members of the cat family (Eiden et al., 2010; Lezmi et al., 2003).
EUEs are found in exotic zoo ruminants of the cattle family (Kirkwood &
Cunningham, 1994). CWD, scrapie, TME and BSE are described below in more
detail.

Chronic wasting disease (CWD), a TSE of free-ranging and captive deer, elk
and moose, is highly contagious (Baeten et al., 2007; Miller et al., 2000; Williams,
2005; Williams & Young, 1980, 1982, 1992). Since it was first recognized in a
wildlife facility in Northern Colorado in 1967 (Williams & Young, 1980), cases of
CWD have increasingly been reported from this and additional states, while other
cases have shown up abroad. As of 2012, CWD has been identified in 18 states:
Colorado, Wyoming, South Dakota, Nebraska, Wisconsin, New Mexico,
Minnesota, Oklahoma, Illinois, Utah, New York State, West Virginia, Kansas,
Michigan, Virginia, Missouri, North Dakota and Maryland (Chronic Wasting
Disease Alliance, 2012). It has also appeared in two provinces (Alberta and
Saskatchewan) in Canada (Chronic Wasting Disease Alliance, 2012). In South
Korea, deer imported from Canada are found to be CWD positive in 2005 (Kim et
al., 2005). Since then, CWD has been recognized in South Korea (Sohn, 2011).
It is difficult to determine how CWD has spread throughout North America,
inasmuch as CWD is not always found in states adjoining the affected states.
Plausible explanations include the simple fact of increased awareness of CWD,
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inadvertent interstate transfer of asymptomatic infected animals, or the possibility
that CWD is a sporadic disease. Thus, CWD’s origins in North America are
unclear.
It has been debated whether endemic levels of CWD are maintained due
to high efficiency of horizontal transmission of CWD in North America. One
possible explanation is that decomposing carcasses of CWD-affected animals,
feces, urine or saliva remain as highly contagious prion sources in an
environment to continue spreading disease in animals. Some studies report that
prions could bind to metal and mineral deposits in the soil and be maintained in
the soil over decades (Johnson et al., 2006; Miller et al., 2004; Seidel et al.,
2007). Prions have been identified in bedding, food and water shared by CWDaffected animals (Mathiason et al., 2009), in saliva (Haley et al., 2009; Mathiason
et al., 2006), in urine (Haley et al., 2009), in feces (Tamguney et al., 2009b) and
in antler velvet (Angers et al., 2009), all of which are potential sources for
infectious transmission. When prions are shed to the environment, whether soil
or aquatic, prions remain in the environment over period of time. When animals
have any contacts with prions remained in the environment, prions could invade
the animals. Even though the levels of prions might be low in the environment,
animals could develop disease by repeated exposures.
Could new CWD strains arise and acquire new host-range properties
during horizontal transmission? It has been questioned whether intraspecies
transmission of CWD increase chances of propagating new strains, which might
have lower cervid to human species barriers (Barria et al., 2011). There is so far
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strong evidence that at least two distinct strains of CWD propagate in deer and
elk (Angers et al., 2010). Since efficient horizontal transmission of CWD has
been evidenced, natural CWD agents are most likely going through serial
passages among cervid in wild or captive environments. Intraspecies
transmissions in vivo and in vitro increased the propagation of human PrPSc in
vitro (Barria et al., 2011), suggesting that there is potential for the spread of CWD
to humans by intraspecies transmissions. In addition, it has been reported that
other forms of prions are able to change transmission properties during
interspecies passages, with resultant change of the host range (Bartz et al.,
1998) and the production of multiple strains (Bessen & Marsh, 1992b). There
thus remains a meaningful potential for the adaptation of CWD prions, so that
they acquire the property of infecting multiple new species, including humans. It
would therefore be important to understand how strains arise in the environment
that CWD is constantly disposed.

Scrapie is a TSE of sheep, goats and moufflon (Dickinson, 1976; Wood et al.,
1992). The first recognized cases of scrapie were documented in England in
1732, with further cases in Germany in 1759 (reviewed in (Prusiner, 2004)).
Thus, scrapie has been recognized for around 300 years and has been spread
across the world, especially in the northern hemisphere, by importing and
exporting domestic sheep. Curiously, Australia and New Zealand are recognized
as scrapie free countries (Hunter & Cairns, 1998). When scrapie turned up in
those countries, entire flocks were terminated to prevent its spread to other
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flocks. Moreover, Australia and New Zealand use more stringent surveillance
systems to maintain a scrapie-free environment.
The transmissibility of TSEs was first demonstrated in sheep using brain
homogenates from scrapie-affected sheep (Cuillé & Chelle, 1936, 1938).
Subsequent sheep studies reported that different scrapie sources produced
different transmission characteristics. In early studies of sheep scrapie, classical
scrapie sheep brain pool number 1 (SSBP/1)-inoculated sheep was classified
positive or negative, developing upon the incubation time after inoculation
(Dickinson, 1976). The gene involved in the incubation period was called Sip (for
scrapie incubation period) and later identified as a PrP gene (Basler et al., 1986)
and two alleles were indicated as sA and pA (partially dominant) (Dickinson &
Outram, 1988). The negative group of sheep survived from subcutaneous (s.c.)
inoculation of scrapie, and the associated gene was characterized as SippApA
(Foster & Hunter, 1991). In contrast, sheep from the positive group developed
disease within 150-400 days after inoculation; here, the genes were identified as
either SipsAsA or SipsApA (Foster & Hunter, 1991). The results indicated that sheep
carrying SipsA developed disease with a shorter incubation time than sheep with
SippApA. Interestingly, the negative group sheep developed diseases with a
shorter incubation time with a different classical scrapie isolate, referred to as
CH1641, and BSE prions than the positive group sheep (Foster & Dickinson,
1988b; Foster et al., 1993), indicating that the gene SippApA, which is associated
with a long incubation time with SSBP/1 prion, behaves differently with other
prion isolates. These studies presented indications that interactions between
6

genetic variations in the ovine PrP gene and prion strains were not
straightforward, and that disease outcomes/incubation times depended upon the
combinations between genetic variations of PrPC and strain variations of PrPSc.
The genetic susceptibility of sheep to scrapie has been studied using
mouse models after the discovery of the PrP gene (Prnp in mice or PRNP in
higher eukaryotes). Since then, the genetic linkage between Prnp and the length
of scrapie incubation time was established in mice (Carlson et al., 1986).
Furthermore, two distinct alleles in Prnp were identified, and the biological
property of short or long scrapie prion incubation times was associated with
these two alleles (Westaway et al., 1987). Later studies demonstrated that one
allele was converted to PrPSc more efficiently over the other; in addition, the copy
number of Prnp in Tg mice controlled the incubation time (Carlson et al., 1994;
Westaway et al., 1987). Interestingly, these findings do not apply for some prion
strains.
Three major scrapie susceptibility-linked polymorphisms were identified in
the ovine PrP gene including amino acid residues at 136 (alanine [A] or valine
[V]), 154 (arginine [R] or histidine [H]) and 171 (glutamine [Q], R or H) (Goldmann
et al., 1991; Goldmann et al., 1994). Transmission studies in Cheviot sheep
showed that homozygosity for V at codon 136 was associated with short
incubation times after inoculation with SSBP/1, while heterozygosity was linked
to longer incubation times (Goldmann et al., 1994). Sheep homozygous for A at
codon 136 were resistant to SSBP/1 inoculation (Goldmann et al., 1994). The
same findings were also reported in studies with US sheep (Maciulis et al.,
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1992), suggesting that the scrapie susceptibility-linked polymorphism at codon
136 was not limited to Cheviot sheep. It has been reported that the polymorphism
of Q or R at residue 171 is also correlated with susceptibility to scrapie
(Goldmann et al., 1994; Westaway et al., 1994a). Q171 is linked to susceptibility
to scrapie, while R171 is correlated with resistant to scrapie. Sheep homozygous
for R at codon 171 did not develop disease upon inoculation of SSBP/1, and
sheep heterozygous for Q/R at codon 171 were relatively resistant. Limited
studies in Cheviot and Icelandic sheep showed that H at residue 154 conferred
resistance to scrapie (Baylis et al., 2004; Hunter et al., 1996; Laplanche et al.,
1993; Thorgeirsdottir et al., 1999). Thus, the H154Q polymorphism is linked to a
small extent to a sheep’s susceptibility.
In contrast, CH1641 isolate has a completely different propensity for those
three polymorphisms. Unlike SSBP/1, A136 and V136 are most susceptible and
resistant to CH1641, respectively (Goldmann et al., 1994). In addition, it has
been reported that homozygosity for Q at codon 171 was linked to short
incubation times, and sheep heterozygous for Q/R at codon 171 presented much
longer incubation time with CH1641 (Goldmann et al., 1994). In conclusion, the
combined effects of genetic polymorphism of the ovine PrP gene and agent
strain variation act to present a complex picture of scrapie susceptibility in sheep.
Taken together, three major sheep PrP polymorphisms participate in
determining susceptibility and resistance to scrapie; however, the participation of
each polymorphism in susceptibility involves in different levels. Since two
dimorphisms and one trimorphism play roles here, 12 combinations of these
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polymorphisms are possible. Nonetheless, only 5 out of 12 combinations have
been reported from the sheep flocks, the frequency of appearance of any of the
other combinations is extremely low (Belt et al., 1995; Ikeda et al., 1995). The
five combinations are A at codon 136, R at codon 154 and R at codon 171
(ARR), ARQ, AHQ, ARH and VRQ, and homozygous for ARR and VRQ are most
resistant and susceptible to scrapie, respectively. Even though two additional
combinations of AHR and VRR were later reported (Kutzer et al., 2002), the five
genotypes appear with higher frequencies. Subsequent studies by multiple
investigators have reported the same polymorphic effects on the susceptibility of
scrapie in vivo and in vitro studies. However, the underlying mechanisms of how
the polymorphisms regulate the susceptibility and resistance to scrapie are still
not clear.

Transmissible mink encephalopathy (TME) is a sporadic form of TSEs found
in farmed mink (Hartsough & Burger, 1965). TME was first reported in 1947 in a
farm in Brown County, Wisconsin, then again later in 1961 in several farms in
Sheboygan, Calumet and Manitowoc Counties, Wisconsin, with a third outbreak
in 1963 in Sawyer County, Wisconsin. The affected farms in Wisconsin all fed
mink with a ready-mix feed supplied and manufactured by the same feed plant,
which suggests that the disease was caused by the consumption of prioncontaminated food (Liberski et al., 2009). The last outbreak was found in 1985 in
Stetsonville, Wisconsin, where it was later found that TME-affected mink had
been fed contaminated cattle meat from downer dairy cows. In order to examine
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whether the contaminated cattle were the cause of TME, infected cattle tissue
was experimentally inoculated into groups of mink, resulting in the development
of fatal diseases (Marsh & Bessen, 1993). Additional TME cases were reported
in Idaho (Hartsough & Burger, 1965), Canada (Hadlow & Karstad, 1968), Finland
and the former East Germany (Hartung et al., 1970; Johannsen & Hartung, 1970)
and the former Soviet Union (Danilov et al., 1974; Dukur et al., 1986).
The interspecies transmission studies of TME-affected mink agents from
the last outbreak in Stetsonville were performed using Syrian golden hamsters,
and TME-infected hamsters showed two distinct clinical presentations including
hyper (HY) and drowsy (DY) after third passages (Bessen & Marsh, 1992b). The
characteristics of the HY and DY differed in incubation time, brain titer, lesion
profiles in the brain, pathogenicity as well as biochemical properties (Bessen &
Marsh, 1992a, b). The HY has a shorter incubation time and high brain titer,
whereas the DY has a longer incubation time and low brain titer. Interestingly,
when the HY and DY agents were inoculated back to mink, only the DY agent
could produce disease in mink (Bessen & Marsh, 1992b). The DY agent was
able to produce disease in hamsters after long incubation time thus still retained
the transmissibility property. These studies suggested that TME from the
Stetsonville contained the mixed strains of both HY and DY, moreover, the DY
was the major pathogen. The studies in TME were the first study to identify the
different biochemical properties of multiple strains present in prions.
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Bovine spongiform encephalopathy (BSE) is a TSE of cattle, and first found in
1986, in Weybridge, United Kingdom (Wells et al., 1987). Since 1986, the
numbers of BSE cases in United Kingdom rapidly increased in the following six
years, and the peak of BSE cases was reported during 1992 and 1993.
Subsequently, the numbers of BSE were gradually declined over the next
decade. BSE incidence was found to coincide with feeding of meat and bone
meal (MBM) as a dietary protein supplement in dairy herds (Wilesmith et al.,
1991). MBM was produced from rendered animal parts, and was generally fed to
cattle from one-week-old of age until the time of slaughter. The identification of
the source of outbreak and vigorous actions were able to control the epidemic of
BSE in Great Britain by 2002. In the course of the epidemiological studies, one
hypothesis was raised that sheep scrapie-contaminated materials were mixed
into the MBM at the slaughterhouse plants and fed to cattle, which developed
disease because scrapie materials were present all the time at the
slaughterhouse (Taylor, 1989; Taylor, 1996; Wilesmith et al., 1991; Wilesmith et
al., 1988). In addition, scrapie is endemic in sheep populations in Great Britain.
However, the hypothesis BSE was derived form a scrapie strain has not been
established.
In 1994, few years after the peak of BSE, the first cases of vCJD were
diagnosed in teenagers and young adults in Great Britain (Will et al., 1996). In
the following years, more vCJD cases were reported in Great Britain as well as in
other countries, and more than 200 individuals with vCJD have been reported
(World Health Organization, 2012). The epidemiological studies of vCJD
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concluded that those individuals with vCJD developed disease because of the
consumption of BSE-contaminated cattle products (Prusiner, 2004). BSE is the
first established case of interspecies transmission of TSE to humans. Since then,
the zoonotic potential of TSEs became more concerns when we thought about
the animals in TSEs.

Prion protein and its isoforms
The PrP gene is well-conserved protein among mammalian species and is
ubiquitously expressed, particularly in the CNS, and especially in neurons, in
both diseased and non-diseased brains (Prusiner, 1998). PrP is a glycoprotein
that is attached to the cell membrane through a glycosylphosphatidylinositol
(GPI) anchor (Stahl et al., 1990; Stahl et al., 1987). PrP transits in the secretory
pathway of endoplasmic reticulum (ER). Posttranslational modification of PrP
starts after entering the ER, which is mediated by an amino (N)-terminal signal
peptide of 22 amino acids (Hope et al., 1986; Turk et al., 1988) and carboxyl (C)terminal signal peptide of 23 amino acids (Heske et al., 2004; Stahl et al., 1990)
(Figure 1.1.) (Holscher et al., 2001). When entered ER, the N-terminal signal
peptide is cleaved by a signal peptidase. During passage through ER, two Nlinked carbohydrate chains are attached to asparagines at residues 180 and 196
(mouse numbers) (Haraguchi et al., 1989), and a disulfide bond is formed
between residues 178 and 213 (mouse numbers) (Turk et al., 1988). Finally, in
order to bring about attachment to the cell membrane, a GPI-anchor is added
following cleavage of the C-terminal signal peptide (Endo et al., 1989; Oesch et
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al., 1985). During the secretory pathway, an ER-based quality control removes
misfolded PrP to the cytosol for proteasomal degradation (Drisaldi et al., 2003).
The whole process of maturation to transportation is accomplished within one
hour (Borchelt et al., 1990; Caughey et al., 1989). The half-life PrPC in chronically
infected cells was found to be approximately 5 hours, while that of PrPSc was
approximately 15 hours (Table 1.1.) (Borchelt et al., 1990).
The ‘natural’ or ‘normal’ functions of PrP have not been clearly identified,
although PrP appears to be involved in signal transduction (reviewed in (Taylor &
Hooper, 2006; Tsui-Pierchala et al., 2002)), synaptic transmission (Collinge et al.,
1994), neuroprotection (reviewed in (Roucou & LeBlanc, 2005; Roucou et al.,
2004)), immunoregulation (reviewed in (Isaacs et al., 2006)), copper binding
(reviewed in (Millhauser, 2007; Vassallo & Herms, 2003), induction of apoptosis
(Kim et al., 2004; Kuwahara et al., 1999), circadian rhythm and sleep (Medori et
al., 1992), adaptation to stress (Nico et al., 2005), and memory processing
(Coitinho et al., 2007; Coitinho et al., 2006). Even though PrP is ubiquitously
expressed in the adult brain, the expression of PrP during early stages of
development is tightly regulated (Mobley et al., 1988), suggesting a possible
important function of PrP during development. However, Prnp deficient (Prnp0/0)
mice develop normally and have a normal lifespan (Bueler et al., 1992), raising
the possibility that loss of PrP might be compensated by unknown functionally
related proteins.
Both PrPC and PrPSc consist of the same primary structure and appear to
possess invariant posttranslational modifications (Stahl et al., 1993). However,
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Fourier-transform infrared (FTIR) and circular dichroism (CD) studies showed
that PrPC consisted mainly of α-helices (40%) and small percent of β-sheets,
while PrPSc contained more β-sheets (45%) and a lesser quantity of α-helices
(30%) (Pan et al., 1993; Pergami et al., 1996). Further, structural studies of
recombinant PrP using solution phase nuclear magnetic resonance (NMR
spectroscopy) identified three α-helices and two regions of β-sheet structures
(Riek et al., 1996; Zahn et al., 2000).
The differing biochemical properties of PrPC and PrPSc are summarized in
Table 1.1. Sensitivity to protease digestion has been used to distinguish PrPC
and some forms of PrPSc (Prusiner, 2004). After protease digestion of PrPSc, it
produces protease-resistant molecules of approximately 142 amino acids with a
molecular mass of 27-30 kDa, referred to as PrP 27-30 (Figure 1.1.) (Bolton et
al., 1982; Prusiner et al., 1982). However, PrPC and some other forms of PrPSc,
referred to as protease-sensitive PrPSc (Gambetti et al., 2008) are completely
digested under the same conditions of protease digestion. It is important to note
the existence of protease-sensitive PrPSc, which has been reported to be
involved in specific types of human prion diseases (Colucci et al., 2006; Gambetti
et al., 2011; Gambetti et al., 2008). Furthermore, PrPSc tends to form oligomers
and/or aggregates including amyloid plaques and fibrils. In contrast, PrPC
remains monomeric. The solubilities of the two isoforms are different: PrPC is
soluble, PrPSc is not. Therefore, after ultracentrifugation at 100,000 x g, PrPSc
can be collected into pellets. As mentioned above, the half-life of PrPC is known
to be approximately 5 hours, whereupon PrPC will be recycled by cells. However,
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PrPSc is known to not merely to survive for long periods, but also to accumulate
to the point of causing disease. PrPC is not infectious. However, when PrPC
undergoes the conformational changes to unfold α-helices and refold into βsheets to convert into PrPSc, it gains a lethal infectivity (Prusiner, 1998).
Furthermore, prions consisting of solely PrPSc are resistant to heat, harsh
chemicals and denaturants (Gordon, 1946) as well as UV irradiation (Alper et al.,
1967).

PrPC → PrPSc conversion models
It is widely accepted that PrPC undergoes a profound conformational structural
change to become the pathogenic PrPSc isoform, and the conformational change
requires PrPC and PrPSc (Prusiner, 1998). The conversion of PrPSc does not
require nucleic acids; however, RNA facilitates conformational conversion in vitro
conversion assays (Deleault et al., 2003; Wang et al., 2010). This “protein only
hypothesis” has been supported by extensive prion researches, even though the
exact PrPC to PrPSc conversion mechanisms have not been yet established.
However, the two important models of PrPSc conversion and propagation have
been proposed: namely the heterodimer template-associated and nucleatedpolymerization models. The template-associated model was proposed to explain
the replication of PrPSc (Cohen et al., 1994). Although the nucleatedpolymerization model was originally offered to explain polymerization of proteins
(Oosawa & Asakura, 1975), it has been employed to explain the amyloid
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formation in the protein misfolding diseases including prion diseases (Gajdusek,
1994a, b; Harper & Lansbury, 1997).
The heterodimer template-associated model suggests that monomeric
PrPSc becomes a template to convert PrPC to PrPSc (Figure 1.2.A) (Cohen et al.,
1994). In this model, PrPC is in equilibrium with an intermediate form, referred to
as PrP*, and PrP* can form a heterodimer complex with PrPSc, which becomes a
template to alter the conformation of PrP* into infectious isoform PrPSc, resulting
in the formation of a homodimer complex. The homodimer complex can
dissociate into two monomers, which can become additional templates to
produce more PrPSc. A hypothetical protein X is thought to play roles in the
conversion of PrPC to PrPSc and also catalyze the PrPSc conversion (Kaneko et
al., 1997; Telling et al., 1995; Telling et al., 1994). In this model, PrPSc is
thermodynamically stable compared to PrPC; furthermore, the conversion of
PrPSc from PrP* is less likely to happen without a catalyst.
Several series of experiments demonstrated the exponential growth of
PrPSc (Kocisko et al., 1995; Kocisko et al., 1994); however, the templateassociated model alone does not accommodate the explanation of rapid
formation of PrPSc fibrils or aggregates. To yield a plausible explanation of this
exponential polymerization event and subsequent rapid accumulation of PrPSc,
two hypotheses were proposed based on the nucleated-polymerization theory
(Masel et al., 1999). One theory is called the autocatalytic nucleatedpolymerization model (Figure 1.2.B.) (Cohen et al., 1994). In this model, PrPC
directly interacts with PrPSc seed in fibril or aggregate forms, and the conversion
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reaction is the rate-limiting step. The PrPSc conversion step might be catalyzed
by protein X. Another scenario is the non-catalytic nucleated-polymerization
model (Figure 1.2.C.) (Caughey et al., 1995). Unlike the autocatalytic model,
PrP* rather than PrPC interacts with the seed to form stable polymers, and the
PrPSc conversion step occurs “non-catalytically”. The rate-limiting step is the
reversible reaction between PrPC and PrP*, and the reaction might be facilitated
by protein X. The rest of the steps to form PrPSc fibrils and aggregates are
irreversible. In the nucleation-associated models, the initial formation of PrPSc
seeds might require a longer time. However, once stable PrPSc seeds are
assembled, the addition of PrPSc to the seeds can be accelerated. In addition,
fragmentation of the fibrils can fabricate more seeds for more nucleation
reactions.
Even though there are three kinetic models of the PrPSc conversion to help
clarify matters, no one model alone can explain every case of the PrPSc
propagation. The heterodimer template-associated model explains an initial
formation of PrPSc. When the accumulation of PrPSc reaches a threshold that
cells cannot clear, PrPSc might form oligomeric fibrils, following which nucleatedpolymerization would ensue to propagate additional PrPSc. Therefore, it might be
more practical to imagine that combinations of these models provide better
insight into the precise mechanisms of the PrPSc conversion.

In vitro conversion of PrPSc: cell-free conversion vs. protein misfolding
cyclic amplification (PMCA)
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The molecular mechanisms underlying the conversion of PrPC to PrPSc have long
been of concern in prion research. One investigative approach was developed
using an in vitro system called cell-fee conversion, which involves mixing labeled
recombinant PrP with a 50-fold molar excess semi-purified PrPSc and incubating
for 2-45 hours at 37°C (Caughey et al., 1995; Kocisko et al., 1994). PrPSc
conversion can be monitored and quantified by monitoring accumulation of newly
converted

labeled

protease-resistant

PrPSc,

and

it

was

reported

that

approximately 20% of PrPC was converted to PrPSc in this cell-free conversion
system (Caughey et al., 1995; Horiuchi & Caughey, 1999). The conversion
process involves two kinetic steps of interaction and conformational change
(DebBurman et al., 1997; Horiuchi & Caughey, 1999). The first step is for PrPC to
interact with PrPSc, where the interaction depends on the compatibility of their
primary structures. The second step is the conversion of PrPC to PrPSc by
undergoing structural change to become a protease-resistant PrPSc (Callahan et
al., 2001; DebBurman et al., 1997; Horiuchi & Caughey, 1999; Rigter & Bossers,
2005).
Soto and his colleagues developed another in vitro system to propagate
PrPSc

called

protein

misfolding

cyclic

amplification

(PMCA),

which

is

accomplished by mixing approximately 30-fold molar excess of either
recombinant PrP or brain homogenates as PrPC source into PrPSc as a template,
then incubating in repeated cycles of sonication and incubation at 37°C (Saborio
et al., 2001). PMCA involves two alternative steps of sonication and incubation.
The first step, sonication, breaks PrPSc fibrils or aggregates into fragments, which
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allows them to become a template or to grow into larger fibrils or aggregates
again, by adding newly synthesized PrPSc onto the nucleation sites. During the
second step, incubation, PrPC is recruited by the PrPSc templates and undergoes
structural change to become PrPSc, whereby it can become a new template or be
added onto the existing PrPSc.
The cell-free conversion system has provided strong evidences, in
addition to numerous animal studies, that PrPSc contains all information
necessary to convert PrPC into PrPSc, and that the conversion process is
independent of nucleic acids. Moreover, the above two in vitro systems gave
proof that PrPSc becomes a template to convert PrPC into PrPSc. More efficient
conversion of PrPSc in PMCA using brain homogenates suggests that other
molecules also facilitate the PrPSc conversion, and it supports the speculation
that conversion of PrPSc requires the presence of protein X. Together, the in vitro
conversion systems can be a powerful tool to understand the kinetics of
conversion of PrPSc.

Zoonotic potential of TSEs from species barriers to prion strains
TSEs are diseases of animals and humans. Transmissions of TSEs are
constrained by a species barrier, which can be described in difficulty or
impossibility of prion propagation from one species to another (Wickner et al.,
2009). The higher the species barrier between a host and donor is, the longer the
incubation time requires. The species barrier is generally difficult to overcome in
the transmission of prions. However, the diseases are unique in a way that the
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pathogen prions, which consist with only proteins, could overcome the species
barrier by propagating new prion strains.
The presence of different strains in scrapie has been recognized since
1960s (Pattison & Millson, 1961). The classical definition of prion strains is
defined by incubation time and neuronal vacuolation profiling (Dickinson et al.,
1968; Fraser & Dickinson, 1973), moreover, the biochemical properties including
PrPSc profiling, deposition, glycosylation and migration patterns are taken into
account for additional characterization of prion strains (Prusiner, 2004). The
unique properties of prion strains can be maintained during propagation and
subsequently passaged onto next hosts. Although the primary structure of PrP is
an important determinant of prion species barriers (Telling et al., 1995; Telling et
al., 1994), prion strains are also involve in the susceptibility to infection of prions
between species. Since prion strains are subject to apparent mutations and
selective amplification (Li et al., 2010), the selection process of prion strains
might allow adapting a new host range and overcoming a species barrier.
Therefore, understanding the molecular mechanisms responsible for interspecies
transmission of prions are essential for controlling the transmissions of prions
horizontally as well as vertically.

Transgenics in prion research
Prion research has benefited from the development of Tg mice, which are
produced by integrating a target gene at random sites using homologous
recombination. The use of Tg mice makes it possible to control the genetic
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background compared to other animal studies, such as, sheep, cervid and
bovine. Tg mouse models not only are cost-effective but also accelerate
understanding of prion diseases and development of new therapeutic
approaches.
The first PrP gene knockout (Prnp0/0) mouse was generated in 1992
(Bueler et al., 1992). Importantly, the Prnp0/0 mice were resistant to prions
(Bueler et al., 1993). The Prnp0/0 mice did not have any developmental issues
and have a normal lifespan (Bueler et al., 1992) even though some studies
showed that altered synaptic behavior, such as, synaptic inhibition in the
hippocampal brain slices of the Prnp0/0 mice (Collinge et al., 1994; Whittington et
al., 1995). However, other groups reported the absence of the synaptic inhibition
in the brains of the Prnp0/0 mice (Herms et al., 1995; Lledo et al., 1996). Other
line of Prnp0/0 mice generated by other group showed ataxia around 70 weeks of
age, and the loss of Purkinje cells were observed in the brain (Sakaguchi et al.,
1996). However, the ataxia and loss of Purkinje cells were rescued by crossing to
Tg mice overexpressing mouse PrP (Nishida et al., 1999), suggesting that PrP
might play roles in the Purkinje cells mediated atrophy, which presents in ataxia.
Mice expressing different expression levels of PrP revealed that the
incubation time after inoculation was inversely proportional to the expression
levels of PrP in Tg mice (Prusiner et al., 1990). In addition, Tg mice
overexpressing Syrian hamster or sheep PrP spontaneously developed disease
at older age (Westaway et al., 1994b). However, overexpression of PrP does not
always produce spontaneous disease. For example, Tg mice expressing human
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PrP with a mutation from glutamic acid (E) to lysine (K) at codon 200, which are
found in FFI patients, did not develop spontaneous disease (Asante et al., 2009).
Gene-targeted knockin (targeted gene insertion to a Prnp specific locus) mice
expressing human PrP encoding a mutation from aspartic acid to asparagine at
codon 177 developed spontaneous disease at older age (Jackson et al., 2009).
Even though locations of the mutations involved in FFI were not exactly same
between the overexpressed (Asante et al., 2009) and knockin (Jackson et al.,
2009) mice, these results suggest that a knockin mouse model is the better
system to study FFI. The knockin mouse model allows determining the functions
of PrP under the endogenous environment since a mouse PrP gene is replaced
with a target gene at the specific locus.
Another advantage of Tg mice is to be able to study the functions of PrP
using chimeric proteins. Tg mice expressing a chimeric PrP between mouse and
human was generated previously, and the study showed that the specific part of
mouse PrP was required for the efficient propagation of PrPSc (Telling et al.,
1995; Telling et al., 1996), suggesting a hypothesis that PrPSc conversion
requires interactions between PrP at the mouse specific site and mouse specific
cofactors or chaperons.

Roles of PrP concerning the pathogenesis of Alzheimer’s disease
Alzheimer’s disease (AD) is a progressive neurologic disease resulting in
dementia and loss of cognitive function (Reitz et al., 2012). Oligomeric and
fibrillar forms of the amyloid β (Aβ) peptide, derived from the amyloid precursor
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protein (APP), are thought to drive the pathogenesis of AD. The formation of
oligomeric Aβ or amyloid fibrils results in reduced neuronal activity and synaptic
plasticity, leading to neuronal cell death in the CNS by unclear mechanisms.
There are similarities between the pathologies of AD and prion diseases.
Both AD and prion disease share common features, such as, amyloid
plaques, significant neuronal loss, abnormal activities of synapses and gliosis
around amyloid plaques (Garcao et al., 2006; Hardy & Gwinn-Hardy, 1998). The
main components of amyloid plaques in AD are Aβ42 and 40 peptides (Debatin
et al., 2008). Interestingly, it has been reported that punctate PrPC was
immunohistochemically detected in Aβ plaques in AD brains (Ferrer et al., 2001).
In prion diseases, the amyloid plaques mainly consist of PrPSc (Garcao et al.,
2006). In both diseases, the mechanisms of neuronal cell death caused by Aβ42
and PrPSc are still unclear.
Recent studies indicated a direct link between prion and AD, and
suggested that PrPC is a receptor for mediating the toxic effects of oligomeric Aβ
(Gimbel et al., 2010; Lauren et al., 2009). Strittmatter and his colleagues
demonstrated that oligomeric Aβ42, but not the monomer, bound to PrPC with
nanomolar affinity and disrupted synaptic plasticity in hippocampal slices from
PrP wild-type mice (Lauren et al., 2009). They further showed that the disruption
by oligomeric Aβ42 was prevented in the absence of PrPC and was blocked by
anti-PrP antibody treatments. They suggested that the binding of oligomeric
Aβ42 to PrPC caused synaptic dysfunction. However, other groups failed to
replicate the same effects of PrPC using the Prnp knockout or mouse PrP
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overexpressing Tg mice (Balducci et al., 2010; Calella et al., 2010). Strittmatter
group demonstrated in the subsequent study that PrPC required for axonal
degradation, loss of synaptic markers, early death and learning and memory
deficits in AD Tg mice (Gimbel et al., 2010).
It has been considered that prion diseases are caused by not only a gain
of neurotoxic function by converting to PrPSc from PrPC but also a loss of
protective function of PrPC (Winklhofer et al., 2008). As explained in the earlier
section, PrPC is involved in signal transduction, synaptic transmission,
neuroprotection and many others; however, a clear picture of the physiological
function of PrPC is still under investigation. Thus, understanding the roles of PrPC
in the pathogenesis of AD will greatly help to identify the function of PrPC.

Dissertation research
This dissertation consists of 6 chapters. In this dissertation, I am addressing the
fundamental question: what are the molecular mechanisms of PrPSc conversion
and genetic susceptibility to infection in prion diseases? I will address the
underlying mechanisms of the transmission/species barrier of prion infection by
investigating the transmission of prions between different species and within the
same species. I will utilize Tg mouse and in vitro PrPSc conversion models to
answer the above question. I will examine the transmission/species barrier of
prions by directly testing the transmission risks of CWD into humans using Tg
mouse models in Chapter 2. Next, I will examine the structural factors underlying
the species barrier and susceptibility to prion infection using cell culture models
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in Chapter 3. I will also discuss the transmission barriers within the same species
in Chapter 4. Finally, I will investigate the function of PrPC in the pathogenesis of
AD in Chapter 5.
Chapter 2 will explore the transmission risks of CWD into humans using
Tg mice expressing human PrP. I will address the impacts of the human PrP
polymorphism at codon 129 coding either methionine or valine on the
interspecies transmission of multiple strains of CWD.
Chapter 3 will discuss the structural factors involve in susceptibility to
prion infection. I will utilize cell culture models to test the hypothesis that the loop
region between the β2-sheet and α2-helix and its interaction site at the Cterminal region of PrP determines the susceptibility to prions. First, I will explain
whether the structural definitions of the β2-α2 loop would change susceptibility to
prions. Then, I will explain whether interrupting the interaction between the β2-α2
loop and C-terminal of PrP would alter susceptibility to prion infection. Finally, I
will explain whether introducing the substitutions of horse specific amino acid
residues in the β2-α2 loop and its interaction region at the C-terminal of mouse
PrP would change susceptibility to prions. The series of cell culture studies were
aimed to understand the roles of the PrP structures in the susceptibility to
infection in prion pathogenesis by systematically introducing substitutions of
amino acids in specific regions of PrP.
Chapter 4 will discuss how the transmission barrier of prions within the
same species is determined by a PrP polymorphism. I will address how the ovine
polymorphism at codon 136 expressing either alanine or valine determines
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susceptibility to infection of classical sheep scrapie isolates using Tg mouse
models and a unique antibody to distinguish the ovine 136 polymorphism. I will
ask the following three questions regarding the effects of co-expressing A136
and V136 alleles on the replication of scrapie.
(1) Are OvPrP-A136 and OvPrP-V136 independently converted to PrPSc, and
their properties also independently maintained?
(2) Does conversion of OvPrPC-V136 dominate that of OvPrPC-A136?
(3) Does expression of either allele inhibit conversion of the other?
In addition, I will apply computational modeling approaches to explain potential
structural differences between the ovine PrP polymorphisms at codon 136, which
might elucidate the effects of genetic susceptibility on prion pathogenesis.
Chapter 5 will explore the role of PrP in the pathogenesis of Alzheimer’s
disease by quantifying the expressed levels of PrP in the brains from individuals
with different stages of AD. I will detail unaltered PrP expression in the
rostrocaudal regions of individuals with different stages of AD. I will also address
whether there is a correlation between the human PrP polymorphism and the
levels of PrP expression, and whether there is a correlation between the human
PrP polymorphism at codon 129 and onset of AD.
In Chapter 6, I will discuss how the findings in the previous chapters are
tied together into the conformational selection model, which explains the
selective conformations between PrPC and PrPSc are determined for conversion
of PrPC to occur. Furthermore, I will propose future studies to further expand the
understanding of the molecular mechanisms of conversion of PrPSc.
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Table 1.1. Biochemical properties of PrP. The cellular isoform of prion protein
(PrPC) retains normal structural conformation and is expressed in healthy and
diseased individuals. The disease-associated pathogenic isoform PrPSc is a
misfolded form of PrP and can polymerize into fibrils and/or aggregates resulting
in highly infectious PK-resistant protein.
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Figure 1.1. Structural features of mouse PrP that encodes a protein of 254
amino acids. The top bar diagram indicates that PrP contains five octarepeats
(PHGGGWGQ), three α-helices and two β-sheets. Two secretory signal peptides
reside at the amino (N)-terminal (residues 1-22) and carboxyl (C)-terminal
(residues 232-254) of PrP. Both of the signal peptides mediate to enter the
secretory pathway of endoplasmic reticulum (ER). Posttranslational modification
of PrP starts after entering the ER. The N-terminal signal peptide is cleaved by a
signal peptidase when entered ER. Then, two N-linked carbohydrate chains
(CHO) are attached to asparagines at codon 180 and 196, and a disulfide bond
(S-S) is formed between codons 178 and 213. Finally, in order to bring about
attachment to the cell membrane, a glycosylphosphatidylinositol (GPI)-anchor is
attached to the C-terminal of PrP at residue 231 following cleavage of the Cterminal signal peptide. The mature PrPC (the second bar diagram) is 209 amino
acids in length (residues 23-231). In the secretory pathway, an ER-based quality
control removes misfolded PrP to the cytosol for proteasomal degradation. The
whole process of maturation to transportation is accomplished within one hour.
The third bar diagram indicates PrPSc has the octarepeats, one disulfide bond
and two glycosylations; however, the secondary structure of PrPSc has not been
well characterized except a β-sheet rich structure. After limited protease
digestion of PrPSc, the C-terminal of PrPSc is remained to form a proteaseresistant molecule of approximately 142 amino acids with a molecular mass of
27-30 kDa, referred to as PrP 27-30 (the bottom diagram).
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Figure 1.2. Template-associated and nucleated-polymerization models of
prion conversion. A. PrPC is in equilibrium with an intermediate form, referred to
as PrP*, and PrP* can form a heterodimer complex with PrPSc, which becomes a
template to alter the conformation of PrP* into infectious isoform PrPSc, resulting
in the formation of a homodimer complex. The homodimer complex can
dissociate into two monomers, which can become additional templates to
produce more PrPSc. A hypothetical protein X is thought to play roles in the
conversion of PrPC to PrPSc and also catalyze the PrPSc conversion. PrPSc is
thermodynamically stable compared to PrPC; furthermore, the conversion of
PrPSc from PrP* is less likely to happen without a catalyst. B. The autocatalytic
nucleated-polymerization model offers an additional explanation of the
exponential growth of PrPSc. In this model, PrPC directly interacts with PrPSc seed
in fibril or aggregate forms, and the conversion reaction is the rate-limiting step.
The PrPSc conversion step might be catalyzed by protein X. Since the seed is
thermodynamically stable, the addition of new PrPSc can accelerate the formation
of longer fibrils or larger aggregates. C. The non-catalytic nucleatedpolymerization model explains that PrP* rather than PrPC interacts with the seed
to form stable polymers, and the PrPSc conversion step occurs non-catalytically.
The rate-limiting step is the reversible reaction between PrPC and PrP*, and the
reaction might be facilitated by protein X. The rest of the steps to form PrPSc
fibrils and aggregates are irreversible.
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Chapter 2

Transgenetic modeling of the CWD species barrier to humans

Introduction
Chronic wasting disease (CWD) is a transmissible spongiform encephalopathy
(TSE) affecting free-ranging and captive deer, elk, and moose, and is highly
contagious (Baeten et al., 2007; Miller et al., 2000; Williams, 2005; Williams &
Young, 1980, 1982, 1992). Since 1967, when the first case of CWD was reported
in Colorado, the endemic area in North America has steadily spread, with other
cases reported abroad (Williams & Young, 1980). In fact, by 2005, CWD was
reported from 12 states in the United States and 2 provinces in Canada with an
additional case in South Korea (Chronic Wasting Disease Alliance, 2012; Kim et
al., 2005; Prusiner, 2004). Moreover, by 2012, new CWD cases had been
identified in those 12 states and in 7 other states as well as in South Korea
(Chronic Wasting Disease Alliance, 2012; Sohn, 2011). The increasing incidence
of CWD in wild and captive-farm animals in North America raises doubts about
the safety of consuming potentially CWD-contaminated cervid meat or products.
The transmissibility risk of CWD into humans remains unclear at the present
time.
The transmission of bovine spongiform encephalopathy (BSE) into
humans has been reported worldwide, and more than 200 people have
developed and died from variant Creutzfeldt-Jakob disease (vCJD) through
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exposure to BSE-contaminated products (Prusiner, 2004; World Health
Organization, 2012). Given that wild game animals, especially deer and elk, are
extensively hunted and consumed throughout North America, and the zoonotic
potential of BSE is now recognized (Bruce et al., 1997; Scott et al., 1999), these
facts arouse related epidemiological concerns as to whether CWD from deer and
elk is transmissible to humans, likewise whether a CWD epidemic in deer and elk
populations might increase transmission risks for humans.
In recent years, numerous approaches have been employed to address
these issues. In one approach, transmissibility of CWD has been tested through
the use of transgenic (Tg) mouse models. To date, studies of this nature report
no evidence of the transmission of CWD into the transgenic mice expressing
human PrP (Kong et al., 2005; Sandberg et al., 2010; Tamguney et al., 2006;
Wilson et al., 2012). Another approach used two nonhuman primate species,
squirrel monkeys and cynomolgus macaques, as a model of CWD transmission
to humans. Two studies reported that squirrel monkeys inoculated orally and
intracerebrally with CWD from deer and elk developed disease, and the
accumulation of PrPSc was detected in their brains (Marsh et al., 2005; Race et
al., 2009b). However, cynomolgus macaques, which are evolutionally closer to
humans (Hayasaka et al., 1988), did not develop any signs of disease following
either oral or intracerebral transmission of deer and elk CWD isolates (Marsh et
al., 2005; Race et al., 2009b). A third approach involves possible links between
the high prevalence of CWD in deer and elk and the incidence of CJD in
Colorado, where CWD is endemic. In this approach, epidemiological surveillance
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studies were conducted. Thus far, no positive associations have been found
(Belay et al., 2004; Mawhinney et al., 2006). Other studies, focusing on the
conversion of human PrPSc, used an in vitro model. These likewise reported that
CWD PrPSc failed to convert human PrPC into PrPSc (Barria et al., 2011; Kurt et
al., 2009). In addition, the extremely inefficient conversion of recombinant human
PrPSc using CWD PrPSc in comparison with the species matched (cervid)
recombinant PrPSc conversion was reported (Raymond et al., 2000). Together,
the above-mentioned studies suggest that there is a high species barrier
between cervid and human.
Although the previously mentioned studies suggest that CWD presents a
low risk of the zoonotic potential, other recent studies remind us that there still
are significant questions about the transmissibility of CWD into humans. One of
those concerns the tissues consumed by humans which are derived from deer or
elk with CWD, including skeletal muscle (Angers et al., 2006), antler velvet
(Angers et al., 2009), blood (Mathiason et al., 2006) and fat (Race et al., 2009a),
particularly when such tissues harbor infectious prions. Another study found that
at least two distinct strains of CWD (referred to as CWD1 and CWD2) propagate
in deer and elk (Angers et al., 2010); however, the host-range properties of
CWD1 and CWD2 are still unknown. A further complication is the fact that prion
strains can mutate to adapt not only within the same species with different
genetic backgrounds, such as animals of same species expressing Prnp
polymorphisms, but also following transmission to a new host (Asante et al.,
2002; Lloyd et al., 2004; Mead et al., 2009; Wadsworth et al., 2004). Such
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mutational events can result in the formation of new prion strains with
unpredictable biological properties, including the acquisition of a new host-range.
Consequently, it is difficult to predict the number of CWD strains that may exist
and propagate in a given population of animals. In this connection, it is extremely
important to assess the transmissibility of new CWD strains into humans when
such strains are identified.
Codon 129, and the corresponding 132 residue in elk, significantly
influenced the transmission of BSE and CWD prions respectively in Tg mouse
models (Green et al., 2008). It would follow from this that, the genetic
susceptibility of humans to CWD should also be determined. Moreover, cervid
PrPSc converted human PrPC after CWD prions were stabilized by successive
passages in vivo and in vitro (Barria et al., 2011), suggesting the potential
adaptation of cervid PrPSc in humans to develop disease. In spite of all these
many and varied concerns, it does seem that the species barrier of prion
transmission species barrier between human and cervid is certainly not easy to
overcome. There remains significant potential that new CWD strains can arise
and acquire new host-range during horizontal transmission.
The studies detailed below aim to test whether CWD1 and CWD2 strains
are transmissible to Tg(HuPrP) mice, and to address the impact of the human
PrP methionine (M) or valine (V) residue 129 polymorphism on the CWD-tohuman species barrier. To address the hypotheses, Tg(HuPrP) mice encoding
either M or V129 human PrP polymorphism referred to as Tg(HuPrP-M129) and
Tg(HuPrP-V129)

mice

were

intracerebrally
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inoculated

with

previously

characterized CWD1 and CWD2 strains. The Soto group demonstrated the
amplification of human PrPSc with the successive stabilized CWD in vitro,
Tg(HuPrP) mice were intracerebrally inoculated with CWD prions that had been
passaged multiple times in Tg mice expressing deer PrP to determine whether
the propagation of human PrPSc could occur with the stabilized CWD isolate in
the animal system.

Materials and Methods
Transgenic mice expressing human PrP. Hemizygous Tg mice expressing
human PrP encoding either M or V at residue 129 (referred to as Tg(HuPrPM129)6816+/-

and

Tg(HuPrP-V129)7826+/-,

respectively)

were

previously

generated (Kurt et al., 2009). Tg mouse lines were maintained by breeding with
Prnp knockout (Prnp0/0) FVB mice on an FVB background, referred to as
FVB/Prnp0/0 mice. Tg offspring were identified by tail biopsy and extraction of
genomic DNA followed by polymerase chain reaction (PCR) screening for the
presence of the transgene using a standard protocol. Briefly, approximately 1 cm
of tail tissue was digested overnight at 55°C with proteinase K (PK) at a final
concentration

of

0.5

mg/ml

in

50

mM

Tris

pH

8.0,

100

mM

ethylenediaminetetraacetic acid (EDTA), 0.5% sodium dodecyl sulfate (SDS), the
DNA extracted with phenol and chloroform and concentrated by ethanol
precipitation. Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- were used in
the following studies. The expression levels of PrP in the brains of Tg(HuPrPM129)6816+/-

and

Tg(HuPrP-V129)7826+/36

mice

are

16-fold

and

2-fold

overexpressed comparing to PrP expressed in the brains of wild-type FVB mice,
respectively (Figure 2.1.).

Transmission studies and CWD inocula. Pertinent information on the CWD
inocula used in the following studies is summarized in Tables 2.1. and 2.3. Elk
CWD isolate (99W12389) was obtained from a CWD affected elk from the
Wyoming State Veterinary Laboratory. Elk Bala05 CWD isolate was obtained
from an elk, which was naturally affected with CWD, from the Canadian Food
Inspection Agency, Ottawa, Ontario Canada. Deer CWD isolate (9179) was
obtained from a deer, which was naturally affected with CWD, from Wyoming
(Angers et al., 2010). Deer H92 CWD isolate was obtained from a mule deer,
which was naturally affected with CWD, from Colorado State University, Fort
Collins, Colorado. The CWD isolates 99W12389, Bala05 and 9179 previously
produced disease in Tg(Deer PrP)1536+/- mice expressing deer PrP, previously
referred to as Tg(CerPrP)1536+/- mice. These isolates were selected because
their biological properties upon transmission reflected phenotypes that were
consistent with CWD1, CWD2 and mixtures of the two CWD types (CWD mix)
(Angers et al., 2010).
In separate studies, H92 isolate was serially passaged three times in
Tg(Deer PrP)1536+/- mice and characterized as CWD mix (Angers et al., 2010).
In the tertiary passage, one Tg(Deer PrP)1536+/- mouse inoculated with the
serially passaged H92 CWD developed disease at 193 days post inoculation
(dpi), which will be referred as a short incubation time; and another Tg(Deer
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PrP)1536+/- mouse with the serially passaged H92 CWD developed disease at
299 dpi, referred as a long incubation time. In this study, two diseased Tg(Deer
PrP)1536+/- mouse brains from the short and long incubation time groups were
used to inoculate Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/-

mice

(Table 2.4.).
Blocks of the CWD-positive brains were prepared as 10% (w/v) in sterile
phosphate buffered saline (PBS) lacking Ca2+ and Mg2+ ions by repeated
extrusion through a series of needles of decreasing diameter from 18 gauge to
22 gauge. Ten-percent brain homogenate was diluted to 1% (v/v) in PBS and
thoroughly homogenized using a 26 gauge needle syringe. Groups of 5-week-old
Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- mice were anesthetized
with halothane and injected with 30 µl of 1 % (w/v) brain homogenate
intracerebrally into the right parietal lobe using a 26 gauge needle syringe.

Determination of incubation time. Animals were monitored for general health
on a daily basis as well as for manifestations of progressive neurological
dysfunction normally associated with prion diseases. The clinical manifestation of
disease was determined by the presence of at least three of the following clinical
signs: truncal ataxia, kyphotic posture, hind-limb paresis, loss of extensor reflex,
difficulty righting from a supine position, flattened gait and tail stiffening. Animals
were diagnosed when at least two investigators agree with the clinical
manifestation of disease. Severity of clinical signs were scored for 13 clinical
signs using 0 = absence, 1 = mild, 2 = moderate and 3= severe. In addition, all
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animals were recorded on video at the time of diagnosis and/or right before
termination. The incubation time was defined as a period of the time between the
day the prion was inoculated and the first day the diagnosis was given; therefore,
the incubation time was indicated in ‘days post inoculation’ (dpi).

Detection of PrPSc by western blotting analysis. The right hemisphere of each
brain was collected for western blot analysis. Ten-percent (w/v) brain
homogenates were prepared in sterile PBS by repeated extrusions through a
series of needles of decreasing diameter from 18 to 22 gauge.
The concentration of total protein in each sample was determined by
bicinchoninic acid assay and standardized for each lane (40 µg per lane).
Proteins

were

resolved

by

sodium

dodecyl

sulfate-polyacrylamide

gel

electrophoresis and transferred to polyvinylidene difluoride Immobilon-FL (PVDF)
membranes (Millipore). The transferred membrane was blocked with 5% (w/v)
non-fat milk in 0.5% (v/v) Tween-20 in Tris-buffered saline (TBST) and
immunoprobed with mouse monoclonal antibody anti-PrP PRC5 followed by
horseradish peroxidase-conjugated anti-mouse secondary antibody. Proteins
were visualized using ECL Plus (GE Healthcare) in an FLA-5000 scanner
(Fujifilm Life Science). The expression levels of PrPC in Tg(HuPrP) mice were
determined by reading each histogram of PrPC signals on the western blot using
MultiGauge (Fujifilm Life Science).
All brain samples from the CWD-inoculated Tg(HuPrP-M129)6816+/- and
Tg(HuPrP-V129)7826+/- mice with and without manifestation of neurological
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dysfunction were analyzed for the presence of PrPSc by western blotting. Four µl
of 10% brain homogenate mixed in PBS with 2% sarkosyl was treated with PK
with a final concentration of 100 µg/ml for 1 hour at 37°C and ultracentrifuged at
100,000 × g for 1 hour at 4°C to concentrate PrPSc. Digested and undigested
samples were assessed by western blotting with appropriate controls. An
FVB/Prnp0/0 (KO) was used as a negative control for the anti-PrP antibody. An
uninfected Tg(HuPrP) was used as a negative control for the presence of PK
resistant PrPSc. The deer CWD (99W12389) was used as a positive control for
the presence of PK resistant PrPSc. Electrophoresis, transfer of proteins to a
PVDF membrane and western blotting using PRC5 were performed as described
above.

Evaluation of spongiform degeneration. Spongiosis development is a
neuropathological feature of prion diseases including CWD, and representative
animals displaying signs of neurological dysfunction were determined for
vacuolation (spongiform change) in the brain. The left hemisphere of each brain
was collected for neuropathological analyses. The half-brains were fixed in 4%
formaldehyde for 24 hours, transferred to sterile PBS and paraffin wax
embedded. Brain sections of 8 µm thickness were coronally cut to areas
corresponding to the four levels of the brain containing the nine brain regions
including

the

medulla,

cerebellum,

midbrain,

hypothalamus,

thalamus,

hippocampus, paraterminal body and cerebral cortex at the levels of the septum
and hippocampus (Figure 2.4.). The brain sections were collected on positively
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charged slides. Harris haematoxylin and eosin (H & E) staining was performed by
a standard method at the Veterinary Diagnosis Laboratory Colorado State
University. Appropriate positive (RML diseased wild-type FVB mouse brains) and
negative

controls

(uninfected

Tg(HuPrP-M129)6816+/-

and

Tg(HuPrP-

V129)7826+/- mouse brains) were also performed with experiments. The H & E
staining provides nuclear staining and counterstaining to provide guidance to
observe the vacuolation development on brain sections. The criteria for
spongiosis development in prion diseases are: (1) region specific (Figure 2.4.),
(2) appearing between nerve cell bodies and (3) the formation of vacuolation,
which can be diffuse but intensive or appearing in the groups which often look to
be a floral form (Figure 2.5.10.) (Prusiner, 2004). In addition to the positive
control explained above, another positive control, CWD-inoculated Tg(Deer
PrP)1536+/- mouse brain, on which the H & E staining was performed previously,
was used (Figure 2.5.10.). The images were taken on a BX60 microscope
equipped with a DP-71 charge-coupled diode (CCD) camera (Olympus) and
composed with Adobe Photoshop.

Statistical analysis. Statistical analysis of impacts of the human PrP
polymorphism at codon 129 on the manifestation of clinical signs in CWDinoculated Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- mice was
performed using a Fisher’s exact test for each CWD prion strain separately.
Statistical analysis of the severity of clinical signs was determined using a
Kruskal-Wallis one-way analysis of variance (ANOVA) to compare six groups
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(CWD1, CWD2 or CWD mix inoculated Tg(HuPrP-M129)6816+/- and Tg(HuPrPV129)7826+/- mice) for each clinical sign. All data were analyzed with GraphPad
Prism 5. Differences with p < 0.05 was considered to be a significant.

Results
Manifestation of clinical signs in CWD-inoculated Tg(HuPrP) mice.
Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- mice expressing PrP in the
central nervous system (CNS) at levels 16-fold and 2-fold higher than an FVB
mouse were used in the following studies, respectively (Figure 2.1.) Three of
eight Tg(HuPrP-M129)6816+/- mice inoculated with CWD1 (99W12389 elk isolate
from Wyoming) developed truncal ataxia, hind-limb paresis and difficulty righting
from a supine posture. The mean incubation time for mice to manifest clinical
signs was 442 ± 90 dpi (± standard error of the mean, SEM) (range, 263–532
dpi) (Table 2.1. Table 2.2. and Figure 2.2.). Additional neurological dysfunctions
including kyphotic posture, tail stiffening, loss of extensor reflex, flattened gait,
head bobbing, aggressive behavior, slowed movement and rough coat, were also
observed in three of the CWD1-inoculated Tg(HuPrP-M129)6816+/- mice. Four of
eight Tg(HuPrP-M129)6816+/- mice inoculated with CWD2 (Bala05 elk-isolate
from Ontario Canada) developed tail stiffening, hind-lib paresis and loss of weight
or condition after an average of 425 ± 60 dpi (range, 284–551 dpi) (Table 2.1.
Table 2.2. and Figure 2.2.). These mice also exhibited some of the following
neurological dysfunctions: truncal ataxia, kyphotic posture, loss of extensor
reflex, difficulty righting, flattened gait, head bobbing, aggressive behavior,
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slowed movement and rough coat. Two of eight Tg(HuPrP-M129)6816+/- mice
inoculated with CWD mix (9179 deer isolate from Wyoming) developed kyphotic
posture, tail stiffening, slowed movement and rough coat after an average of 354
± 70 dpi (range, 315–393 dpi) (Table 2.1. Table 2.2. and Figure 2.2.). These two
mice also exhibited some of the following neurological dysfunctions: truncal
ataxia, loss of extensor reflex, circling and loss of weight or condition.
One of eight Tg(HuPrP-V129)7826+/- mice inoculated with CWD1
developed tail stiffening, head bobbing and rough coat after 543 dpi (Table 2.1.
Table 2.2. and Figure 2.2.). None of eight Tg(HuPrP-V129)7826+/- mice
inoculated with CWD2 presented clinical signs after 657 dpi (Table 2.1. Table
2.2. and Figure 2.2.). One of seven Tg(HuPrP-V129)7826+/- mice inoculated with
CWD mix developed truncal ataxia, kyphotic posture, tail stiffening, loss of
extensor reflex, flattened gait, slowed movement, dull or rough coat and loss of
weight or condition after 488 dpi (Table 2.1. Table 2.2. and Figure 2.2.). Other
study animals did not present with clinical signs associated with prion disease
and died from unrelated medical issues, such as, skin irritation, development of
abdominal mass or pulmonary issues

(open circles in Figure 2.2.). The

remaining animals in these studies were terminated at 657 dpi due to aging
(triangles in Figure 2.2.).
Severity of clinical signs manifested by CWD-inoculated Tg(HuPrPM129)6816+/- and Tg(HuPrP-V129)7826+/- mice was scored and summarized in
Table 2.2. Scores were determined by each clinical sign in each animal, and a
sum of scores given for each animal was indicated under each clinical sign
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(Table 2.2). A total score of severity of clinical signs in CWD1-inouclated
Tg(HuPrP-M129)6816+/- mice was 42 consisting of scores of 11 clinical signs:
truncal ataxia (a score was 6, scores will be indicated in parenthesis for the
following clinical signs), kyphotic posture (1), tail stiffening (5), hind-limb paresis
(6), loss of extensor reflex (4), difficulty righting from a supine position (5),
flattened gait (4), head bobbing (2), aggressive behavior (1), slowed movement
(3) and dull or rough coat (5) (Table 2.2.). A total score of severity of clinical
signs in CWD2-inouclated Tg(HuPrP-M129)6816+/- mice was 56 consisting of
scores of 12 clinical signs: truncal ataxia (2), kyphotic posture (4), tail stiffening
(8), hind-limb paresis (4), loss of extensor reflex (4), difficulty righting from a
supine position (4), flattened gait (6), head bobbing (1), aggressive behavior (6),
slowed movement (4), dull or rough coat (6) and loss of weight or condition (7)
(Table 2.2.). A total score of severity of clinical signs in CWD mix-inoculated
Tg(HuPrP-M129)6816+/- mice was 14 consisting of scores of 8 clinical signs:
truncal ataxia (1), kyphotic posture (2), tail stiffening (2), loss of extensor reflex
(1), slowed movement (2), circling (1), dull or rough coat (4) and loss of weight or
condition (1) (Table 2.2.). A total score of severity of clinical signs in CWD1inouclated Tg(HuPrP-V129)7826+/- mice was 3 consisting of scores of 3 clinical
signs: tail stiffening (1), head bobbing (1), and dull or rough coat (1) (Table 2.2.).
A total score of severity of clinical signs in CWD mix-inoculated Tg(HuPrPV129)7826+/- mice was 11 consisting of scores of 8 clinical signs: truncal ataxia
(1), kyphotic posture (2), tail stiffening (1), loss of extensor reflex (1), flattened
gait (1), slowed movement (1), dull or rough coat (2) and loss of weight or
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condition (2) (Table 2.2.). Statistical analysis of the severity of the clinical signs
was performed using a Kruskal-Wallis one-way ANOVA between groups. The
total scores of severity of clinical signs between different CWD prions and
between

Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- mice were not

statistically significant; however, one clinical sign, difficulty righting from a supine
position was turned out to be statistically significant (p<0.043) (Table 2.2.). Two
other clinical signs including hind-limb paresis and loss of weight or condition
were borderline significant (p<0.055 and p<0.061, respectively) (Table 2.2.).
CWD1 and CWD2 inoculated Tg(HuPrP-M129)6816+/- mice exhibited
multiple clinical signs, which were rapidly progressed. On the other hand, CWD
mix inoculated Tg(HuPrP-M129)6816+/- mice developed fewer neurological signs
compared to CWD1 and CWD2 inoculated Tg(HuPrP-M129)6816+/- mice. CWD1
and CWD mix inoculated Tg(HuPrP-V129)7826+/- mice also exhibited fewer
neurological signs than CWD-inoculated Tg(HuPrP-M129)6816+/- mice. A
Fisher’s exact test was performed to determine whether the human PrP 129
polymorphism impacted on the manifestation of clinical signs in CWD-inoculated
Tg(HuPrP-M129)6816+/-

and

Tg(HuPrP-V129)7826+/-

mice;

however,

no

statistically significant difference (p<0.05) between M and V at the 129
polymorphism was found in each CWD-inoculated animal group. The p-value of a
Fisher’s exact test in CWD2-inoculated Tg(HuPrP-M129)6816+/- and Tg(HuPrPV129)7826+/- mice turned out to be a borderline significance (p>0.077) (Table
2.1.). Overall, Tg mice expressing the HuPrP polymorphism M129 mice tended to
develop more overt clinical signs compared to Tg(HuPrP-V129)7826+/- mice.
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No evidence of PrPSc in the CWD inoculated Tg mouse brains. The right halfbrains of all the animals in the studies were analyzed for the presence of PK
resistant PrPSc in western blotting analyses. Even though the samples were
enriched for the presence of aggregated PrP, by ultracentrifugation in the
presence of non-denaturing detergents, which is a property of diseaseassociated PrP, PrPSc was not detected by western blotting in any of the study
animals. Two representative samples from each group of the CWD1, CWD2 and
CWD mix inoculated Tg(HuPrP) mice are shown along with PK-digested and undigested samples, as well as with appropriate positive and negative controls,
in Figure 2.3. As negative control, uninfected Tg(HuPrP) mouse brains were
used and showed the presence of PrPC but not PrPSc. As positive control, deer
CWD (99W12389) isolate was used and revealed PrPSc in the sample,
demonstrating our ability to distinguish disease-associated PrP in this assay.

Absence of spongiform degeneration in the brains of clinically affected
CWD inoculated Tg(HuPrP) mice. Selected brains from animals manifesting
clinical signs were further analyzed for the development of spongiosis. Nine brain
regions, including the medulla, cerebellum, midbrain, hypothalamus, thalamus,
hippocampus, paraterminal body, cerebral cortex at the levels of the septum and
hippocampus, were assessed for the development of disease-related vacuolation
in CWD inoculated Tg(HuPrP) mice, which manifested clinical signs (Table 2.4.).
Even though the CWD inoculated Tg(HuPrP) mice presented prion disease-
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associated clinical signs, disease-associated spongiosis was not observed in any
of the analyzed mice (Figure 2.5.). Some spongiosis observed in the brains was
not region specific and did not appear to be the result of neuronal vacuolation
those observations were inconsistent with the types of prion disease-associated
spongiosis (Figure 2.5.10.). Since many of the study animals were aged (some
were close to 600 days old), the spongiosis observed in those animal brains were
more likely associated with aging.

No signs of disease in Tg(HuPrP) mice inoculated with CWD prions
passaged multiple times in Tg(Deer PrP)1536+/- mice. In separate studies,
Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- mice were intracerebrally
inoculated with CWD isolates that had been passaged multiple times in Tg(Deer
PrP)1536+/- mice (Table 2.4.). None of the mice developed neurological
dysfunctions, and all died from unrelated medical issues (range, 162-646 dpi)
(Table 2.4. and Figure 2.6.). Ten Tg(HuPrP-V129)7826+/- mice, which did not
develop any clinical signs, were terminated at 560 dpi, while eight Tg(HuPrPM129)6816+/- mice, which did exhibit clinical signs, were further observed for the
progression of neurological dysfunction. Four Tg(HuPrP-M129)6816+/- mice
inoculated with serially passaged CWD from a short incubation time group, and
another four Tg(HuPrP-M129)6816+/- mice inoculated with serially passaged
CWD from a long incubation time group, did not progress the clinical signs in the
next 100 days. Thus, all remaining mice were terminated at 646 dpi.
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Discussion
To model the species barrier between humans and CWD prions, Tg(HuPrPM129)6816+/-

and

Tg(HuPrP-V129)7826+/-

mice

were

tested

for

their

susceptibility to CWD1 and CWD2 strains as well as isolates containing a mixture
of both. A subset of CWD-inoculated animals developed the progressive clinical
signs; however, the examination of brain material from these diseased mice
failed to confirm the presence of protease-resistant human PrPSc or
neuropathological signs associated with prion disease (Table 2.2. and Figure
2.3.). These results are consistent with a significant species barrier in humans to
these CWD strains. The additional assessment of the susceptibility to the serially
passaged CWD isolates was also performed using Tg(HuPrP-M129)6816+/- and
Tg(HuPrP-V129)7826+/- mice. None of the serially passaged CWD inoculated
animals developed disease with the absence of clinical signs and PrPSc in the
brains. Because of the lack of disease, the impact of human PrP 129
polymorphism on the susceptibility of CWD was inconclusive in the above
studies.
In these studies, the species barrier between the CWDs and Tg(HuPrP)
mice was not overcome in the primary transmission. PrPSc deposition and
spongiform development were not identified in the 16-fold and 2-fold
overexpressing Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- mouse
brains, respectively. However, the presence of progressive signs of neurological
dysfunction in the CWD-inoculated Tg(HuPrP) mice cannot be ignored. This
suggests that the conversion of human PrPSc might occur, but slowly, when
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cervid PrPSc is intracerebrally inoculated into Tg(HuPrP) mice. Race and
colleagues demonstrated that gradual adaptation of hamster PrPSc to mouse
PrPC occurred slowly in two distinct phases, including an abnormal proteaseresistant PrP (PrP-res)-negative phase followed by a replication phase during
serial passages (Race et al., 2002). In addition, protease-resistant PrPSc was not
always detectable in both of the phases (Race et al., 2002). In the present study,
the PK-resistant PrPSc and spongiform change were undetectable in the brains
from the CWD-inoculated Tg(HuPrP) mice; however, the propagation of PKsensitive PrPSc might occur in the brains causing the clinical signs. Moreover, the
formations of PK-sensitive PrPSc plaques and spongiform degenerative have
been identified in diseased human brains (Gambetti et al., 2008; Zou et al.,
2010b). Another group also reported that sheep scrapie diseased brains in some
cases contained far more PK-sensitive PrPSc than PK-resistant PrPSc, and the
PK-sensitive PrPSc had an ability to produce PK-resistant PrPSc in vitro (Thackray
et al., 2007; Tzaban et al., 2002). These studies raise a question whether PKsensitive PrPSc is present in the CWD-inoculated Tg(HuPrP) mice. If so, the
manifestation of clinical signs in those Tg(HuPrP) mice might be a result of
accumulation of PK-sensitive PrPSc in the brain.
If true prion transmission has occurred, the CWD-inoculated Tg(HuPrP)
mice in the studies might be in either PrP-res-negative or replication phases.
Therefore, a subset of the CWD-inoculated Tg(HuPrP) mice manifested the
neurological dysfunction, which might be caused by the accumulation of human
PrPSc, in the absence of a detectable amount of proteinase-resistant PrPSc in the
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brains. To fully address this issue in the near future, one might find it useful to
serially passage the brain materials from the CWD-inoculated Tg(HuPrP) mice
displaying clinical signs into the genotype matched Tg(HuPrP) mice.
Prion disease incubation times in humans are known to extend for
decades. In fact, Kuru, a human prion disease found in Papua New Guinea, has
a report incubation time of over 50 years (Collinge et al., 2006; Collinge et al.,
2008). This shows that quite lengthy periods are required for replication of PrPSc
in humans, before disease development without a species barrier. In the present
study, most of the CWD inoculated Tg(HuPrP) mice remained without signs of
prion disease for >600 dpi even though a subset of the animals are clinical
(Figure 2.2.). Four other studies also reported the negative transmissions of
CWD into Tg mice expressing human PrP encoding either M or V at residue 129
(Kong et al., 2005; Sandberg et al., 2010; Tamguney et al., 2006; Wilson et al.,
2012). The Gambetti group reported that three out of 29 CWD-inoculated Tg
mice expressing human PrP M 129 polymorphism (Tg40) presented mild ataxia
without accumulation of either PK-resistant and PK-sensitive PrPSc after >756
dpi, and another group of CWD-inoculated humanized mice expressing the M
129 polymorphism (Tg1) did not present any clinical signs after >657 dpi. Based
on the absence of PrPSc and lack of such key neuropathological features as,
spongiform change, gliosis and PrPSc plaques in the brain, it was concluded that
the mild ataxia in three Tg40 mice was not associated with prion disease. The
Prusiner group inoculated 8 different CWD isolates from elk and deer into
Tg(HuPrP-M129)440 hemizygous mice and reported no clinical signs in CWD-
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inoculated Tg440 mice after >500 dpi. The Collinge group also reported no
clinical signs in CWD-inoculated Tg(HuPrP-M129)45, Tg(HuPrP-M129)35 and
Tg(HuPrP-V129)152 homozygous mice after >700 dpi. The histology of CWDinoculated Tg(HuPrP) mouse brains was not different from age-matched noninoculated Tg(HuPrP) mouse brains. The Barron’s group reported no clinical
signs in CWD-inoculated Tg(HuPrP-M129) and Tg(HuPrP-V129) homozygous
mice, or in Tg(HuPrP-M/V129) hemizygous mice after >680 dpi, >722 dpi, >730
dpi, respectively. Considering the long incubation times in human for prion
diseases, one has reason to think the incubation time of 500-700 days might be
insufficient for accumulation of detectable amounts of PrPSc in the brain, or to
cause CWD disease in Tg(HuPrP) mice.
Furthermore, the hamster-to-mouse species barrier of prion was
overcome after three serial passages of a total of 1200 to >1550 days (Race et
al., 2002). PK-resistant PrPSc started appearing in the brains of asymptomatic
mice inoculated with brain homogenates from the mouse passaged hamster
prions from the secondary transmission; and in the next transmission with brain
homogenates from the secondary transmission, disease was produced in mice.
The study demonstrated that the gradual adaptation of hamster prion required a
substantial amount of time even between the rodents. Therefore, serial passages
of the materials from the CWD-inoculated Tg(HuPrP) mice need to be evaluated
for clearly establishing lack of transmission of CWD into humans.
It was essential to further analyze the CWD-inoculated Tg(HuPrP) mice
with clinical signs for the development of prion diseases due to the inconclusive
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results of the presence of the clinical signs without PrPSc deposition in the Tg
mice. Spongiosis development, which is a neuropathological feature of prion
diseases including CWD, was also examined in the clinical Tg(HuPrP) mice with
CWD. The features for spongiosis development in prion diseases are: (1) region
specific (Figure 2.4.), (2) appearing between nerve cell bodies and (3) the
formation of vacuolation, which can be diffuse but intensive or appearing in the
groups which often look to be a floral form (Figure 2.5.) (Prusiner, 2004). The
analyzed CWD-infected Tg(HuPrP) mouse brains with clinical signs presented
fewer vacuolations between or on cells; in those which did show, vacuoles
appeared only randomly in their brains. Therefore, vacuolation found in these
animals was not associated with prion diseases. More precise evaluation of the
disease associated spongiosis development in the CWD inoculated Tg(HuPrP)
mouse brains could be done if a PBS inoculated age matched Tg(HuPrP) mouse
brain was available for a prion disease negative control. The age matched control
from the genotype matched Tg mice would be a great help in evaluating whether
vacuolation in the brain is due to aging or to prion diseases. As an additional
positive control, Tg(HuPrP) mice with human prion diseases would be useful.
Other groups have been utilizing the Tg(HuPrP) mouse model to study the
interspecies transmission of prions as well as the biochemical properties of PrPSc
(Asante et al., 2002; Wadsworth et al., 2004). Information based on the Tg
mouse model has advanced our understanding of the species barrier of prions to
humans including BSE (Asante et al., 2002; Wadsworth et al., 2004). In future
studies, the named positive and negative controls would be extremely helpful in
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assessing any associations among the intensity of vacuolation in specific
regions, clinical signs and presence or absence of PrPSc deposition or plaques in
CWD-inoculated Tg(HuPrP) mice.
Codon 129 polymorphism of the human PrP has an impact on the
susceptibility to prion diseases including BSE, and the M 129 polymorphism was
reported to be more susceptible to BSE and variant CJD (Lloyd et al., 2004;
Wadsworth et al., 2004). In the present studies, we expected that the CWDinoculated Tg(HuPrP-M129)6816+/- mice were more likely to develop multiple
clinical signs than were Tg(HuPrP-V129)7826+/- mice (Table 2.2.). However, it
was not clear whether the PrP 129 polymorphism impacted on the development
of the multiple clinical sings in Tg(HuPrP-M129)6816+/- mice. The higher number
of Tg(HuPrP-M129)6816+/- mice which manifested the multiple clinical signs
might be due to the overexpression of PrP because Tg(HuPrP-M129)6816+/mice express 8-fold higher levels of PrP than do Tg(HuPrP-V129)7826+/- mice. It
has been reported that there is a reciprocal relationship between the expression
level of PrP and onset of disease (Prusiner et al., 1990). The higher the level of
PrP expressed in Tg mice, the shorter the incubation time after inoculation with
prions. Since protease-resistant PrPSc could not be detected in either the CWDinoculated Tg(HuPrP-M129)6816+/- or the Tg(HuPrP-V129)7826+/- mice, there is
perhaps reason to support that the human 129 polymorphism might not have an
impact on the conversion efficiency of PK-resistant PrPSc during the primary
transmission.
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The present study showed that a significantly high species barrier
between cervid and humans exists. CWD transmission studies in Tg(HuPrP)
mice were performed by the intracerebral inoculation, which is considerably more
efficient in transmitting prions than oral consumption (Prusiner et al., 1985; Race
et al., 2009b). If CWD is transmitted to humans, consumption of CWDcontaminated products is the most likely route into humans. The present studies
and others show that none of the CWD-inoculated Tg(HuPrP) mice accumulated
PK-resistant PrPSc in their brains, suggesting a lower risk of transmission of CWD
into humans. In view of the substantial incubation times for humans prion
diseases, as well as the remarkable persistence of prions in adapting within both
the same and in different species, it is important to continue evaluating the
transmission of CWD in serial passages, as well as to test new strains of CWD
as identified for verifying the transmission of CWD into humans.
Mindful of existing data on the successful amplification of human PrPSc
with serially stabilized CWD isolates in vivo and in vitro, Tg(HuPrP) mice were
also inoculated with the CWD isolates which had been passaged multiple times
in Tg(Deer PrP)1536+/- mice. The intent was to test whether the selected CWD
PrPSc increased its pathogenicity to humans during adaptation through the
multiple passages in Tg(Deer PrP)1536+/- mice. Unlike in the in vitro study,
evidence of PrPSc propagation was not observed in the CWD-inoculated
Tg(HuPrP) mice; none of the mice developed any clinical signs after >646 dpi.
The different results might be due to the use of two different systems. The
present study used an animal model, and the previous study used a cell free
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amplification system in vitro. In addition, as discussed above, the length of the
incubation time even up to 646 dpi might not be long enough to see disease
development in those study animals.
Even though the present studies did not prove the CWD transmission into
Tg(HuPrP) during the primary passage, the zoonotic potential of CWD has not
been eliminated. As there is always the possibility of preclinical and subclinical
carriers of BSE in humans, it is important to take into consideration that a similar
situation might occur with CWD. The modified hypothesis is that PK-sensitive
PrPSc is first propagated in CWD-inoculated Tg(HuPrP) mouse brain with or
without the presentation of clinical signs; later PK-resistant PrPSc becomes
detectable. To address this hypothesis, brain materials from the CWD-inoculated
Tg(HuPrP) mice with clinical signs in these studies will be passaged to genotype
matched Tg(HuPrP) mice. When the mice manifest clinical signs, the presence of
both PK-sensitive and resistant PrPSc needs to be determined in addition to the
neuropathological features.

Copyright © Eri Saijo 2012
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Table 2.1. Transmission of CWD isolates into Tg(HuPrP-M129)6816+/- and
Tg(HuPrP-V129)7826+/- mice. Incubation time indicates days post inoculation
(dpi) in mean ± SEM (standard error of the mean). The PrP expression was
determined by comparing to a wild-type FVB mouse. A Fisher’s exact test was
performed to determine whether the human PrP 129 polymorphism impacted on
the manifestation of clinical signs in CWD-inoculated Tg(HuPrP-M129)6816+/and Tg(HuPrP-V129)7826+/- mice; however, no statistically significant difference
(p<0.05) between M and V at the 129 polymorphism was found in each CWDinoculated animal group. The p-value of a Fisher’s exact test in CWD2-inoculated
Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- mice turned out to be a
borderline significance (p>0.077).
Prion

CWD1

CWD2

CWD mix

Isolate

99W12389

Bala05

9179

Location

Wyoming

Ontario Canada

Wyoming

Origin

Elk

Elk

Deer

Recipient Tg

HuPrP
M129

HuPrP
V129

HuPrP
M129

HuPrP
V129

HuPrP
M129

HuPrP
V129

PrP expression
(n-fold)

16

2

16

2

16

2

Incubation time
(dpi)

442 ± 90

543

425 ± 60

-

354 ± 70

488

No. of animals
with clinical
signs/ a total
No. of animals
inoculated

3/8

1/8

4/8

0/8

2/8

1/7
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Table 2.2. Summary of neurological dysfunctions manifested in the CWD
inoculated Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- mice. The
number of CWD-inoculated Tg(HuPrP) mice with clinical signs is indicated in
parentheses in each section of clinical signs. Severity of clinical signs were
scored for 13 clinical signs using 0 = absence, 1 = mild, 2 = moderate and 3=
severe. A total score of clinical signs manifested in animals were indicated in
each section of clinical signs. A total score of all clinical signs were shown in the
last row under each CWD-inoculated animal group. Statistical analysis of severity
of clinical signs was determined using a Kruskal-Wallis one-way analysis of
variance. A p-value is reported only when the value is significant (p<0.05) or
borderline significant. ‘No’ indicates p>0.1.
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Recipient Tg

p<0.1

Inoculum
No. of animals with
clinical signs/ a
total No. of animals
inoculated

HuPrP-M129

HuPrP-V129

CWD1

CWD2

CWD
mix

CWD1

CWD
mix

3/8

4/8

2/8

1/8

1/7

Truncal ataxia

No

6 (3)

2 (2)

1 (1)

1 (1)

Kyphotic posture

No

1 (1)

4 (3)

2 (2)

2 (1)

Tail stiffening

No

5 (2)

8 (4)

2 (2)

Hind-limb paresis

0.055

6 (3)

4 (3)

Loss of extensor
reflex

No

4 (2)

4 (3)

Difficulty righting
from a supine
position

0.043

5 (3)

4 (2)

Flattened gait

No

4 (2)

6 (3)

Head bobbing

No

2 (1)

1 (1)

Aggressive behavior

No

1 (1)

6 (2)

Slowed movement

No

3 (2)

4 (3)

Circling

No

Dull or rough coat

No

Loss of weight or
condition

0.061

Total score

No

1 (1)

1 (1)

1 (1)

1 (1)

1 (1)
1 (1)

2 (2)

1 (1)

1 (1)
5 (3)

42
58

6 (3)

4 (2)

7 (4)

1 (1)

56

14

1 (1)

2 (1)
2 (1)

3

11

Table 2.3. Origin of CWD isolate used in serial transmission studies.

Prion

CWD mix

Original isolate

H92

Location

Colorado

Origin

Mule deer
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Table 2.4. Transmission of serially passaged CWD isolates into Tg(HuPrPM129)6816+/- and Tg(HuPrP-V129)7826+/- mice. Elk CWD H92 isolate was
passaged three times in Tg(Deer PrP)1536+/- mice prior to testing the
transmission of CWD in Tg(HuPrP) mice in this study. Two individual samples
were chosen from a pool of short incubation time group (200 dpi) and a pool of
long incubation time group (300 dpi) to inoculate groups of Tg(HuPrPM129)6816+/- and Tg(HuPrP-V129)7826+/- mice. Incubation time or time of death
indicates days post inoculation (dpi). Time of death shows a period of time from
the day that a first animal was terminated to the day that a last animal was
terminated. The PrP expression was determined by comparing to a wild-type
FVB mouse.
H92 CWD passaged multiple times in Tg(Deer PrP) mice
Inoculum
Short incubation time
(193 dpi)

Long incubation time
(299 dpi)

Recipient Tg

HuPrP
M129

HuPrP
V129

HuPrP
M129

HuPrP
V129

PrP expression
(n-fold)

16

2

16

2

Time of death (dpi)

543 – 646

171 – 560

162 – 646

451 - 560

No. of animals ill/ No.
of animals inoculated

0/6

0/7

0/6

0/7

60

KO

FVB M129 V129

50k
40k
30k
20k

Figure 2.1. The expression levels of PrP in the transgenic mouse brains
compared to a wild-type FVB mouse brain. The PrPC expression levels in
Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- mouse brains were
determined by comparing to a wild-type FVB mouse brain in western blot using
anti-PrP PRC5 monoclonal antibody. The PrPC levels in Tg(HuPrP-M129)6816+/and Tg(HuPrP-V129)7826+/- overexpressed 16-fold and 2-fold more than the
FVB, respectively. A total amount of protein was standardized to 40µg per lane.
An FVB/Prnp0/0 (KO) is used as a negative control. Molecular markers indicate
50, 40, 30 and 20 kDa from top to bottom. Two cropped images are from the
same exposure of the same blot.
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Mix
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Tg(HumanPrP M129)
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Onset of disease or time of death
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CWD2

CWD 1

750

Figure 2.2. Summary of incubation times of CWD-inoculated Tg(HuPrP)
Manifested
clinical manifested
signs
mice. Some inoculated
animals
clinical signs associated with prion
Atypical death
disease that were rapidly progressive (filled circles). Atypical death indicates that
Terminated due to aging
animals die from unrelated causes (open circles). Animals not developing prion
disease were sacrificed 650 days after inoculation (triangles). The incubation
times of CWD-inoculated Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/mice with clinical signs were summarized in the table. Incubation time indicates
days post inoculation (dpi) in mean ± SEM (standard error of the mean).
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Uninfected Deer CWD

A
KO
PK +

CWD1

-

+

-

+

KO
PK +

-

+

-

+

+

-

+

-

CWD1

+

-

+/-

+

-

CWD2

Tg(HuPrP
CWD
V129)
99W12389
+/7826

-

CWD mix

Tg(HuPrP-M129)6816

Uninfected Deer CWD

B

CWD
2

Tg(HuPrP
CWD
M129)
99W12389
+/6816

+

-

CWD mix
+/-

Tg(HuPrP-V129)7826

-

+

-

+

-

+

-

+

-

+

-

Figure 2.3. Western blot analysis showed that there is no evidence of
protease-resistant PrPSc deposition in the brains from CWD-inoculated
Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- mice. Representative
samples from each group of the CWD1, CWD2 and CWD mix inoculated
Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- mice were shown in A and
B, respectively. Blots were probed with anti-PrP PRC5 monoclonal antibody. An
FVB/Prnp0/0 (KO) is used as a negative control for the anti-PrP antibody. An
uninfected Tg(HuPrP) was used as a negative control for the presence of
proteinase K (PK) resistant PrPSc. The deer CWD (99W12389) was used as a
positive control for the presence of PK resistant PrPSc. Samples, which were
treated with PK, indicate (+). Samples without PK digestion indicate (-). Molecular
markers indicate 53, 36, 28 and 19 kDa from top to bottom.
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Figure 2.4. Evaluation of spongiosis degeneration in the mouse brain with
prion disease. Nine brain regions were assessed for the development of
spongiosis in diseased animals. A. paraterminal body (7) and cerebral cortex (9)
at the level of the septum. B. hypothalamus (4), thalamus (5), hippocampus (6)
and cerebral cortex (8). C. midbrain (3). D. medulla (1) and cerebellum (2).
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1. Medulla

2. Cerebellum

3. Midbrain

4. Hypothalamus

5. Thalamus

6. Hippocampus

7. Paraterminal body

8. Cerebral
cortex

9. Cerebral cortex

10. Positive control
Hippocampus

10-A. Enlarged image
from positive control

A

B
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10-B. Enlarged image
from positive control

Figure 2.5. No spongiosis degeneration in the brains of CWD-inoculated
Tg(HuPrP) mice was observed. Nine brain regions were assessed for the
development of disease related vacuolations in CWD-inoculated Tg(HuPrP)
mice, which manifested clinical signs. Nine brain regions are (1) medulla, (2)
cerebellum, (3) midbrain, (4) hypothalamus, (5) thalamus, (6) hippocampus, (7)
paraterminal body, (8 and 9) cerebral cortex. A positive control of spongiosis
degeneration from a CWD1-inoculated Tg(Deer PrP)1536+/- mouse brain
(hippocampus) (10). Two enlarged image of the positive control (10) are shown in
10-A and 10-B. The circle in 10-A indicates a size of vacuoles varies in the brain,
and vacuoles appear between dark purple spots (cell nuclei), showing that
spongiform changes appear between cells. Arrows in 10-B indicates vacuolations
are diffuse but intensive in the specific brain regions and appear in the groups.
The magnification of the images (1-10) is 100X.
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Figure 2.6. No Tg(HuPrP) mice developed prion disease after 500 days post
inoculation of serially passaged deer CWD isolates. Tg(HuPrP-M129)6816+/and Tg(HuPrP-V129)7826+/- mice inoculated with the mule deer CWD H92
isolates that had been passaged multiple times in Tg(Deer PrP)1536+/- mice, did
not develop signs of prion disease. Filled circles indicate CWD inoculated
Tg(HuPrP-M129)6816+/- mice. Open circles indicate CWD inoculated Tg(HuPrPV129)7826+/- mice.
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Chapter 3

Investigating the role of the β2-α2 loop and its interaction site of the Cterminal region of mouse prion protein in prion propagation using cell
culture models

Introduction
Transmissibility of prion diseases within the same species is highly efficient;
however, prions are not always transmittable from one species to another. This
phenomenon is referred to as a species barrier or transmission barrier. The
ability of prions to cross a species barrier has been recognized, for example, the
interspecies transmission of bovine spongiform encephalopathy (BSE) into
humans (Bruce et al., 1997; Scott et al., 1999). Since then, the zoonotic potential
of prions is particularly important in understanding the interspecies transmission
of prions.
The primary structure of prion protein (PrP) is well conserved among
mammalian species (Prusiner, 1998). A small difference in the primary structures
of mammalian PrPs is concentrated in the loop region between the β2-sheet and
α2-helix, therefore, it has been proposed that the β2-α2 loop of PrP governs a
species barrier (Billeter et al., 1997; Schatzl et al., 1995). Further, mouse-human
chimeric transgenic (Tg) studies suggest that the species barrier between human
and mouse is mediated by a hypothetical ‘protein X’ (Telling et al., 1995), while
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an NMR structural study postulated that a potential binding site of protein X in
PrP is located within the loop region between the β2-sheet and α2-helix (Billeter
et al., 1997). Since the C-terminal domain of PrP with residue 121-231 among
mammalian species has a 90% identity, the three-dimensional structure of
PrP(121-231) was anticipated to be identical among species (Billeter et al.,
1997). However, numerous NMR studies revealed fine differences in the tertiary
structures of mammalian PrPs, especially in the β2-α2 loop region, suggesting
that the subtle differences in the tertiary structure of PrP plays a role in a species
barrier (Christen et al., 2008; Christen et al., 2009; Fernandez-Funez et al., 2011;
Gossert et al., 2005; Perez et al., 2010; Zhang, 2011). Sigurdson and her
colleagues generated Tg mice expressing the altered β2-α2 loop and challenged
the Tg mice with prions, resulting in changes in incubation times (Sigurdson et
al., 2010; Sigurdson et al., 2011).
The loop linking the β2-sheet and α2-helix in PrP resides in amino acid
residues between 164 and 174 (mouse numbers), and its structure in mammals
is highly diverged among mammals (Gossert et al., 2005). NMR structural
studies reported that, in mice, humans and bovines, the β2-α2 loop of PrP was
highly disordered, meaning that the loop was flexible (Gossert et al., 2005),
whereas in elk, bank voles, wallabies, horses, dogs, cats, pigs, rabbits and sheep
carrying a polymorphism at residue 168 expressing either histidine or arginine,
PrP have distinctly well-defined structure, meaning that the loop is rigid (Christen
et al., 2009; Gossert et al., 2005; Lysek et al., 2005; Perez et al., 2010; Zhang,
2011). The Prusiner and Wüthrich groups resolved the structure of Syrian
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hamster PrP, and later the Wüthrich group reported that the structure of the β2α2 loop in Syrian hamster PrP was partially defined and shown to be similar to
elk PrP (Gossert et al., 2005). A comparison of primary structures of mouse PrP
with a flexible loop, and elk PrP with a rigid loop reveals that two amino acid
residues are different at 169 and 173. Focusing on those two residues, the
Wüthrich group performed a NMR structural study and showed that the double
substitutions S169N and N173T in recombinant mouse PrP could produce a rigid
loop, while the single substitution N173T was not sufficient to produce a rigid
loop (Gossert et al., 2005). The following molecular dynamics simulation study
demonstrated that amino acid at residue 169 in the β2-α2 loop of PrP controlled
the structure of the loop (Gorfe & Caflisch, 2007). The single substitution S169N
in mouse PrP changed the β2-α2 loop to rigid, therefore, it would seem that
residue 169 has more impact on conferring rigidity on the loop structure than
does residue 173 (Gorfe & Caflisch, 2007).
Intrigued by the afore-mentioned series of NMR structural studies, the
Aguzzi group generated Tg mice overexpressing mouse PrP with the double
substitutions S169N and N173T in the β2-α2 loop on a Prnp knockout
background, referred to as tg1020 mice, and reported that tg1020 mice
spontaneously developed disease at 145 to 637 days of age (Sigurdson et al.,
2009). The brains of diseased mice accumulated PK-resistant PrPSc, and disease
was shown to be transmissible (Sigurdson et al., 2009). Subsequently, Tg mice
expressing mouse PrP with the single substitution D166S in the β2-α2 loop on a
Prnp knockout background (TgMoPrP166) were generated, and these mice
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spontaneously developed disease around 500 days of age (Sigurdson et al.,
2011). In contrast to tg1020, these diseased mice accumulated PK-sensitive
PrPSc in the brain (Sigurdson et al., 2011). Moreover, mouse-adapted RML
scrapie prions and CWD prions produced disease in tg1020 mice at 323 ± 92
days post inoculation (dpi) and 279 ± 48 dpi, respectively, demonstrating that, in
comparison with wild-type mice, disease onset with RML is delayed, but with
CWD is accelerated (Sigurdson et al., 2010). Interestingly, both tg1020 and
TgMoPrP166 mice had the rigid β2-α2 loop based on the previous NMR structural
studies (Gossert et al., 2005; Perez et al., 2010), respectively.
The Sigurdson group further demonstrated that the species barrier could
be lowered by presenting the identical amino acid residue at 169 between donor
and host PrP (Bett et al., 2012). Similarly, when TgMoPrP166 mice were
inoculated with RML and CWD, only RML-infected TgMoPrP166 mice developed
disease, indicating the substitution D166S had little impact on the susceptibility of
these mice to mouse prions (Bett et al., 2012). Additionally, the single
substitutions D166A, D166G, D166S and D166E were introduced in mouse PrP
and generated in a catecholaminergic differentiated (CAD) neuronal cell culture
system, and all of the variant mouse PrPs were susceptible to RML infection
(Bett et al., 2012). These findings resulted in the hypothesis that the primary
structural elements within the β2-α2 loop of PrP are what determine the species
barrier, rather than the structure of the loop, whether flexible or rigid.
However, there could be additional regions determining the susceptibility
to prions. The C-terminal region of PrP cannot be ignored since codon 225
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polymorphism of cervid PrP either serine (S) or phenylalanine (F), strongly
influences susceptibility to CWD (Jewell et al., 2005). The frequency of SF
(heterozygous) or FF (homozygous) genotypes in CWD-positive free-ranging
deer was significantly lower than cervid homozygous for SS, suggesting that deer
PrP with either genotype heterozygous for SF or homozygous for FF is less likely
to develop CWD prion disease (Jewell et al., 2005). Another finding of the NMR
structural study is that a long-range interaction between the β2-α2 loop and Cterminal region of PrP in tammar wallaby exists (Christen et al., 2009). It was
reported that residue 165 (mouse number) in the β2-α2 loop and residue 224
(mouse number) interacted closely, suggesting that the interaction of two regions
rather than the β2-α2 loop alone determines susceptibility to prions (Christen et
al., 2009). Therefore, it becomes essential to study whether long-range
interaction between the β2-α2 loop and C-terminal region of PrP does indeed
control the susceptibility of prions.
Which residues in the β2-α2 loop and C-terminal region of PrP do in fact
control the susceptibility of prions? In attempt to answer this question, the
primary structures of horse and mouse PrP were aligned. As a result, three
amino acid residues in the β2-α2 loop and two amino acid residues in the Cterminal region were mismatched. Interestingly, no TSEs have thus far been
reported in horses. Studying the effects of introducing horse-specific substitutions
into mouse PrP could help to clarify more precisely which specific amino acid
residues determine the transmission efficiency.
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In the present study, it is hypothesized that the β2-α2 loop and C-terminal
region as a whole determines the susceptibility of prions. To study the
hypothesis, various substitutions were introduced to mouse and horse PrP to see
whether the substitutions altered the susceptibility to RML, CWD or horse prions
in cell culture. The study consists of three parts; the susceptibility of prions was
determined in association with 1) the structural definition of the β2-α2 loop of PrP
with either flexible or rigid, 2) the interaction between the β2-α2 loop and Cterminal region of PrP, and 3) unique amino acid residues in the β2-α2 loop and
C-terminal region of horse PrP.

Materials and Methods
Cell cultures. Rabbit epithelial kidney (RK13) cells (ATCC, CCL-37, Manassas,
VA) were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma,
St. Louis, MO) supplemented with 10% fetal bovine serum (FBS) and 1%
penicillin/streptomycin (Pen/Strep) at 37°C in a humidified 5% CO2 incubator.
RK13 cells were observed daily and split at 1:10 dilution every 5 days.

Plasmid constructions. The mouse PrP encoding sequence with a point or
double mutation(s) were designed between two restriction endonuclease enzyme
sites AflII at the 5’ and EcoRI at the 3’ end. Mutated expression cassettes were
synthesized and cloned into pUC57 by GenScript (Piscataway, NJ). Digested
expression cassettes were cloned into the AflII and EcoRI restriction sites of the
mammalian expression vector pIRESpuro3 (Clontech, Mountain View, CA). The
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presence of the inserts was verified by colony polymerase chain reaction (PCR).
Table 3.1. summarizes the information about the 15 constructs generated in the
study. Six expression vectors carrying a point mutation in the β2-α2 loop of
mouse PrP are referred to in the following way: mouse PrP with the substitution
of serine (S) with asparagine (N) at codon 169 (mPrP[S169N] for short), mouse
PrP with the substitution of N with threonine (T) at codon 173 (mPrP[N173T]),
mouse PrP with the substitution of valine (V) with alanine (A) at codon 165
(mPrP[V165A]), mouse PrP with the substitution aspartic acid (D) with S at codon
166 (mPrP[D166S]), mouse PrP with the substitution of glutamine (Q) with
glutamic acid (E) at codon 167 (mPrP[Q167E]) and mouse PrP with the
substitution of N with lysine (K) at codon 173 (mPrP[N173K]). Three expression
vectors containing double mutations in the β2-α2 loop of mouse PrP are referred
to as mPrP[S169N, N173T], mPrP[D166S, Q167E] and mPrP[D166S, N172K].
Four expression vectors carrying a point mutation in the C-terminal interaction
site of mouse PrP with the substitution of tyrosine (Y) with A at codon 224
(mPrP[Y224A]), the substitution of Y with A at codon 225 (mPrP[Y225A]), the
substitution of Y with phenylalanine (F) at codon 224 (mPrP[Y224F]) and the
substitution of Y with Q at codon 225 (mPrP[Y225Q]). One expression vector
carrying a double mutation in the C-terminal interaction site of mouse PrP is
referred to as mPrP[Y224A, Y225A]. One expression vector harboring a point
mutation in the β2-α2 loop of horse PrP is referred to as HorsePrP[S167D].
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Generation of stably transfected RK13 cells expressing mutant mouse or
horse PrP. RK13 cells were plated in 6-well plates with DMEM/FBS lacking
antibiotics one day prior to transfection. Transfection was performed using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). DNA-Lipofectamine complexes
were prepared by mixing 4 µg of DNA with 10 µl of lipofectamine in Opti-MEM I
Reduced Serum Medium (Invitrogen, Carlsbad, CA) without serum. RK13 cells
were rinsed with Opti-MEM to remove residual serum, then 200 µl of the DNALipofectamine complexes were gently added onto the monolayer of cells. After 5
hours incubation, the complexes were removed from cell cultures, and DMEM
with FBS and Pen/Strep was added onto the transfected RK13 cells. After 48
hours, the medium was replaced with DMEM/10% containing 1 µg/ml of
puromycin. Selective medium was changed every 3 days until resistant cells
were obtained. Expression levels of PrP were determined by western blotting
comparing expression levels to that of RK13 cells expressing a wild-type mouse
PrP (RKM). RK13 cells were also transfected with empty pIRESpuro3 vectors. As
negative controls for transfection, additional RK13 cells were transfected with
DNA alone without lipofectamine and with lipofectamine alone without DNA.

Prion inocula. A pool of wild-type FVB mouse brains, which died following
infection with mouse-adapted Rocky Mountain Laboratories (RML) scrapie
prions, was used as mouse prion inoculum. A brain from a transgenic (Tg)
mouse expressing elk PrP, referred to as Tg(ElkPrP)5037, which had succumbed
to disease following infection with a pool of CWD-affected elk brains, referred to
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05-0306 obtained from our collaborators at the Canadian Food Inspection
Agency, Ottawa, Ontario Canada was used as the CWD inoculum. These prioninfected brains were prepared at 10% (w/v) in Opti-MEM by repeated extraction
through successively decreasing needle diameter from 18 to 22 gauge. Further,
10% brain homogenates from RML and CWD prions were diluted, respectively,
to 0.2 and 1% (w/v) in Opti-MEM and thoroughly homogenized using a 26 gauge
needle syringe.
Hemizygous Tg mice expressing horse PrP encoding K at residue 175
were previously generated on a Prnp knockout FVB background, and referred to
as Tg(EqPrP)5525+/-. Groups of Tg(EqPrP)5525+/- mice were infected with sheep
scrapie SSBP/1 prions, as a result, 2 out of 6 Tg(EqPrP)5525+/- mice developed
disease (unpublished data). It is important to note that the brain materials from
two diseased Tg(EqPrP)5525+/- mice were inoculated into another groups of
Tg(EqPrP)5525+/- mice; however, none of the mice developed disease
(unpublished data). A brain homogenate from a diseased Tg(EqPrP)5525+/mouse, referred to as horse prion, was used for cell infections in this study. The
brain homogenate was diluted to 0.8% (w/v) in Opti-MEM as described above.

Cell infections. For cell infection, 106 cells/ml were plated in 6-well plates one
day prior to infection. Cells were rinsed with cold PBS twice, then either RML or
CWD prions in a total volume of 1 ml per well was added to cell monolayers.
After 5 hours, 2 ml of Opti-MEM medium containing 10% FBS was added. Next
day, cells were transferred at 1:1 dilution to 10 cm plates and split at 1:10 dilution
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every 5 days up to 5 passages. Cells were lysed in cold lysis buffer (0.5%
sodium deoxycholate, 0.5% Igepal CA-630, 150 mM NaCl, and 50 mM Tris, pH
7.5) for 5 minutes in ice. Cell lysates were analyzed for PrPC or PrPSc in western
blotting.

Analysis of PrPC and PrPSc. Cell lysates from each cell line including both
infected and uninfected samples were collected at passage 3 and 5 after
infection. The concentration of total protein in each sample was determined by
bicinchoninic acid assay. For undigested samples, the total amount of proteins
was standardized at 30 µg per lane when anti-PrP 6H4 or PRC5 antibodies were
used for analysis. The total amount of proteins was standardized at 90 µg per
lane when anti-PrP PRC9 antibody was used for analysis. For proteinase K (PK)
digestion, total protein in cell lysates was normalized to 2 mg/ml in cold lysis
buffer with PK added at a final concentration of 50 µg/ml. PK-digested cell
lysates were ultracentrifuged at 100,000 x g for 1 hour at 4°C. The pellet was
resuspended in sodium dodecyl sulfate-polyacrylamide (SDS)-page loading
buffer, boiled at 100°C for 5 minutes and examined by western blotting. Proteins
were resolved by SDS gel electrophoresis and transferred to polyvinylidene
difluoride Immobilon-FL (PVDF-FL) membranes (Millipore). The membrane was
blocked with 5% non-fat milk in 0.5% Tween-20 in Tris-buffered saline (TBST)
and immunoprobed with anti-PrP mouse monoclonal antibody (mAb) 6H4
(Prionics AG, Schlieren-Zurich), PRC5, or PRC9 followed by horseradish
peroxidase-conjugated anti-mouse secondary antibody. Proteins were visualized
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using ECL Plus (GE Healthcare) using an FLA-5000 scanner (Fujifilm Life
Science). The expression levels of PrPC in cell lines were determined by
densitometric analysis of PrPC signals on the western blot using MultiGauge
(Fujifilm Life Science).

Cell blotting. Cells were plated onto plastic coverslips in 12-well plates five
passages after infection. Cells were grown to confluence, medium removed and
washed twice with cold PBS. The side of the coverslips on which cells were
grown was placed face down onto a PVDF membrane pre-soaked with cold lysis
buffer and pressed firmly for 1 minute to transfer all cells onto the membrane.
Coverslips were carefully removed. Membranes were air-dried for 2 hours and
stored at -20°C. Membranes were re-wetted with cold lysis buffer and treated
with PK at a final concentration of 5 µg/ml in cold lysis buffer for 90 minutes at
37°C with constant shaking. Protease digestion was terminated by the addition of
phenylmethylsulfonyl fluoride (PMSF) at a final concentration of 2 mM for 20 min.
Membranes were rinsed four times with distilled water and immersed in 3 M
guanidine isothiocyanate/10 mM Tris-HCl, pH 8.0 for 10 minutes then rinsed four
times with distilled water. Membranes were immunoprobed with 6H4 in the same
way as with western blots described above.

Results
In this study, rabbit epithelial kidney (RK13) cells were used to assess the
correlations between the β2-α2 loop and prion susceptibility. RK13 cells have
78

been used to study the propagation of PrPSc in vitro since the Vilette group
established that RK13 cells expressing rodent, ovine and cattle PrP were
permissive to multiple prion infections (Courageot et al., 2008; Vilette et al.,
2001). The use of a RK13 cell culture model accelerates studies in the
pathogenesis of prions by as a quicker and cost-effective model in addition to
animal models. No detectable amount of endogenous PrP is expressed in RK13
cells, even though RK13 cells have a Prnp gene. Thus, RK13 cells are effectively
natural PrP knockout cells. In contrast to animal models, the use of cell culture
systems in general allow us to control more variables in experiments, making
them an ideal in vitro cell model to study the propagation of prions.

Levels of PrP in RK13 cells expressing mutant PrP. All of the newly
generated 15 cell lines showed detectable levels of PrP on western blots using
6H4 or PRC5 (Figure 3.1. and 3.2.). Most of the mutant cell lines expressed 1.6fold to 1.9-fold higher PrP levels than RKM on the western blot probed with 6H4
except for 1.2-fold in RKM[V165A], 3.5-fold in RKM[Y225A], 2.2-fold in
RKM[Q167E] and 2.5-fold in RKM[D166S, Q167E] (Figure 3.2.). The blot probed
with PRC5 showed 1.2-fold to 1.6-fold higher PrP levels compared to RML in
most of the cell lines except 0.8-fold in RKM[V165A] and 2-fold in RKM[Y225A]
(Figure 3.2.). Both results showed that RKM[V165A] expressed relatively lower
levels of PrP and RKM[Y225A] expressed relatively higher levels of PrP
compared to RKM. The rest of the cell lines expressed a similar range of PrP
levels. In addition, it is important to point out that PrP was not detected in RK13
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cells with an empty pIRESpuro3 vector (RKV), confirming that RK13 cells did not
express detectable levels of PrP (Figure 3.1.).
Both 6H4 and PRC5 antibodies equally recognized the mutant mouse PrP
in cell culture; however, reactivity with PRC9 antibody was dependent on
mutations within PrP. PRC9 could not recognize the mutant mouse PrP when
amino acid residue at 224 was mutated from tyrosine (Y) to either alanine (A) or
phenylalanine (F) (Table 3.2. and Figure 3.2.). Moreover, PRC9 lost reactivity
when Y at residue 225 in mouse PrP was mutated to glutamine (Q) but not F
(Table 3.2.). In addition, mouse PrP with the substitution V165A was not
recognized by PRC9. For this reason, in the following experiments, only 6H4 and
PRC5 were used for immunoblotting since PRC9 varies in reactivity with the
mutant mouse PrP’s.

Changing the β2-α2 loop structure of mouse PrP altered susceptibility to
RML but not CWD. Two amino acids are different between mouse and elk PrP
within the β2-α2 loop. Mouse PrP contains serine (S) at residue 169 and
asparagine (N) at residue 173 and keeps the β2-α2 loop flexible, while elk PrP
contains N at residue 169 (mouse number) and threonine (T) at residue 173
(mouse number) and has a rigid loop (Gossert et al., 2005).
In the first experiment, the flexible β2-α2 loop of mouse PrP was changed
to the rigid loop by introducing the double mutation at residue 169 from S to N
and at residue 173 N to T. The western blot showed that PrPSc did not
accumulate in RML-infected RKM[S169N, N173T] cells at passage 3 (Figure
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3.3.A). Next, the single substitution S169N was introduced in to mouse PrP, and
this substitution was sufficient to change the flexible β2-α2 loop of mouse PrP to
the rigid loop (Sigurdson et al., 2011). RKM[S169N] cells also lost the
susceptibility to RML at passage 3 (Figure 3.3.B). RML-infected RKM[S169N]
cells were maintained for up to five passages after infection to see if delayed
propagation of PrPSc occurred. However, PrPSc was absent in the RML-infected
cells at passage 5 on western blot, suggesting that RKM[S169N] cells were
resistant to RML (Figure 3.3.C). This result indicates that changing the loop
structure in mouse PrP led to loss of susceptibility to RML. In contrast, the lack of
PrPSc in CWD-infected RKM[S169N, N173T] and RKM[S169N] cells showed that
introducing the rigid loop in mouse PrP was not sufficient to confer susceptibility
to CWD (Figure 3.4.A and B, respectively).
Subsequently, the substitution N173T was introduced into mouse PrP.
Even though this single substitution was sufficient to maintain a flexible β2-α2
loop (Gossert et al., 2005), the point mutation resulted in inhibition of PrPSc
formation following infection with RML (Figure 3.3.D).
PrPSc was not identified in CWD-infected RKM[N173T] cells at passage 3,
showing that the substitution were not sufficient to confer susceptibility to an
otherwise mouse PrP primary structure to CWD prions (Figure 3.4.C).
For RML infection, both RML/FVB and RML/RKM presented PK-resistant
PrPSc in each blot, indicating our ability to detect RML PrPSc on western blots
(Figure 3.3.). The presence of PrPC and absence of PrPSc in the uninfected cell
lines were confirmed, showing that the positive signal of PrPSc was valid. Every
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blot showed the absence of signals in uninfected RKV samples indicating that the
antibody recognition on western blots was specific to PrP. In addition, the
absence of signals in infected RKV controls indicates that no residual PrPSc from
the inoculum remained at passage 3 or 5. The presence of PK-resistant PrPSc in
RML-infected RKM indicated the cell infection was successful.
Likewise, for CWD infection, both CWD/Tg(ElkPrP) and CWD/RKE
presented PK-resistant PrPSc in each blot, indicating our ability to detect CWD
PrPSc on western blots (Figure 3.4.). The presence of PrPC and absence of PrPSc
in the uninfected cell lines were confirmed showing that the positive signal of
PrPSc is valid. The absence of signals in CWD-infected RKM indicating that no
residual PrPSc from the inoculum remained at passage 3. The presence of PKresistant PrPSc in CWD-infected RKE indicates the cell infection was successful.
Those positive and negative controls demonstrated that it was possible to infect
cells and detect newly generated PrPSc in this assay.
The antibody specificity and absence of residual inocula was verified by
examining the absence of PrPC and PrPSc in RKV on western blots. The ability to
detect RML PrPSc on western blots was verified by presenting the PK-resistant
PrPSc from brain homogenates from RML-infected wild-type FVB mice
(RML/FVB) and/or cell lysates from RML-infected RKM cells (RML/RKM). The
presence of PrPC and absence of PrPSc in the uninfected cell lines were
confirmed, thus the accumulation of PrPSc was due to prion infection. The
presence of PK-resistant PrPSc in RML-infected RKM indicated that the cell
infection was successful.
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In addition to the above controls, the detectability of CWD PrPSc on
western blots was verified by presenting the PK-resistant PrPSc from brain
homogenates from Bala05 CWD-infected Tg(ElkPrP) mice (CWD/Tg(ElkPrP))
and cell lysates from CWD-infected RKE cells (CWD/RKE). Successful CWD
infection was demonstrated by presenting the presence of PK-resistant PrPSc in
CWD-infected RKE. RKM was used as a negative control for the infection of
CWD prion because mouse PrP is resistant to PrPSc propagation. The absence
of signals in CWD-infected RKM indicates that no residual PrPSc from the
inoculum remained at passage 3. Those positive and negative controls
demonstrated that the ability to infect cells and detect newly generated PrPSc in
this assay.
For dot blotting, infected and uninfected samples were determined for the
accumulation of PrPSc. As negative control, uninfected samples were used for the
absence of PrPSc. As positive control, cell lysates from RK13 cells expressing elk
PrP (RKE) chronically infected with sheep scrapie SSBP/1 or 48x35 isolates
were used. The absence and presence of PrPSc in the negative and positive
controls demonstrated this technique’s ability to detect PrPSc.

Interrupting the interaction between the β2-α2 loop and C-terminal region in
mouse PrP changed the susceptibility to RML. Inspired by the NMR study of
tammar wallaby PrP (Christen et al., 2009), alanine substitutions were introduced
to mouse PrP at residues 165, 224 and 225, in order to establish whether
interrupting the interaction between the β2-α2 loop and C-terminal regions
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altered susceptibility to RML. The alanine substitution at residue 165 in the β2-α2
loop of mouse PrP has been previously shown to make the flexible loop of
mouse PrP into the rigid loop (Christen et al., 2009). The western blot showed
ambiguous signals of PrPSc from RML-infected RKM[V165A] cells; however,
these were most likely due to leaked signals from neighboring samples (Figure
3.5.A.). In the following experiment, the dot blot confirmed that RML failed to
propagate PrPSc in RKM[V165A] cells (Figure 3.7.). The absence of PrPSc
accumulation in RML-infected RKM[Y224A] and RKM[Y225A] cells was verified
by western and dot blotting, indicating that two residues in the C-terminal
interaction site are important determinants for the susceptibility to RML (Figure
3.5.B. and 3.7.). Although RKM[Y224A] and RKM[Y225A] cells was flexible and
rigid loops between the β2-sheet and α2-helix, respectively (Christen et al.,
2009), both of the cell lines lost susceptibility to RML, indicating that the
structural definition of the β2-α2 loop did not correlate with the susceptibility of
RML. In addition, the double mutation at residue 224 and 225 failed to propagate
PrPSc upon RML infection (Figure 3.5.A.). Some signals were shown in PKdigested uninfected RKM[Y224A] and RKM[Y225A] cells (Figure 3.5.A). These
were most likely due to either undigested PrP or leaked samples from the
neighboring lanes since PK-resistant core of PrPSc at 27-30 kDa was not present
in those lanes. Moreover, the dot blot, which is a sensitive assay for PrPSc
detection

(Scott

et

al.,

1993),

confirmed

RML-infected

RKM[Y224A],

RKM[Y225A] and RKM[Y224A, Y225A] cells could not produce PrPSc at passage
3 (Figure 3.7.). The above results indicate that secondary structural constrains,
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producing rigidity or flexibility within the β2-α2 loop, do not determine
susceptibility to RML prions. Rather, the results suggest that specific primary
determinants at key residues within the β2-α2 loop and C-terminal regions
determine susceptibility to RML.

Horse-specific substitutions within the β2-α2 loop and its interaction site of
mouse PrP resulted in loss of susceptibility to RML. In order to study unique
amino acid residues in the β2-α2 loop and C-terminal regions of horse PrP, horse
specific substitutions at residues 166, 167,172, 224 and 225 were introduced into
the mouse PrP primary structure. RK13 cells expressing those mutant mouse
PrP constructs were tested for susceptibility to RML prions. It should be noted
that previous work showed substitution of D166S in the β2-α2 loop of mouse PrP
changed the loop from flexible to rigid, whereas other single or double
substitutions except the double substitution of D166S and Q167E did not alter
the structure of the β2-α2 loop (Perez et al., 2010). Our western blot data
showed that a weak signal of PK-resistant PrPSc around 19 and 27-25 kDa in the
sample from RML-infected RKM[D166S] cells at passage 3 (Figure 3.6.A.).
Moreover, the dot blot showed no accumulation of PrPSc in RML-infected
RKM[D166S] cells at passage 5 (Figure 3.7.). The results of the western and dot
blotting indicate that conversion of PrPSc was inefficient and unstable in RMLinfected RKM[D166S] cells. Accumulation of PrPSc was not detected in RMLinfected RK13 cells expressing horse PrP with a substitution of S to D at codon
167 (HorsePrP[S167D]) by both western and dot blotting. In conclusion,
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changing a single residue in horse PrP at residue 167 to corresponding residue
in mouse PrP was insufficient to induce susceptibility to RML prions (Figure
3.6.A. and Figure 3.7.).
Although the apparent signal in the PK-digested sample from RMLinfected RKM[Q167E] cells was present, the signal was most likely due to the
undigested PrP or leaked sample from the neighboring lanes (Figure 3.6.B.).
Moreover, the dot blot showed no accumulation of PrPSc in RML-infected
RKM[Q167E] cells (Figure 3.7.). The absence of PrPSc was shown in
RKM[D166S, Q167E] cells by both western and dot blotting (Figure 3.6.B.).
RKM[N172K] and RKM[D166S, N172K] cells failed to accumulate PrPSc upon
RML infection (Figure 3.6.C. and Figure 3.7). Therefore, the substitutions Q167E
and N172K with or without D166S in mouse PrP resulted in the loss of
susceptibility to RML. Both western and dot blotting failed to detect PrPSc in RMLinfected RKM[Y224A] and RKM[Y225A] cells (Figure 3.6.D. and Figure 3.7). The
substitutions Y224A and Y225A in the C-terminal region, which is the interaction
site of the β2-α2 loop, of mouse PrP kept the loop flexible but resulted in the loss
of the susceptibility to RML.

Horse-specific substitutions in mouse PrP were not sufficient to stimulate
susceptibility to horse prion. RK13 cells expressing selected mutant mouse
PrP including RKM[D166S], RKM[D166S, Q167E], RKM[D166S, N172K],
RKM[Y224F], RKM[Y225Q] and RK13HorsePrP[S167D] were infected with horse
prions generated in Tg mice expressing horse PrP (unpublished data). The dot
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blot showed that none of above horse-prion infected cells accumulated PrPSc at
passage 5 (Figure 3.7.). In addition, horse prion infected RKM cells also failed to
produce PrPSc, indicating the presence of species barrier between mouse and
horse PrP (Figure 3.7.).

Discussion
NMR structural studies have shown that specific residues within the β2-α2 loop
and the C-terminal region interact in the tertiary structure of PrP (Christen et al.,
2009). In order to test the hypothesis that these residues play a role in
determining susceptibility to prion infection, various mutations were introduced in
the β2-α2 loop and/or the C-terminal region. RK13 cells expressing those variant
mouse PrP were infected with RML or CWD to determine whether these
mutations altered the ability of the expressed PrP to be converted to PrPSc (Table
3.1.). Substitutions in the β2-α2 loop and C-terminal region of mouse PrP were
sufficient to prevent PrPSc conversion upon RML prion infection (Figure 3.3., 3.5.,
3.6. and 3.7.). Introducing the rigid loop in mouse PrP created the transmission
barrier to RML (Figure 3.3.) but did not lower the transmission barrier of CWD
(Figure 3.4.). Disrupting the interaction between the β2-α2 loop and C-terminal
region of mouse PrP also offered protection from the RML transmission (Figure
3.3. and 3.4.). The results of detailed examination of diverged amino acid
residues in the β2-α2 loop and C-terminal region of mouse PrP identified more
precisely the specific amino acid residues playing critical roles in prion
transmission. In other words, changing the primary structure of the β2-α2 loop
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and C-terminal region modifies susceptibility to prions, suggesting that the
distinctive amino acid residues in those critical regions of PrP make a significant
contribution to constructing a species barrier.
The diverged primary structures of PrP in the β2-α2 loop region among
mammals guided us to this investigation of the role of the loop in a species
barrier. NMR structural and animal studies suggested that the structural definition
of the β2-α2 loop decides the susceptibility of RML and CWD (Gorfe & Caflisch,
2007; Gossert et al., 2005; Sigurdson et al., 2010). In addition, the most recent
study from the Sigurdson group suggested that the narrowed area of the primary
structure of the β2-α2 loop determined the interspecies prion conversion (Bett et
al., 2012). In the present study, the series of experiments with RML transmission
demonstrated that the point mutations in the β2-α2 loop and C-terminal
interaction region were sufficient to create a transmission barrier in cell cultures,
although some substitutions maintained the flexible loop. Even though the β2-α2
loop of PrP is involved in determining a species barrier, choosing either flexible
or rigid loop between β2-sheet and α2-helix in PrP does not regulate the
susceptibility to prions. Consistent with the recent report from the Sigurdson
group (Bett et al., 2012), the structural definition of the β2-α2 loop of PrP has little
involvement in prion transmission.
To investigate whether the interaction between the β2-α2 loop and Cterminal region plays a role in prion transmission, single or double substitutions
were introduced in mouse PrP at residues 165, 224 and 225. Long-range
interactions were reported between residue 165 in the β2-α2 loop and residue
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224 in the C-terminal region of tammar wallaby PrP (Christen et al., 2009). Since
the previous NMR study showed that alanine substitutions at residue 165, 224
and 225 interrupted the interaction between the loop and C-terminal region of
PrP (Christen et al., 2009), in the present study, it was anticipated that
interrupting the interaction could change the prion transmission. To directly
address this question, we infected RK13 cells expressing the variant mouse PrP
lacking the interaction with RML prions. As a result, all of the variant PrP lost the
susceptibility to RML, suggesting that the interaction between the β2-α2 loop and
C-terminal region of PrP has a great impact on a species barrier.
The β2-α2 loop of PrP consists of eleven amino acids, and four out of
eleven are conserved among mammalian species. Two amino acid residues at
166 and 172 (mouse number) are conserved among the mammalian species
except horses. One amino acid at residue 170 is conserved among species but
unique in tammar wallaby PrP. Another four amino acid residues at 165, 167,
169 and 173 are divergent among the species. The studies in vivo and vitro
demonstrated that the amino acid residue 169 played significant roles in the
conversion of PrPSc (Avbelj et al., 2011; Kurt et al., 2009; Sigurdson et al., 2010),
suggesting the residue has an important role in the prion transmission. In
addition, horse-specific amino acid residue 166 had been reported to have a little
influence on the prion transmission (Bett et al., 2012). However, roles of the five
other diverged amino acid residues have not been studied in relation to prion
transmission. In order to study the roles of each amino acid in the β2-α2 loop and
C-terminal region of PrP in the prion transmission, the above diverged seven
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amino acid residues in the loop and its interaction site were mutated in mouse
PrP. As anticipated, the substitution S169N in mouse PrP altered susceptibility to
RML in cell culture consistent with the result of Tg mouse expressing mouse PrP
with the S169N substitution (Sigurdson et al., 2010). Even though the conversion
of PrPSc was not efficient in RK13 cells expressing mouse PrP[D166S], the
substitution did not completely prevent the PrPSc propagation.
The present study also supports the data that the Tg mice expressing
MoPrP166 maintained susceptibility to RML and produced PK-resistant PrPSc
(Sigurdson et al., 2011). An additional study might explain the reason why the
substitution of D166S in mouse PrP is susceptible to RML. TgF35 mice
expressing deletion mutant mouse PrP (Δ32-134) spontaneously developed
disease; however, TgF35 mice were rescued by either coexpressing wild-type
mouse PrP or mouse PrP[D166S], suggesting that mouse PrP[D166S] could
serve similar functions to wild-type PrP (Sigurdson et al., 2010).
In the present study, substitutions of other five residues at 165, 167, 170,
172 and 173 were also examined as to whether susceptibility to RML was altered
in cell culture. As a result, the conversion of PrPSc prevented in the RML-infected
RK13 cells expressing those five variant mouse PrP, suggesting those five
residues have significant effects on the prion transmission. The present study
evinces the specific six amino acid residues in the β2-α2 loop of mouse PrP that
play significant roles in deciding the susceptibility of RML.
The present study showed that introducing elk PrP residues in mouse PrP
(S169N and N173T) was not sufficient to lower the transmission barrier of CWD
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in cell culture. Additionally, RML failed to propagate in RK13 cells expressing
most of the variant mouse PrP except D166S. The results suggest that lowering
the existing species barrier is challenging; however, a single amino acid
substitution of mouse PrP is sufficient to inhibit the propagation of PrPSc with
RML. In order to further test the transmission barrier, RK13 cells expressing
variant mouse PrP with horse specific substitutions were infected with horse
prion. The horse specific substitutions of D166S, Q167E, N172K, Y224F and
Y225Q in mouse PrP were unable to convert PrPSc responding to horse prion
infection, indicating that the single substitutions were not able to lower the
transmission barrier of horse prion. Nonetheless, the limitations to the
experiments with horse prion infection in cell culture need to be discussed. The
horse prion has not yet proven to be transmissible because the secondary
passage of the material could not produce disease in Tg(EqPrP)+/- mice.
Because the transmissibility properties of horse prion remain unclear, a positive
control for the infection assay with horse prion was unavailable. RK13 cells
expressing a wild-type horse PrP (RK13HorsePrP) were not included, although
the transmissibility of horse prion was uncertain in cell culture. In the present
study, horse prion infection was performed along with RML infection, and the cell
infection procedure was verified by presenting successful RML infection results.
In future studies, it will be interesting to examine whether the same amino acid
residues required for RML transmission in mouse PrP also determines the
susceptibility of horse prion.
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The primary structure of PrP is not the only critical determinant for the
transmission barrier of prions. The primary structures of human and cattle PrP
are not identical; however, BSE prions have an ability to produce disease-related
PrPSc in Tg mice expressing human PrP (Lloyd et al., 2004; Wadsworth et al.,
2004). This suggests that there are additional requirements for the transmission
of prions. Another possible requirement for prion transmission is a threedimensional

compatibility

between

host

PrPC

and

donor

PrPSc.

The

conformational compatibility can be obtained even when there are variations in
the primary structures of host and donor PrP. In any study of the effects of
compatibility between donor PrPSc and host PrPC on the transmission barrier of
prions, it will be extremely challenging to directly obtain the structural information
of native PrPC and especially PrPSc because there are still limitations to the
resolution of current technologies. Instead, by way of an extension to the present
study, systematic studies of introducing multiple substitutions in mammalian PrP
may well be useful in gaining more insight into the transmission of prions.
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Table 3.1. Summary of expression vectors for point or double mutation(s)
to alter the structure of the β2-α2 loop in mouse PrP. The mammalian
expression plasmid pIRESpuro3 carrying 15 different mutant PrP were
constructed. Three mutants followed by an elk PrP include elk specific
substitutions at residues 169 and/or 173 in mouse PrP. Four mutants followed by
a wallaby PrP include alanine substitutions at residues 165, 224 and/or 225 in
mouse PrP. Seven mutants followed by a horse PrP include horse specific
substitutions at residues 166, 167, 172, 224 and/or 225 in mouse PrP. The last
mutant in the table is a horse PrP variant with a point mutation at residue 167
(horse number which is equivalent to 166 in mouse). Bold letters indicate
mutated amino acid residues in the constructs. N/D indicates that the loop
structure has not been determined by NMR.
Amino acid residue (mouse number)

165

166

167

169

172

173

224

225

Structure of
β2-α2 loop
based on
NMR

Mouse PrP (mPrP)

V

D

Q

S

N

N

Y

Y

Flexible

Elk PrP

V

D

Q

N

N

T

Y

Y

Rigid

mPrP[S169N]

V

D

Q

N

N
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Table 3.2. Reactivities of anti-PrP mAbs with the PrP variants carrying the
altered β2-α2 loop and its interaction at the C-terminal of PrP. The
expression levels of PrP in RK13 cells expressing variant mouse or horse PrP
were determined using three different anti-PrP mAbs including 6H4, PRC5 and
PRC9. A positive (+) indicates a mAb could recognize a variant PrP, whereas a
negative (−) indicates a mAb did not recognize a variant PrP. N/D indicates the
β2-α2 loop structure has not been determined by NMR or the reactivity of an
antibody has not been determined.
mAb

Structure of
β2-α2 loop
based on NMR
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Figure 3.1. Expression of PrP in RK13 cells expressing variant mouse PrP.
The expression of PrP was determined in RKM[S169N], RKM[N173T] and
RKM[S169N, N173T] on western blots using mAb 6H4 (A) and PRC9 (B). The
above western blots showed all of three cell lines expressed the sufficient levels
of PrP. RK13 cells with an empty vector (RKV) were used as a negative control.
RK13 cells expressing a wild-type mouse PrP (RKM) were used as a positive
control. Molecular markers indicate 53, 36, 28 and 19 kDa from top to bottom.
Cropped images are from the same exposure of the same blot.
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Figure 3.2. PrP expression levels in RK13 cells expressing variant mouse
PrP carrying the altered β2-α2 loop. The western blots with anti-PrP mAb 6H4
(A) and PRC5 (B) showed that all of the cell lines expressed sufficient levels of
PrP. The last western blot was probed with anti-PrP mAb PRC9, which is a
mouse specific antibody (C). PRC9 recognizes some of the mutant cell lines but
not all of the lines. Lanes 1. RK13 cells with an empty pIRESpuro vector (RKV);
2. RK13 cells expressing a wild-type mouse PrP (RKM); 3. RKM[V165A]; 4.
RKM[Y224A]; 5. RKM[Y225A]; 6. RKM[Y224A, Y225A]; 7. RKM[D166S]; 8.
RKM[Q167E]; 9. RKM[N172K]; 10. RKM[D166S, Q167E]; 11. RKM[D166S,
N172K]; 12. RKM[Y224F]; 13. HorsePrP[S167D]. The numbers shown under the
blots (A and B) indicate the levels of PrP in each cell line through comparison to
RKM. Molecular markers indicate 53, 36, 28 and 19 kDa from top to bottom.
Cropped images are from the same exposure of the same blot.
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Figure 3.3. Altering the structure of the β2-α2 loop in mouse PrP changed
the susceptibility to RML. All western blots were probed with anti-PrP 6H4
antibody. A. The western blot showed that PrPSc did not accumulate in RMLinfected RKM[S169N, N173T], the flexible β2-α2 loop of mouse PrP was
changed to the rigid loop, suggesting that RKM[S169N, N173T] cells lost
susceptibility to RML prions at passage 3. B. RML-infected RKM[S169N] cells
also did not show accumulation of PrPSc at passage 3. C. RML-infected
RKM[S169N] cells were maintained for up to five passages after infection to see
if delayed propagation of PrPSc occurred. However, PrPSc was absent in the
RML-infected cells at passage 5 on western blot, suggesting that RKM[S169N]
cells were resistant to RML. D. RML failed to produce PrPSc in RKM[N173T]
cells, even though this single substitution was sufficient to maintain a flexible β2α2. RML/FVB indicates brain homogenates from RML-infected wild-type FVB
mice. RKM is RK13 cells expressing a wild-type mouse PrP. RML/RKM are RMLinfected RKM. Samples treated with proteinase K (PK) indicate (+). Samples
without PK digestion indicate (-). Molecular markers indicate 53, 36, 28 and 19
kDa from top to bottom.
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Figure 3.4. Introducing the rigid loop in mouse PrP was not sufficient to
gain susceptibility to CWD. CWD infected mutant cells were examined for the
conversion of PrPSc at passage 3. All western blots were probed with anti-PrP
6H4 antibody. A. CWD-infected RKM[S169N, N173T] cells failed to produce
PrPSc. B. CWD-infected RKM[S169N] also did not accumulate PrPSc. The lack of
PrPSc in CWD-infected RKM[S169N, N173T] and RKM[S169N] cells showed that
introducing the rigid loop in mouse PrP was not sufficient to confer susceptibility
to CWD. C. PrPSc was not identified in CWD-infected RKM[N173T] cells at
passage 3, showing that the substitution were not sufficient to confer
susceptibility to an otherwise mouse PrP primary structure to CWD prions.
CWD/Tg(ElkPrP) indicates brain homogenates from CWD (Bala05)-infected
Tg(ElkPrP) mice. RKE is RK13 cells expressing elk PrP. CWD/RKE is RKE cells
were chronically infected with CWD. RKM is RK13 cells expressing a wild-type
mouse PrP. Samples treated with proteinase K (PK) indicate (+). Samples
without PK digestion indicate (-). Molecular markers indicate 53, 36, 28 and 19
kDa from top to bottom.

100

A

Uninfected

PK

RKV

RKM

-

-

+

B

Infected w/ RML

RKM
Y165A
+

-

+

RKM
Y224A
Y225A
-

+

RKV

RKM

-

-

+

Uninfected

PK

RKV

RKM

-

-

+

-

-

+

RKM
Y224A
Y225A
-

+

Infected w/ RML

RKM
Y224A
+

+

RKM
Y165A

+

RKM
Y225A
-

+

RKV

RKM

RKM
Y224A

RKM
Y225A

-

-

-

-

+

+

+

+

Figure 3.5. Interrupting the interaction between the β2-α2 loop and Cterminal of mouse PrP changed susceptibility to RML prions. Infected and
uninfected samples were determined for the propagation of PrPSc followed by the
infection of RML prions at passage 3. All western blots were probed with anti-PrP
mAb PRC5. Introducing substitution Y165A in the β2-α2 loop of mouse PrP
changes the interaction between the β2-α2 loop and C-terminal region, and the
substitution resulted in loss of susceptibility to RML (A). Additionally, the point or
double substitutions at Y224A and/or Y225A at the C-terminal of mouse PrP were
introduced. PrPSc did not accumulate in RK13 cells expressing RKM[Y224A,
Y225A] (A). Further, both RML prions failed to accumulate PrPSc in RKM[Y224A]
and RKM[Y225A] cells. Interrupting the interaction between the β2-α2 loop and
C-terminal of mouse PrP was sufficient to lose susceptibility to RML prions. RKV
is RK13 cells with an empty vector. RKM is RK13 cells expressing a wild-type
mouse PrP. Samples treated with proteinase K (PK) indicate (+). Undigested
samples indicate (-). Molecular markers indicate 53, 36, 28 and 19 kDa from top
to bottom.
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Figure 3.6. Horse-specific substitutions within the β2-α2 loop and its
interaction site of mouse PrP resulted in loss of susceptibility to RML. In
order to study unique amino acid residues in the β2-α2 loop and C-terminal
regions of horse PrP, horse specific substitutions at residues 166, 167, 172, 224
and 225 were introduced into the mouse PrP primary structure. RK13 cells
expressing those mutant mouse PrP constructs were tested for susceptibility to
RML prions. Infected and uninfected samples were determined for the
conversion of PrPSc followed by the infection of RML prions at passage 3. All
western blots were probed with mAb PRC5. A. The western blot showed that a
weak signal of proteinase K (PK)-resistant PrPSc around 19 and 27-25 kDa in
RML-infected RKM[D166S] cells. However, accumulation of PrPSc was not
detected in RML-infected RK13 cells expressing horse PrP with a substitution of
S to D at codon 167 (HorsePrP[S167D]). B. Although the apparent signal in the
PK-digested sample from RML-infected RKM[Q167E] cells was present, the
signal was most likely due to the undigested PrP or leaked sample from the
neighboring lanes. RML-infected RKM[Q166S, Q167E] cells did not accumulate
PrPSc. C. RKM[N172K] and RKM[D166S, N172K] cells failed to accumulate PrPSc
upon RML infection. D. The western blot failed to detect PrPSc in RML-infected
RKM[Y224A] and RKM[Y225A] cells. RKV is RK13 cells with an empty vector.
RKM is RK13 cells expressing a wild-type mouse PrP. Samples treated with
proteinase K (PK) indicate (+). Samples without PK digestion indicate (-).
Molecular markers indicate 53, 36, 28 and 19 kDa from top to bottom.
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Figure 3.7. Absence of PrPSc in RML or horse prion infected RK13 cells
expressing mutant mouse PrP on cell blotting analysis at passage 5. Prion
infected and uninfected samples were determined for the accumulation of PrPSc
using a cell blotting technique, and the analyses confirmed the absence of PrPSc
in the mutant RK13 cells followed by the infection of RML or horse prions.
Selected variant mouse PrP including the hore-specific substitutions at residues
166, 167, 172, 224 and/or 225 (mouse numbers), were tested for susceptibility of
horse prion. Additionally, the variant horse PrP (HorsePrP[S167D]) was also
tested for susceptibility to horse prion. However, horse prion-infected
RK13HorsePrP[S167D] cells failed to convert PrPSc. As positive controls, RK13
cells expressing elk PrP, which were chronically infected with sheep scrapie
48x35 (C1) or SSBP/1 (C2) were used for the presence of PrPSc signals. RKV is
RK13 cells with an empty vector. RKM is RK13 cells expressing a wild-type
mouse PrP. 1. RKM[V165A]; 2. RKM[Y224A]; 3. RKM[Y225A]; 4. RKM[Y224A,
Y225A]; 5. RKM[D166S]; 6. RKM[Q167E]; 7.RKM[N172K]; 8. RKM[D166S,
Q167E]; 9. RKM[D166S, N172K]; 10. RKM[Y224F]; 11. RKM[Y225Q] 12. RK13
HorsePrP[S167D].
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Chapter 4

A ‘dominant’ OvPrPSc-V136 conformation leads to forced templating of
OvPrPC-A136

Introduction
Classical scrapie, long documented as a lethal infectious neurological disease in
sheep, goat and moufflon, is by now classified as a transmissible spongiform
encephalopathy (TSE)- a prion disease (Dickinson, 1976; Wood et al., 1992).
Though its causative agent is now known, scrapie remains a serious problem
with growing numbers of cases reported from many countries, necessitating
vigilant monitoring and surveillance worldwide in sheep industries. As one result,
the European Union and the United States have begun selective breeding of
scrapie resistant sheep to increase the frequency of scrapie resistant genotypes
(Commission, 2003; U.S. Department of Agriculture, 2012). There is, however,
some debate as to whether the reduction of genetic variability in sheep results in
loss of some of rare breeds (Alvarez et al., 2007; Windig et al., 2007; Windig et
al., 2004). A further concern is that such selective breeding might make possible
the emergence or adaptation of new strains of scrapie in the selected genotypes.
In order to optimize the selective breeds most effectively and to prevent the worst
scenario from happening, we require better understanding of how ovine
polymorphisms affect both susceptibility and resistance of scrapie.
The ovine PrP (OvPrP) gene is known to be highly polymorphic; however,
three major polymorphisms at codon 136 (alanine [A] or valine [V]), 154 (arginine
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[R] or histidine [H]), and 171 (glutamine [Q], R or H) have been identified to have
the most impact on susceptibility to classical scrapie (Goldmann et al., 1991;
Goldmann et al., 1994). The common haplotype is A at codon 136, R at codon
154 and Q at codon 171 (ARQ), which is a less susceptible genotype to classical
scrapie isolate SSBP/1 (sheep-passaged scrapie isolate 1); on the other hand, it
is also the haplotype most susceptible to another scrapie isolate CH1641 (Baylis
& Goldmann, 2004; Dickinson & Outram, 1988; Foster & Dickinson, 1988b;
Goldmann et al., 1994). Genetic susceptibility to SSBP/1 and CH1641 isolates
has been characterized experimentally by passaging through different breeds of
sheep (Goldmann et al., 1994; Westaway et al., 1994a) and transgenic (Tg) mice
expressing OvPrP encoding either ARQ (Baron et al., 2004) or VRQ (Tamguney
et al., 2009a). Studies with sheep revealed that five combinations of the above
polymorphisms appeared with any degree of frequency, and they are ARR, ARQ,
AHQ, ARH and VRQ (Belt et al., 1995; Ikeda et al., 1995). In addition, sheep
homozygous for ARR and VRQ are most resistant and susceptible to scrapie,
respectively (Goldmann et al., 1994). In contrast, A136 and V136 are most
susceptible and resistant to CH1641, respectively (Goldmann et al., 1994).
Taken together, numerous studies of scrapie isolates have continuously shown
that scrapie susceptibility is strongly linked to polymorphisms (Hunter, 2007);
however, the molecular mechanisms that link the PrP genotype to scrapie
susceptibility and incubation period continued to be poorly understood.
Immunological tools that are able to distinguish polymorphic alleles
especially at codon 136 and 171 are extremely useful in studying the effects of
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polymorphisms on scrapie propagation. The previous studies have shown
monoclonal antibodies (mAbs) to be capable of distinguishing OvPrP between
Q171 and R171 alleles (Bilheude et al., 2007; Jacobs et al., 2011; Moudjou et al.,
2004), and four antibodies are available to differentiate the OvPrP 171
polymorphism. Moudjou et al. produced two mAb antibodies; mAb V5 identifies
R171, mAb V61 identifies Q171. Another mAb, 2A11, was produced by a French
group and had reactivities with Q and H but not R at codon 171 (Bilheude et al.,
2007). The Langeveld group used mAb SAF84, which recognizes Q at codon
171, to demonstrate that substantially reduced level of OvPrPSc with R171 was
converted under conditions of co-expression of Q171 and R171 (Jacobs et al.,
2011). However, the mAb known as PRC5 is the first antibody to differentiate
OvPrP alleles expressing A and V at codon 136 (Kang et al., 2012), and, we
show here, was additionally able to provide insight into polymorphic effects on
scrapie conversion.
In the present study, we employ transgenic and immunological tools to
assess the mechanisms by which the OvPrP 136 polymorphism controls scrapie
susceptibility. The use of mouse mAb PRC5 enabled differentiation of OvPrPA136 from OvPrP-V136 in Tg(OvPrP) mice co-expressing A136 and V136. With
those tools, we could pursue the following three questions regarding the effects
of co-expressing A136 and V136 alleles on the replication of scrapie.
(1) Are OvPrP-A136 and OvPrP-V136 independently converted to PrPSc, and
their properties also independently maintained?
(2) Does conversion of OvPrPC-V136 dominate that of OvPrPC-A136?
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(3) Does expression of either allele inhibit conversion of the other?
In light of the study on the Q171R polymorphism (Jacobs et al., 2011) and of
above questions, we hypothesized that OvPrPC-V136 was preferentially
converted to PrPSc under co-expressions of OvPrPC-A136 and OvPrPC-V136,
and that the survival time of SSBP/1 in Tg(OvPrP-A/V136) would be relatively
longer than SSBP/1-inoculated Tg(OvPrP-V136) mice.
First, heterozygous Tg(OvPrP) mice expressing the A and V at codon 136
(Tg(OvPrP-A/V136)) were generated and intracerebrally inoculated with SSBP/1
scrapie prions. When SSBP/1-inoculated animals developed disease, the
properties of OvPrPSc-A136 and OvPrPSc-V136 were examined by western
blotting and histoblotting analyses using mAb anti-PrP PRC5 and 6H4. Next, the
kinetics of PrPSc conversion were studied in relation to the interactions of multiple
allelic forms of PrPC to different allelic forms of PrPSc using protein misfolding
cyclic amplification (PMCA). We demonstrated for the first time that the
templating characteristics including the kinetics of conversion and properties of
PrPSc (deposition patterns) are independently unique to each allele. Moreover,
the present study showed that the templating characteristics of OvPrPSc-V136
are dominant over OvPrPSc-A136 when both of the alleles are present.

Materials and Methods
Generation of ovine transgenic mice. Hemizygous Tg mice expressing ovine
PrP encoding either A or V at residue 136 were previously generated and are
referred to as Tg(OvPrP-A136)3533+/- and Tg(OvPrP-V136)4166+/-, respectively
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(Green, 2007). Briefly, ovine PrP (OvPrP) ARQ and VRQ open reading frame
cassettes containing the mouse signal peptide instead of an ovine signal peptide
were obtained from Dr. Nora Hunter. The OvPrP-ARQ and OvPrP-VRQ
sequences were cloned into the cosSHa.Tet cosmid expression vector for
transgene expression as described previously (Scott et al., 1992). The purified
OvPrP-ARQ and OvPrP-VRQ DNA were then microinjected into the pronuclei of
fertilized FVB/Prnp0/0 and wild-type FVB oocytes, respectively. Positive
transgenic founders were identified by polymerase chain reaction (PCR)
screening of the genomic DNA. Tg(OvPrP) mice were backcrossed to a Prnp
knockout (Prnp0/0) background to maintain hemizygous transgenic lines. To
produce Tg(OvPrP-A/V136) heterozygous mice, homozygous lines of Tg(OvPrPA136) and Tg(OvPrP-V136) were produced, and Tg(OvPrP-A136)+/+ and
Tg(OvPrP-V136)+/+ homozygous mice were mated to generate a heterozygous
line of Tg(OvPrP-A/V136) mice expressing OvPrP with A/V at residue 136. The
relative expression levels of PrP in the brains of each Tg mouse line were
determined by comparison with PrP expressed in the brains of wild-type FVB
mice on western blots using anti-PrP mAb 6H4 (Prionics).

Analysis of sheep polymorphism at codon 136. Genomic DNA was extracted
from brain homogenates of healthy Tg(OvPrP-A136)3533+/- and Tg(OvPrPV136)4166+/- mice. The sense primer (5’-GGACAGGGCAGTCCTGGA-3‘) and
antisense primer (5’-GATGAGGAGGATCACAGGAGG-3') were used to amplify
the Prnp encoding sequence using PCR. The Prnp codon 136 polymorphism was
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assessed by digestion of the amplicons with endonucleases BspHI (New
England Biolabs. Inc.), and the digested products were analyzed on 1% agarose
gels.

Transmission studies and scrapie isolates. Three natural sheep scrapie
isolates SSBP/1, CH1641 and 48x35 and two goat scrapie isolates 76/12/14 and
76/12/22 were used for the transmission experiments to Tg mice. Classical
sheep scrapie isolate SSBP/1 is a pool of six to eight natural sheep scrapie
brains that were subsequently passaged through Cheviot sheep at the
Neuropathogenesis Unit (NPU), Edinburgh UK. The polymorphisms of the
original pooled sheep inoculum included VRQ, ARQ and possibly others
(Dickinson, 1976), but the genetic makeup of sheep propagating the
subsequently passaged SSBP/1 is unclear. The 48x35 sheep scrapie isolate was
recovered from a natural scrapie case in a heterozygous VRQ/ARQ Cheviot
sheep with L at codon 141 in the ARQ allele the NPU. CH1641 is also the result
of a naturally infected Cheviot sheep from the NPU flock. SSBP/1, 48x35, and
CH1641 were obtained from Dr. Nora Hunter, NPU. The US goat scrapie
76/12/14, and 76/12/14 isolates were obtained from Dr. Jason Bartz (Creighton
University, Omaha NE) and were the results of experimental studies at Creighton
University. In addition, two isolates of cervid adapted SSBP/1 were used. These
cervid adapted SSBP/1 isolates were generated by inoculating natural sheep
scrapie SSBP/1 into Tg(CerPrP)1536+/- and Tg(CerPrP-L132)1973+/-, which
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express wild-type deer PrP, and deer PrP genetically modified to express leucine
at residue 132, respectively, at the University of Kentucky (Green et al., 2008).
Natural isolates of US sheep scrapie positive and negative sheep brain
samples were collected from the scrapie flock in Idaho, and sheep were exposed
to scrapie either during young or adult ages. Those sheep brain samples were
obtained from Dr. Jürgen Richt (Kansas State University, Manhattan KS). The
genotyping of sheep PrP was performed by the laboratory at Idaho State
University.
Ten-percent brain homogenates of scrapie-positive brains were prepared
at 10% (w/v) in sterile phosphate buffered saline (PBS) lacking Ca2+ and Mg2+
ions by repeated extrusions through a series of needles of decreasing diameter
from 18- to 22- gauge. Ten-percent brain homogenates were further diluted to
1% (w/v) in PBS and thoroughly homogenized using a 26-gauge needle syringe.
Groups of 5-week-old Tg(OvPrP-A136)3533+/-, Tg(OvPrP-V136)4166+/- and
Tg(OvPrP-A/V136) mice were anesthetized with halothane and injected with 30
µl of 1% (w/v) brain homogenate intracerebrally into the right parietal lobe using a
26- gauge needle syringe. Hemizygous Tg(OvPrP-A136)3533+/- and Tg(OvPrPV136)4166+/- mice were inoculated with SSBP/1, CH1641, 48x35, 76/12/22, or
76/12/14, and cervid adapted SSBP/1. Tg(OvPrP-A/V136) mice heterozygous for
A/V codon 136 were inoculated with SSBP/1.

Determination of incubation time. The general health of the mice was
monitored on a daily basis. The onset of prion diseases was diagnosed by
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observation of the progressive development of at least three of the following
clinical signs: truncal ataxia, loss of extensor reflex, difficulty righting from a
supine position, plastic tail, head bobbing or tilting, kyphotic posture, circling and
paresis/paralysis. Animals were diagnosed when at least two investigators
agreed with the clinical manifestation of disease. In addition, selected animals
were recorded on video at the time of diagnosis and/or right before termination.
The incubation time of prion diseases is defined as a period of time from the day
of inoculation to the first day of the diagnosis. Therefore, the incubation time was
indicated in days post inoculation (dpi).

Western blot analysis. The right hemisphere of each brain was collected for
western blot analysis. Ten-percent brain homogenates, prepared as described
previously, were digested with 40 µg/ml of proteinase K (PK) (Roche) in the
presence of 2% sarkosyl for 1 hour at 37°C. The concentration of total protein in
each sample was determined by bicinchoninic acid assay. Undigested brain
samples were also examined. For the study of mAb PRC5, total protein
concentrations were standardized for each lane (40 µg per lane in Figure 4.1.).
Natural sheep and goat scrapie isolates were standardized for 20 µg
(undigested) and 150 µg (digested) of total protein per lane (Figure 4.5.). US
sheep scrapie isolates were standardized for 20 µg (undigested) and 80 µg
(digested) of total protein per lane (Figure 4.6.). In the transmission studies of
SSBP/1 into Tg mice, undigested and digested samples were standardized for 25
and 100 µg of total protein per lane, respectively (Figure 4.8.). Unless otherwise
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indicated, undigested samples were prepared by mixing 20 µl of 10% brain
homogenate with 40 µl of PBS and 20 µl of 4X sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) sample loading buffer (200 mM
Tris-HCl pH 6.8, 8% SDS, 40% glycerol, 50mM ethylenediaminetetraacetic acid
(EDTA), and 0.08% bromophenol blue), and 30 µl of the mixture was loaded in
each lane. For digested samples, 50 µl of 10% brain homogenate was prepared
in 200 µl of PBS in the presence of 2% sarkosyl and digested with PK. The
digested sample was mixed with 90 µl of 4X SDS-PAGE sample loading buffer.
Each lane contained with 100 µl of the sample mixture.
Proteins

were

resolved

by

discontinuous

SDS-PAGE

and

electrophoretically transferred to Immobilon-FL polyvinylidene difluoride (PVDF)
membranes (Millipore). The transferred membrane was blocked with 5% non-fat
milk

in

Tris-buffered

saline

containing

0.5%

Tween-20

(TBST)

and

immunoprobed with anti-PrP mAbs 6H4, PRC1 or PRC5 followed by horseradish
peroxidase-conjugated anti-mouse IgG secondary antibody. Proteins were
visualized using enhanced chemiluminescence (ECL Plus, GE Healthcare) using
an FLA-5000 scanner (Fujifilm Life Science). The expression levels of PrPC in
Tg(OvPrP) mice were determined by densitometric analysis of PrPC signals on
the western blot using MultiGauge (Fujifilm Life Science).

Histoblots. Histoblots were performed according to the protocol previously
described (Taraboulos et al., 1992). Briefly, 10 µm thick coronal brain sections
were prepared on uncoated glass slides and transferred to nitrocellulose
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membrane. The membranes were either treated or untreated with 1.8 mg/ml of
PK and probed with mAb 6H4 and PRC5 followed by alkaline phosphataseconjugated goat anti-mouse secondary antibody (Southern Biotech). Images
were documented with a NikonDMX 1200F digital camera in conjunction with
Metamorph software (Molecular Devices).

Protein Misfolding Cyclic Amplification (PMCA) Assay. Brains from healthy
Tg(OvPrP-A136)3533+/-, Tg(OvPrP-V136)4166+/- and FVB/Prnp0/0 mice were
perfused with 5 mM EDTA in PBS. Ten-percent brain homogenates of the
perfused brains were prepared in conversion buffer (150 mmol/L NaCl, 1.0%
Triton X-100 and Roche’s Complete Protease Inhibitor Cocktail in PBS) and
briefly centrifuged (60 seconds at 500 rpm) to spin down debris. The PrP
expression level in Tg(OvPrP-A136)3533+/- is twice as high as in Tg(OvPrPV136)4166+/- (Figure 4.7.C.). Therefore, the substrate of OvPrP-A/V136 was
prepared by mixing 10% brain homogenates of Tg(OvPrP-A136)3533+/- and
Tg(OvPrP-V136)4166+/- mice at 1:2 dilution. OvPrP-A136 substrate alone was
prepared by mixing 10% brain homogenates of Tg(OvPrP-A136)3533+/- mice with
an equal volume of 10% brain homogenate of FVB/Prnp0/0 mice. Undiluted 10 %
brain homogenate of Tg(OvPrP-V136)4166+/- mice was used for OvPrP-V136
substrate alone.
Ten-percent

brain

homogenates

of

SSBP/1-infected

Tg(OvPrP-

A136)3533+/- and Tg(OvPrP-V136)4166+/- diseased mice were used as SSBP/1A136 and SSBP/1-V136 seeds, respectively. The PMCA with SSBP/1-A136 seed
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was performed by serial dilutions of seed in substrate at 1:30, 1:90, 1:270 and
1:810 dilutions for a total of 48 cycles. The PMCA with SSBP/1-V136 seed was
performed with a fixed ratio of seed in substrate at 1:180 dilution, and samples
were collected every 2 hours during a total of 12 hours’ reaction (24 cycles).
Undiluted 10% brain homogenates of CH1641-infected Tg(OvPrP-A136)3533+/diseased mice were used as CH1641-A136 seed. The PMCA with CH1641-A136
seed was performed with a fixed ratio of seed to substrate at 1:60 dilution, and
samples were collected every 12 hours over the course of 48 hours (96 cycles).
One cycle is 20 seconds sonication followed by 30 minutes incubation at 37°C.
Controls were also prepared by incubating samples at 37°C for the duration
indicated above. The SSBP/1-V136 PMCA experiments were repeated three
times using three different seeds and substrates, and the CH1642-A136 PMCA
experiments were performed twice with two different seeds and substrates.
Amplified and control samples were digested with PK at a final concentration of
0.33 µg/µl and analyzed on western blots using mAb 6H4 and PRC5. Amplified
PrPSc was quantified by densitometric analysis of PrPC signals on the western
blot using MultiGauge (Fujifilm Life Science), and PrPSc signals were normalized
to signals of 37°C incubated controls at the same time points. The normalized
PrPSc values and standard errors of the mean were prepared in graphs using
GraphPad Prism 5 (GraphPad Software, Inc.).

Statistical

analysis.

Survival

curves

of

SSBP/1-inoculated

Tg(OvPrP-

V136)4166+/- and Tg(OvPrP-A/V136) mice were statistically analyzed using a

115

Log-rank test. Statistical analysis of western blot data from the SSBP/1-V136
PMCA and CH1641-A136 PMCA was performed using a one-way analysis of
variant (ANOVA) at the fixed time points separately. When appropriate,
differences between groups were probed using a Newman-Keuls post hoc test.
All data were analyzed with GraphPad Prism 5. Differences with P < 0.05 was
considered to be a significant and indicated with asterisks.

Comparative computational modeling of ovine PrP. Structural differences in
the A136 and V136 variants of ovine PrP (residues 114-228) were visualized in
VMD

(the

NAMD

molecular

dynamics

http://www.ks.uiuc.edu/Research/vmd/).

Each

visualizer,
of

the

two

available
structures

at
was

compared based on the 2.5-Å-resolution crystal structures of the corresponding
antibody-bound PrP variant (Eghiaian et al., 2004). The computational modeling
was performed in corroboration with Dr. Michel Sheetz (Center for Computational
Science, University of Kentucky).

Results
Distinguishing the OvPrP polymorphism between A136 and V136 using
mAb PRC5. Western blot analyses show that mAb PRC5 is able to recognize
PrP from a wide range of species including mouse, deer, elk, bovine, equine, and
human with methionine (M) or valine (V) 129 polymorphism (Figure 4.1.B.).
However, the reactivity of mAb PRC5 is limited to OvPrP-A136, and OvPrP-V136
is not recognized (Figure 4.1.B.). The expression of PrP in all species including
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OvPrP-V136 was confirmed in western blots probed with mAb 6H4 (Figure
4.1.A.). The absence of signals in FVB/Prnp0/0 (KO) samples show the
recognition of the antibodies is specific to PrP (Figure 4.1.). The ability to
distinguish OvPrP 136 polymorphism was further tested with increased numbers
of Tg(OvPrP) samples, and mAb PRC5 recognized only OvPrP-A136 samples
(Figure 4.2.B.). The PrP expression of Tg(OvPrP-V136)4166+/- and Tg(OvPrPA136)3533+/- was verified by mAb 6H4 (Figure 4.2.A.).
Next, brain homogenates from multiple diseased Tg(OvPrP-A136)3533+/and Tg(OvPrP-V136)4166+/- mice were assessed for the accumulation of PKresistant PrPSc using mAb PRC5. Consistent with previous data (Figure 4.1. and
4.2.), mAb PRC5 recognized PrPC-A136 as well as PrPSc-A136 in diseased
Tg(OvPrP-A136)3533+/- mice (Figure 4.3.B.).
The genotype of the Tg(OvPrP) mouse brain samples used to study the
characteristics of mAb PRC5 was verified by RFLP using endonuclease BspHI,
which recognizes the DNA sequence at V136 in ovine PrP and digests into two
fragments of 279 and 251 base pairs (bp). All of the OvPrP-V136 samples (V0-7)
showed two digested fragments of 279 and 251 bp, indicating that the genotype
of the samples matched with the expressed 136 polymorphism of PrP (Figure
4.4.). All of the OvPrP-A136 samples (A1-5) showed only undigested bands at
530 bp, confirming correspondence of PrP 136 polymorphism with the genotype.
Together, all the above data demonstrated that mAb PRC5 is a uniquely
appropriate tool for distinguishing the A or V OvPrP polymorphism at codon 136.

117

Furthermore, sheep and goat scrapie samples including three classical
sheep isolates SSBP/1, CH1641 and 48x35 and two goat isolates 76/12/14, and
76/22/15 isolates were characterized using mAb 6H4 and PRC5. The western
blot probed with PRC5 showed that SSBP/1 and 48x35 isolates contained a
lesser amount of OvPrPSc-A136 (Figure 4.5.). CH1641 sheep and two goat
scrapie isolates were recognized by both 6H4 and PRC5 (Figure 4.5.). The
presence of PrPC and absence of PrPSc in non-diseased sheep sample as well
as the absence of PrP signals in KO samples demonstrated that the ability to
detect disease-associated PrPSc in this assay.
Brain samples from the US sheep scrapie affected flock were examined
on western blots using mAb 6H4 and PRC5. The US sheep scrapie positive
samples showed PK resistant PrPSc (Figure 4.6.). However, low levels of PrPSc
were detected in one out of four samples homozygous for V at codon 136 and Q
at codon 171 and one sample heterozygous for A/V at codon 136, homozygous
for R at codon 154 and Q at codon 171 (Figure 4.6.A.). PK-resistant PrPSc was
absent in the scrapie negative samples (Figure 4.6.). The presence of OvPrPScA136 was identified in the samples heterozygous for A/V at codon 136 using
mAb PRC5 (Figure 4.6.B.). Three out of four samples of heterozygous A136V
polymorphism showed significantly low levels of OvPrPSc-A136, and only one
sample presented relatively higher levels of OvPrPSc-A136 (Figure 4.6.B.).
Interestingly, the expression of OvPrP-A136 was not identified by mAb PRC5 in
one scrapie negative sample heterozygous for A136V polymorphism (Figure
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4.6.B.); thus, the genotype of the sample should be validated by DNA
sequencing.

Susceptibility to multiple scrapie isolates is strongly dependent on OvPrP
A136V polymorphism. Transmission studies of scrapie isolates into Tg(OvPrPA136)3533+/- and Tg(OvPrP-V136)4166+/- mice, which were previously performed
in our group, are summarized in Table 4.1., and pertinent information includes
the origin of scrapie inocula, mean incubation time, attack rates and number of
animals inoculated with scrapie (Green, 2007). The transmission studies of
multiple

scrapie

isolates

demonstrated

that

Tg(OvPrP-A136)3533+/-

and

Tg(OvPrP-V136)4166+/- mice were vulnerable to prion infection, and the
susceptibility of the scrapie isolates was tightly regulated by OvPrP A136V
polymorphism. For instance, the attack rates in SSBP/1-inoculated Tg(OvPrPA136)3533+/- and Tg(OvPrP-V136)4166+/- mice were 100%; however, the
incubation times were significantly different between the Tg(OvPrP) mice (Table
4.1. and Figure 4.7.A.). SSBP/1-inoculated Tg(OvPrP-V136)4166+/- mice
developed disease at 132 ± 2 dpi, while SSBP/1-inoculated Tg(OvPrPA136)3533+/- mice required much longer times to develop disease, e.g. 412 ± 49
dpi (Table 4.1. and Figure 4.7.A.). On the other hand, CH1641 could produce
disease in Tg(OvPrP-A136)3533+/- mice at 310 ± 21 dpi, whereas not in
Tg(OvPrP-V136)4166+/- at >450 dpi (Table 4.1. and Figure 4.7.B.). The results of
the transmission studies in Tg(OvPrP) mice are consistent with previously
published sheep studies about the effects of polymorphisms on scrapie
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susceptibility, and it has been reported that OvPrP-V136 is more susceptible to
SSBP/1 and less susceptible to CH1641 (Goldmann et al., 1994). In addition, the
OvPrP-A136 is most resistant genotype for SSBP/1 but most susceptible for
CH1641 (Goldmann et al., 1994). Moreover, another UK sheep scrapie isolate
48x35 produced disease only in Tg(OvPrP-V136)4166+/- mice at 365 ± 21 dpi but
not in Tg(OvPrP-A136)3533+/- at >575 dpi, and the genetic susceptibility or
resistance of 48x35 isolate was similar to SSBP/1 (Table 4.1.). Two US goat
scrapie isolates 76/12/22 and 76/12/14 could produce disease in Tg(OvPrPA136)3533+/- at 313 ± 15 and 270 ± 3 dpi, respectively.
Interspecies transmission studies of SSBP/1 were previously performed
by inoculating SSBP/1 into Tg(CerPrP-M132) and Tg(CerPrP-L132) mice, and
both animals manifested clinical signs at 241 ± 16 and 290 ± 6 days, respectively
(Green et al., 2008). These cervid-adapted SSBP/1 prions were transmitted back
to Tg(OvPrP-A136)3533+/- and Tg(OvPrP-V136)4166+/- mice. As a result,
Tg(CerPrP-M132) mouse passaged SSBP/1 produced disease in Tg(OvPrPV136)4166+/- mice at 150 ± 5 dpi and Tg(OvPrP-A136)3533+/- mice at 231 ± 14
dpi (Table 4.1.), and the incubation times were extended in Tg(OvPrPV136)4166+/- mice and substantially shortened in Tg(OvPrP-A136)3533+/- mice,
when compared to the transmission date with original SSBP/1 in those Tg mice.
Tg(CerPrP-L132)

passaged

SSBP/1

produced

disease

in

Tg(OvPrP-

V136)4166+/- mice at 335 ± 14 dpi and Tg(OvPrP-A136)3533+/- mice at 248 ± 14
dpi (Table 4.1.), and the genetic susceptibility was inverted compared to the
transmission data of original SSBP/1 in Tg(OvPrP) mice. Thus, modification of
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the transmission properties of SSBP/1 occurred during the propagation of these
prions in the Tg(CerPrP) mice.
The above Tg mouse studies confirmed that the susceptibility and
resistance of SSBP/1 and CH1641 scrapie isolates were tightly regulated by the
OvPrP A136V polymorphism. Moreover, it was demonstrated that Tg(OvPrPA136)3533+/- and Tg(OvPrP-V136)4166+/- are ideal animal models to investigate
the underlying mechanisms of how the OvPrP genotype acts upon scrapie
susceptibility and incubation time. In addition, the use of mAb PRC5 makes it
possible to distinguish the A136V polymorphism and further to study the
conditions of co-expressing OvPrP-A136 and OvPrP-V136. To study the PrPSc
conversion in the heterozygous state, Tg(OvPrP-A/V136) mice was generated by
crossing homozygous Tg(OvPrP-A136)3533+/+ and Tg(OvPrP-V136)4166+/+.
The expression levels of PrPC in Tg(OvPrP-A136)3533+/-, Tg(OvPrPV136)4166+/- and Tg(OvPrP-A/V136) mouse brains were determined through
comparison with wild-type FVB mouse brains on western blots using mAb 6H4
and PRC5. Tg(OvPrP-A136)3533+/- mice express 30% higher levels of PrP, and
Tg(OvPrP-V136)4166+/- mice express 35% lower levels of PrP (Figure 4.7.C.).
The levels of PrP were 23% higher in heterozygous Tg(OvPrP-A/V136) mice
compared to FVB mice (Figure 4.7.C.). The levels of PrP in all three Tg(OvPrP)
mouse lines are fairly close to those of wild-type FVB mice. It is interesting to
note that Tg(OvPrP-V136)4166+/- mice express less PrP than Tg(OvPrPA136)3533+/- mice. However, SSBP/1-inoculated-Tg(OvPrP-V136)4166+/- mice
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developed disease with much shorter incubation times than do Tg(OvPrPA136)3533+/- mice (Table 4.1. and Figure 4.7.A.).

Ample replication of PrPSc-A136 was identified in SSBP/1-inoculated
Tg(OvPrP-A/V136) heterozygous mice. SSBP/1-inoculated Tg(OvPrP-A/V136)
mice manifested clinical signs at 105 ± 5 dpi and developed disease even faster
than Tg(OvPrP-V136)4166+/- mice (p<0.0001, Figure 4.7.A.). The accumulation
of PK-resistant PrPSc in the brains of SSBP/1-inoculated Tg(OvPrP-A/V136) mice
was examined by western blotting using mAb 6H4 and PRC5 along with the
control

brain

samples

of

SSBP/1-inoculatd

Tg(OvPrP-A136)3533+/-

and

Tg(OvPrP-V136)4166+/- mice (Figure 4.8.). All diseased Tg(OvPrP) mouse brains
contained PK-resistant PrPSc which could be detected on western blots with 6H4
(Figure 4.8.A.). The western blot probed with PRC5, only detects OvPrP-A136,
revealed that OvPrPC-A136 was already converted to PrPSc in Tg(OvPrP-A/V136)
mice at 105 ± 5 dpi (Figure 4.8.B.). Considering that SSBP/1-inoculated
Tg(OvPrP-A136)3533+/- developed disease at 412 ± 49 dpi (Table 4.1. and
Figure 4.8.), the conversion of OvPrPSc-A136 in SSBP/1-inoculated Tg(OvPrPA/V136) mice at around 110 days dpi was unexpected. Signals in brain
homogenates from SSBP/1-inoculated Tg(OvPrP-V136)4166+/- mice were absent
in the western blot with mAb PRC5, confirming PRC5 is capable to distinguish
OvPrP-A136 from OvPrP-V136 (Figure 4.8.B.).
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OvPrPSc-A136 acquired properties of OvPrPSc-V136 in SSBP/1-inoculated
Tg(OvPrP-A/V136) mice. To determine the global deposition patterns of PrPSc in
the CNS of diseased Tg mice, we analyzed coronal brain sections including the
following regions: septum to hippocampus, hippocampus to thalamus, mid-brain
to pons and oblongata from SSBP/1-infected Tg(OvPrP-A136)3533+/-, Tg(OvPrPV136)4166+/- and Tg(OvPrP-A/V136) mice and examined them by histoblots
using either mAb 6H4 or PRC5 in the presence or absence of PK (Figure 4.9.).
The use of mAb PRC5 made it possible to identify the presence of OvPrPScA136. Consequently, the punctate deposition pattern of OvPrPSc-A136 was
revealed in SSBP/1-inoculated Tg(OvPrP-A136)3533+/- by mAb PRC5 (left
images in Figure 4.9.) and 6H4 (data not shown). On the other hand, a diffuse
deposition pattern of OvPrPSc-V136 was observed in SSBP/1-inoculated
Tg(OvPrP-V136)4166+/- using mAb 6H4 (2nd image from right in Figure 4.8,);
however, the PrPSc-V136 signals were not identified by mAb PRC5 (2nd image
from left in Figure 4.8.), confirming that mAb PRC5 only identified OvPrP-A136.
Interestingly,

SSBP/1-inoculated

Tg(OvPrP-A/V136)

mice

presented

an

accumulation of OvPrPSc-A136, and the deposition pattern was diffuse, which
was indistinguishable from that of Tg(OvPrP-V136)4166+/- (right in Figure 4.8.),
suggesting that OvPrPSc-A136 acquires the properties of OvPrPSc-V136 in
SSBP/1-inoculated Tg(OvPrP-A/V136) mice. Additionally, the expression of PrPC
in the brains of diseased animals was confirmed by histoblotting in the absence
of PK (data not shown), and brain samples of uninfected animals showed only
PrPC but not PrPSc (data not shown). The absence of PrPC and PrPSc was
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confirmed in brain samples from KO mice, indicating the ability to detect diseaseassociated PrPSc.

Propagation of OvPrPSc-A136 with SSBP/1-V136 seed was promoted by the
presence of OvPrPSc-V136. The above immunoblotting data suggest that
OvPrPC-A136 used OvPrPSc-V136 as a template to convert itself to PrPSc. As a
result, OvPrPSc-A136 would appear to have acquired the property of OvPrPScV136 in SSBP/1-inoculated Tg(OvPrP-A/V136) mice. To further investigate the
interactions between PrPC and PrPSc under conditions of co-existence of
OvPrPC-A136 and OvPrPC-V136, we used PMCA to quantify the amplification of
PrPSc at subsequent multiple time points or serial dilutions of seed to substrate.
In addition, we examined whether either OvPrPC-A136 or OvPrPC-V136 was
preferentially converted to PrPSc with the homogenous genotype of SSBP/1-A136
or SSBP/1-V136 seeds, and whether the presence of either inhibited conversion
of the other.
In order to study the rates of PrPSc conversion, we collected samples
every 2 hours for a total of 12 hours of PMCA. As predicted, the amplification of
SSBP/1-V136 seed with the genotype matched substrate OvPrPC-V136 resulted
in the efficient propagation of OvPrPSc-V136 (Figure 4.10.B.). On the other hand,
SSBP/1-V136 was not able to convert OvPrPC-A136 to PrPSc by PMCA (Figure
4.10.A. and D.), suggesting that the interaction of OvPrPSc-V136 and OvPrPCA136 was not sufficient to produce OvPrPSc-A136. Interestingly, the propagation
of OvPrPSc-A136 was identified when both of OvPrPC-V136 and OvPrPC-A136
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substrates were mixed together (Figure 4.10.F.). The quantification of amplified
PrPSc signals showed that the conversion of OvPrPSc-V136 was first identified
after 6 hours of amplification, and the conversion of OvPrPSc-A136 was
recognized after 8 hours of amplification under the co-existence of both alleles
(Figure 4.11.), indicating that the preferential conversion of PrPSc-V136 was
followed by the propagation of OvPrPSc-A136. Moreover, the different rates of
conversion of PrPSc between OvPrP-A136 and OvPrP-V136 in the presence of
both alleles suggest that OvPrPSc-V136 helps the propagation of OvPrPSc-A136.
Statistical analyses were performed at fixed time points (2, 4, 6, 8, 10 or
12 hours separately) using a one-way ANOVA, and significant difference was
reported at 10 hours (p<0.0016) and 12 hours (p<0.01). A Newman-Keuls
multiple comparison post-hoc test showed the following groups are statistically
significant at 10 hours: A/V136-PRC5 vs. A/V136-6H4. Moreover, the NewmanKeuls reported that the following groups are also statistically significant at 12
hours: A/V136-PRC5 vs. V136-6H4.

SSBP/1-A136 produced successful conversion of PrPSc only with OvPrPCA136 substrate. PMCA of SSBP/1-A136 was performed in serial dilutions of
seed to substrate to see whether PrPSc could be amplified for 98 cycles (48
hours). The amplification of SSBP/1-A136 seed to OvPrPC-A136 substrate at
1:30, 1:90, 1:270 and 1:810 dilutions was able to produce PrPSc (Figure 4.12.A.
and D.). However, inefficient amplification of PrPSc-V136 was observed at 1:90
and 1:270 dilutions. PrPSc signals at 1:30 dilution in Figure 4.12.B. and E were
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most likely coming from the seed SSBP/1-A136. Since OvPrPSc-V136 would not
be recognized by mAb PRC5, the amplified signal on the western blot probed
with mAb PRC5 indicated that PrPSc signals at 1:30 dilution were from the seed.
Under the co-presence of OvPrP-A136 and OvPrP-V136 alleles, the PrPSc
conversion was not as efficient as the amplification with OvPrPC-A136 alone.
Some amplification of PrPSc was observed at 1:30 and 1:90 dilutions, but no
amplification of PrPSc was detected at 1:270 and 1:810 dilutions (Figure 4.12.C.
and F.). These data indicated that PMCA of SSBP/1-A136 was able to amplify
PrPSc with OvPrPC-A136 compared to OvPrPC-V136 or the mixture of both.

Reduced amount of PrPSc-A136 was amplified with CH1641-A136 seed in
PMCA when the both A136 and V136 alleles existed. PMCA of CH1641-A136
seed with OvPrP-A136, OvPrP-V136 and the mixture of both was performed
independently, twice, to examine the compatibility of the seed and substrates for
the conversion of PrPSc. In addition, the amplified samples were collected every
12 hours in a total of 48 hours amplification to study the rate of PrPSc conversion.
As predicted on the basis of the animal studies, the genotyped matched reaction
of CH1641-A136 seed and OvPrPC-A136 substrate produced OvPrPSc-A136
efficiently (Figure 4.14.A. and D.). However, inefficient amplification of OvPrPScV136 was observed with PMCA of CH1641-A136 (Figure 4.14.B.). When two
substrates were mixed, reduced amplification of OvPrPSc in PMCA of CH1641A136 was observed (Figure 4.14.C. and F.). Interestingly, the western blot probe
with mAb PRC5 showing only OvPrPSc-A136 allele displayed that the efficiency
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of OvPrPSc-A136 conversion was reduced remarkably (Figure 4.14.F.). Statistical
analyses were performed at fixed time points (12, 24, 36 or 48 hours separately)
using a one-way ANOVA, and statistical significance was reported at 24 hours
(**p<0.013). A Newman-Keuls multiple comparison post-hoc test showed the
following groups are statistically significant at 24 hours: A/V136-PRC5 vs. A136PRC5 and A/v136-6H4 vs. A136-PRC5. The quantification of PMCA amplified
signals from each group revealed that the amplification of OvPrPSc-A136 was
inhibited when two substrates were mixed (Figure 4.15.).
CH1641-A136 was compatible with OvPrPC-A136 but not OvPrPC-V136
for the conversion of PrPSc. Unlike SSBP/1-V136, the presence of another allele,
in this case OvPrP-A136, did not promote the conversion of incompatible allele
OvPrP-V136 in PMCA of CH1641-A136 under the co-presence of two alleles.
Instead, the presence of OvPrP-V136 obstructed conversion of OvPrPSc-A136.
These data suggest that the rates of PrPSc conversion were efficient when
the genotype of seed and substrate were identical. If the seed and substrate
carry different genotypes, the amplification of PrPSc becomes inefficient. In
addition, the rates of PrPSc conversion were also different among three scrapie
isolates. Even though the different effects of the A136V polymorphism on the
propagation of PrPSc were demonstrated by the animal and PMCA studies, it is
still not clear what are the differences between OvPrP-A136 and OvPrP-V136
besides in the primary structures.

127

Computational modeling of structures of OvPrP-A136 and OvPrP-V136
predicted local structural differences in the α-helices and the long-range
interaction between the β2-α2 loop and tyrosine at codon 228. To gain more
insight into possible conformational differences, we visualized the structures of
OvPrP-A136 and OvPrP-V136 corresponding to amino acid residues 114-228 in
VMD (Figure 4.17.). Each of the structures includes the disordered N-terminal
structure and three α-helices (H1-3) shown in red ribbons (Figure 4.17.). When
the structures of OvPrPA-136 and OvPrP-V136 were superimposed, the
composed image showed that the two structures were not aligned exactly the
same (Figure 4.18.). The most apparent difference between two OvPrP
structures was the orientation of Y at codon 228 in the C-terminal region
(indicated in a yellow circle in Figure 4.18.). In OvPrP-V136, the ring structure of
Y228 at the C-terminal region faced down and was positioned in close proximity
to the loop between the β2-sheet and α2-helix, suggesting the long-range
interaction of the Y at codon 228 and β2-α2 loop. On the other hand, the ring
structure of Y228 flipped away from the β2-α2 loop in OvPrP-A136. The NMR
structural study of tammar wallaby PrP reported a long-range interaction between
the β2-α2 loop and C-terminal region, which appeared to work together to control
the susceptibility to prions (Christen et al., 2009). Additionally, a series of the cell
culture studies in Chapter 3 above demonstrated that the interference of the
long-range interaction by the substitutions of amino acids in the β2-α2 loop and
C-terminal region altered susceptibility to prions (Figure 3.5 to 3.7.). Based on
those findings, we surmised that the difference in the orientation of Y228 is a
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possible explanation of differences in the susceptibility or resistance to classical
scrapie isolates.
Furthermore, the subtle differences between OvPrP-A136 and OvPrPV136 were found in the structures of three α-helices (H-1, H-2 and H-3), and
most conformational changes were concentrated in H-1. The N-terminal of H-1
was relaxed and C-terminal of H-1 opened up in OvPrP-A136; therefore, the
diameter of H-1 in OvPrP-V136 was relatively smaller than OvPrP-A136 (Figure
4.19.C.). In addition, the N-terminal of H-1 had less twist in OvPrP-A136. The
difference in H-2 was that the C-terminus had an additional twist in OvPrP-V136
but not OvPrP-A136 (Figure 4.19.A and B.). In more detail, the conformational
differences were found in the orientation of the following amino acid residues:
asparagine at codon 147 and glutamic acid at codon 155 in H-1, asparagine at
codon 176 and lysine at codon 188 in H-2, and glutamic acid at codon 203 in H-3
and Y at codon 228.

Discussion
Our transmission studies of classical sheep scrapie isolates in Tg(OvPrPA136)3533+/-

and

Tg(OvPrP-V136)4166+/-

mice

demonstrated

that

the

susceptibility and resistance to the scrapie isolates were consistent with the
previously reported sheep study (Goldmann et al., 1994). In contrast to the
findings reported in previous sheep transmission studies that the incubation time
of SSBP/1-affected sheep heterozygous for the A136V genotype rise between
those of sheep homozygous for A136 and V136 (Goldmann et al., 1994),
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SSBP/1-inoculated Tg(OvPrP-A/V136) heterozygous mice developed disease
even faster than did Tg(OvPrP-V136)4166+/- mice. This relatively rapid incubation
time might be associated with the propagation of both PrPSc-A136 and PrPScV136. Western blots and histoblots demonstrated that the conversion of
OvPrPSc-A136 occurred at around 100 dpi in SSBP/1-infected Tg(OvPrP-A/V136)
mice, and the deposition patterns of OvPrPSc-A136 were indistinguishable from
OvPrPSc-V136

under

co-expressions

of

OvPrP-A136

and

OvPrP-V136,

suggesting that the dominant conformational selection occurred during the
propagation of SSBP/1. PMCA of SSBP/1-A136, SSBP/1-V136 and CH1641A136 demonstrated that the rates of PrPSc conversion were different between
A136 and V136 polymorphisms. Furthermore, the comparative structural studies
revealed differences in the orientation of amino acid molecules located in three αhelices, resulting in the conformational differences between OvPrP-A136 and
OvPrP-V136. Taken together, the above data provide new models for explaining
how the polymorphism participates in the propagation of PrPSc as described
details in the section below.
The levels of PrP in Tg(OvPrP-A136)3533+/-, Tg(OvPrP-V136)4166+/- and
Tg(OvPrP-A/V136) mice are close to those found in wild-type FVB mice (Figure
4.7.). In this regard, those Tg mouse lines are unique compared to other
overexpressing Tg(OvPrP) mice, such as: TgOvPrP4 (3-fold to sheep),
TgOvPRC59 (3-fold to sheep), TgShp XI (4-8 fold), Tg338 (8-10 fold to sheep),
and Tg301 (8-fold to sheep) (Cordier et al., 2006; Kupfer et al., 2007; Le Dur et
al., 2005; Vilotte et al., 2001). Even though the levels of PrP in Tg(OvPrP-
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V136)4166+/- mice is half of the levels expressed in Tg(OvPrP-A136)3533+/- mice,
SSBP/1-inoculated Tg(OvPrP-V136)4166+/- mice developed disease much faster
than Tg(OvPrP-A136)3533+/- mice. Therefore, we feel justified in concluding that
susceptibility was primarily controlled by the A136V polymorphism instead of the
expression levels of PrP.
The unique immunological tool, mAb PRC5 distinguishing OvPrP-A136
from OvPrP-V136 allowed us to study the mechanism of conversion of SSBP/1
scrapie in Tg(OvPrP) mice. Western blots probed with mAb PRC5 presented
evidence that a significant amount of PrPSc-A136 was already converted in
SSBP/1-inoculated Tg(OvPrP-A/V136) heterozygous mice around 110 dpi. Even
though it is not certain whether the propagation of PrPSc-A136 occurred as early
as 110 dpi in SSBP/1-inoculated Tg(OvPrP-A136)3533+/- mice, which required
around 400 dpi, we unexpectedly found the ample conversion of PrPSc-A136 in
SSBP/1-inoculated Tg(OvPrP-A/V136) mice. The Langeveld group reported that
low levels of PK-resistant OvPrPSc-R171 in classical scrapie inoculated
Tg(OvPrP-A/V136, R/R154, R/Q171) heterozygous mice were detected using
mAb SAF84 which identifies OvPrP-Q171 (Jacobs et al., 2011). These studies
suggest that two polymorphisms at codon 136 and 171 within OvPrP serve
different functions in the propagation of PrPSc.
The deposition patterns of PrPSc have been well-characterized for prion
strain-typing in classical scrapie-affected sheep brains (Beck et al., 2010; Jeffrey
& Gonzalez, 2007; Spiropoulos et al., 2007) since the development of spongiosis
is not always the hallmark of prion pathogenesis in classical scrapie. This is
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especially true with regard to SSBP/1 (Begara-McGorum et al., 2002; Houston et
al., 2002) and to CH1641 (Foster & Dickinson, 1988a). In addition, the PrPSc
profiling on western blotting appears to be homogenous and does not provide
much information about differences in scrapie-affected brain samples (Jeffrey &
Gonzalez, 2007). It was also true in the present study that the western blot
profiles did not distinguish among A136, V136 and A/V136 samples (Figure 4.8.).
The deposition patterns of PrPSc in brains of scrapie-affected sheep homozygous
for ARQ/ARQ were described in terms of predominant “granular deposits” or
“highly distinctive deposits” (Beck et al., 2010; Jeffrey & Gonzalez, 2007;
Spiropoulos et al., 2007), all of which indicates punctate deposition patterns of a
sort also shown in SSBP/1-inoculated Tg(OvPrP-A136)3533+/- mice in the
present study (left images in Figure 4.9.). In contrast, the PrPSc profiling in
scrapie-affected sheep homozygous for VRQ/VRQ was illustrated as consisting
of “mild diffused” or “coalescing plaques” (Beck et al., 2010; Jeffrey & Gonzalez,
2007; Spiropoulos et al., 2007), consistent with the diffuse deposition pattern in
SSBP/1-inoculated Tg(OvPrP-V136)4166+/- mice (the 2nd image from right in
Figure 4.9.). The distinctive PrPSc profiling differences found between OvPrPA136 and OvPrP-V136 do correspond to the pathology of scrapie-diseased
sheep brains. Moreover, scrapie-affected sheep heterozygous for ARQ/VRQ
showed “coalescing plaques” or “widespread general neutrophil deposition”
(Beck et al., 2010; Spiropoulos et al., 2007), and these observations were also in
line with diffuse PrPSc deposition in SSBP/1-inoculated Tg(OvPrP-A/V136) mice
(right images in Figure 4.9.). Even though the previously reported studies used
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immunohistochemistry to profile the PrPSc deposition patterns, we consider that
the histoblotting technique used in the present study was sensitive enough to
represent the distinctive patterns of PrPSc in SSBP/1-inoculated Tg(OvPrP) mice.
In addition to the previously reported findings, the use of mAb PRC5 provided the
information exclusive to the OvPrPSc-A136 profiling, and the present study
showed that OvPrPSc-A136 could attain the properties of OvPrPSc-V136 upon coexpression of both alleles.
Furthermore, PMCA of SSBP/1-V136 demonstrated that the conversion of
OvPrPSc-A136 was assisted by the presence of OvPrP-V136 in the presence of
both alleles. Accordingly, it is hypothesized that a ‘dominant’ OvPrPSc-V136
conformation leads to forced templating of OvPrPC-A136. However, the
‘dominant’ conformational selection was not observed in PMCA of CH1641-A136.
This suggests that the templating mechanism of OvPrPSc-V136 might be unique
to the SSBP/1 isolate. Bossers group reported that the OvPrP Q171R
polymorphism had a dominant-negative inhibition on the conversion of PrPCR171 to PrPSc, and that the inhibition was not due to the lack of binding or
interaction of PrPC-R171 to PrPSc (Rigter & Bossers, 2005). Hence, OvPrP-V136
has a dominant-positive templating effect, while OvPrP-R171 has a dominantnegative inhibition. Thus, the ‘dominant’ templating mechanism of OvPrPSc-V136
might be unique to the 136 polymorphism. Together, the above data indicate that
the scrapie susceptibility-linked polymorphisms affect the conversion of PrPSc by
modulating the properties of both PrPC and PrPSc.
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Based on the animal and PMCA studies, I propose the potential
mechanisms of propagation of SSBP/1 as illustrated in Figure 4.13. The following
proposed models are based on the heterodimer template-associated model
(Cohen et al., 1994). Thus, PrPC is in equilibrium with an intermediate form of
PrP*, and the formation of PrP* is thought to be facilitated by a hypothetical
protein X (Kaneko et al., 1997; Telling et al., 1995; Telling et al., 1994). The
conversion of PrP* to PrPSc is a catalytic step, and the operative catalyst might
be protein X or other molecules. It is important to note that although natural
sheep scrapie isolate SSBP/1 consists of mainly a VRQ genotype, it is a pool of
multiple combinations of genotypes, suggesting that different conformations of
PrPSc are available in the isolate (a box on the top right corner in Figure 4.13.).
The first model in Figure 4.13. indicates that the conversion of OvPrPSc-V136 is
efficient with the genotype matched SSBP/1-V136, therefore, the survival time of
SSBP/1-inoculated Tg(OvPrP-V136) mice is relatively shorter than Tg(OvPrPA136) mice. On the other hand, the propagation of SSBP/1-A136 with OvPrPCA136 is not as efficient a process as the propagation of SSBP/1-V136 with
OvPrPC-V136 even though the genotypes between PrPSc and PrPC are identical.
Therefore, the survival time of SSBP/1-inoculated Tg(OvPrP-A136) mice is much
longer due to the slow conversion rate of OvPrPSc-A136 (2nd model in Figure
4.13.). In those proposed models, the conformations of PrPSc differ between
OvPrPSc-V136 (pentagon) and OvPrPSc-A136 (triangle), inasmuch as the
histoblotting data showed diffuse vs. punctate deposition patterns of PrPSc in
SSBP/1-inoculated Tg(OvPrP-V136)4166+/- and Tg(OvPrP-A136)3533+/- mice,
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respectively (Figure 4.9.). The last model in Figure 4.13. indicates that OvPrPCA136 and OvPrPC-V136 are co-expressed, the conversion of OvPrPSc-V136
occurs followed by the conversion of OvPrPSc-A136. The intermediate forms of
OvPrP*-V136 and OvPrP*-A136 interact to transform the conformation of
OvPrP*-A136 into the conformation of OvPrP*-V136, and the adaptation of
OvPrP*-V136 conformation in PrP*-A136 allows SSBP/1-V136 to become a
template for the conversion to PrPSc. Therefore, the conformation of OvPrPScA136 is identical to OvPrPSc-V136. The histoblots probed with mAb PRC5, which
identifies only OvPrP-A136, indicated that the diffuse deposition patterns of
OvPrPSc-A136

in

SSBP/1-inoculated

Tg(OvPrP-A/V136)

mice

were

indistinguishable from the pattern in SSBP/1-inoculated Tg(OvPrP-V136) mice
(Figure 4.9.). In the final proposed model, the conversion of OvPrPSc-A136 is
promoted by the presence of the other allele, V136, and the conversion of both
alleles can promote quicker development of disease in SSBP/1-inoculated
Tg(OvPrP-A/V136) mice compared to Tg(OvPrP-V136) mice.
In the final proposed model (Figure 4.13.), the intermediate form PrP* may
play an important role in the conversion of SSBP/1-V136 with the co-expression
of OvPrPC-A136 and OvPrPC-V136. PrPC has been proposed to undergo a
dramatic unfolding of α-helices to generate the β-sheet rich structure of PrPSc
(Cobb et al., 2007; Lu et al., 2007). The presence of unfolded intermediates of
PrP has been detected (Chen et al., 2011), and these intermediate forms are
proposed as a more proximal precursor of PrPSc than PrPC (Roder & Colon,
1997). The kinetic unfolding study of OvPrP ARQ and ARR identified a
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population of intermediates formed during unfolding and refolding candidates.
ARQ resulted in a larger population of unfolded intermediates compared to ARR,
suggesting that differences in the population of intermediates can govern the
susceptibility to scrapie isolates (Chen et al., 2011). In general, ARR is a more
resistant allele for classical sheep scrapie isolates (Goldmann et al., 1994).
These previously published studies support the involvement of unfolded
intermediate isoforms of PrPC in the structural conversion of PrPSc as well as the
susceptibility to scrapie.
The propagation mechanisms of SSBP/1-A136 and CH1641-A136 exhibit
similarities in the effects of the A136V polymorphism with co-expressions of
OvPrPC-A136 and OvPrPC-V136. When only OvPrPC-A136 is available, does
propagation of OvPrPSc-A136 occur. However, the propagation of OvPrPSc-A136
is interfered with when OvPrPC-V136 is also available for the conversion of PrPSc
(Figure 4.16.). Even though the inhibitory effect of OvPrP-V136 was observed in
PMCA of CH1641-A136 and SSBP/1-A136, it is not clear which isoforms of PrPC,
PrP* or PrPSc inhibit the conversion of OvPrPSc-A136 in the presence of both
alleles. The question arises as to whether the SSBP/1-A136 isolate becomes
more similar to CH1641-A136 or whether CH1641-A136 is originated from a
SSBP/1-A136 isolate.
To answer these questions, we consider that the deposition patterns of
PrPSc and neuropathological examinations in either CH1641-A136 or SSBP/1A136-inouclated animals would be informative. Serial passage of SSBP/1-A136
into Tg(OvPrP-A136) mice might answer whether SSBP/1-A136 can adapt
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different strain properties, such as those of CH1641. For example, an incubation
time might become similar to CH1641-inoculated mice, and/or OvPrP-V136 might
become no longer susceptible to SSBP/1-A136.
Our interspecies transmission studies of cervid adapted SSBP/1 isolates
in Tg(OvPrP-A136)3533+/- and Tg(OvPrP-V136)4166+/- mice demonstrated that
the properties of original SSBP/1 were altered during the incubation of SSBP/1 in
Tg(CerPrP-L132)1973+/- and Tg(OvPrP-M132) mice. The genetic susceptibility of
cervid adapted SSBP/1 isolates in Tg(OvPrP-A136)3533+/- and Tg(OvPrPV136)4166+/- mice turned out to be completely different from original SSBP/1.
These studies indicated that new prion strains could arise from an existing strain,
for example, SSBP/1 during the adaptation of PrPSc in new host species.
Biophysical structural studies demonstrated that the action of structural
change of PrPC required the unfolding of H1 to open up the globular domain
between the S1-H1-S2 and H2-H3 (Adrover et al., 2010; Eghiaian et al., 2007).
When PrPC undergoes unfolding, the S1-H1-S2 and H2-H3 domains were
separated while linked by the S2-H2 loop (Prigent & Rezaei, 2011). Therefore,
the conformation of the S2-H2 loop plays a role in oligomerization. The unfolding
process was initiated by binding hypothetical protein X to the S2-H2 loop
(Kaneko et al., 1997). The present computational studies comparing the
structures between OvPrP-A136 and OvPrP-V136 revealed that the majority of
differences were found in the H1, and the orientation of Y at codon 228 was
located in closer proximity to the S2-H2 loop in OvPrP-V136 but not in OvPrPA136. These findings suggest that the structural differences between the
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polymorphic variants are associated with the susceptibility to scrapie. It might be
that either protein X or PrPSc favors one conformation over the other to trigger the
unfolding events of PrPC to obtain the β-sheet rich structure of PrPSc, ultimately
leading to oligomerization of PrPSc.
In conclusion, the templating characteristics including the kinetics of
conversion and properties of PrPSc found in the propagation of SSBP/1 appeared
to be unique to the scrapie isolate. Under conditions of co-expression, OvPrPCV136

facilitates

the

conversion

of

OvPrPSc-A136,

and

the

templating

characteristics of OvPrPSc-V136 are dominant over OvPrPSc-A136. On the other
hand, CH1641 does not have the same templating characteristics, and the
scrapie susceptibility-linked polymorphisms could control the conversion of PrPSc
by modulating both PrPC and PrPSc.
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Table 4.1. Transgenic modeling of the OvPrP 136 polymorphism on scrapie
susceptibility. Incubation times indicate days post inoculation (dpi) in mean ±
SEM (standard error of the mean). ND indicates that transmission studies of the
goat scrapie isolates into Tg(OvPrP-V136)4166+/- were not performed.

Mean incubation time (± SEM) days,
(n/n0)
Tg(OvPrP-

Tg(OvPrP-

Scrapie
Isolate

Origin

SSBP/1

UK Sheep

132 ± 2 (8/8)

412 ± 49 (6/6)

48x35

UK Sheep

365 ± 21 (7/7)

>575 (0/5)

CH1641

UK Sheep

> 450 (0/5)

310 ± 21 (6/6)

76/12/22

US Goat

ND

313 ± 15 (7/7)

76/12/14

US Goat

ND

270 ± 3 (4/4)

Cer-SSBP/1

Tg(CerPrP)1536+/-

150 ± 5 (7/7)

231 ± 14 (7/7)

Cer-SSBP/1

Tg(CerPrP-L132)1973+/-

335 ± 14 (8/8)

248 ± 14 (4/4)

V136)4166

139

+/-

A136)3533

+/-

KO

FVB

Deer

Elk

Bovine Equine

A

Human Human Ovine
M129 V129 V136

Ovine
A136

B

Figure 4.1. Anti-PrP mAb PRC5 is capable of distinguishing the ovine PrP
polymorphism alanine from valine at codon 136. Western blot analyses of
brain homogenates from Tg mice expressing multiple species of PrP shows mAb
PRC5 has reactivities with a wide-range of PrP species but not OvPrP-V136. A.
Western blot probed with anti-PrP mAb PRC1 shows the presence of PrP in both
OvPrP-A136 and OvPrP-V136 samples. B. The western blot including the same
PrP samples determined in the western blot with mAb PRC1 (A) was probed with
mAb PRC5 shows that the absence of PrP signals in OvPrP-V136 but the
presence of the signals in OvPrP-A136, indicating that PRC5 is an OvPrP-A136
specific antibody. FVB is a wild-type mouse. A Prnp0/0 knockout (KO) is used as
a negative control. Molecular markers indicate 50, 40, 30 and 20 kDa from top to
bottom.
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Genotype

V136

ID V1

A

1

A136

V2

A1

A2

2

3

4

V136

A136

V3

V4

V5

V6

V7

A3

A4

A5

5

6

7

8

9

10

11

12

B

Figure 4.2. Further testing the specificity of mAb PRC5 against OvPrP-A136
polymorphism with a larger number of Tg(OvPrP) samples. Lane 1, 2 and 5
to 9 include brain homogenates from Tg(Ovine PrP-V136)4166+/-. Lane 3, 4 and
10 to 12 contain brain homogenates from Tg(Ovine PrP-A136)3533+/-. Animal
identifications (ID) are indicated above lane numbers. A. Western blot probed
with mAb 6H4 shows that all brain samples include PrP. B. Western blot including
the same samples presented in A was examined with mAb PRC5. Consistent
with the previous data (Figure 4.1.), PRC5 distinguishes OvPrP-A136 from
OvPrP-V136. Molecular markers indicate 50, 40, 30 and 20 kDa from top to
bottom.
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Genotype

V136
V1

ID

A

B

1

PK -

A136

V6
2

+

3

-

V7

4

+

5

-

A1
6

+

7

-

A2

A3

A4

8

9

10

11

12

13

14

+

-

+

-

+

-

+

Figure 4.3. Anti-PrP mAb PRC5 can recognize both PrPC and PrPSc on
western blotting. Representative samples from the previous experiment (Figure
4.2.) was either digested or undigested with proteinase K (PK) and tested
whether mAb PRC5 is able to recognize PrPSc. Lane 3 to 6 include brain
homogenates from diseased Tg(OvPrP-V136)4166+/- mice. The animal with an ID
number V1 was inoculated with sheep scrapie CH1641, which could not produce
disease in Tg(OvPrP-V136)4166+/-. Thus, the signal of PrPSc should be absent as
shown in lane 2. Lane 7 to 14 contains brain homogenates from diseased
Tg(OvPrP-A136)3533+/- mice. PK digested (+) and undigested (-) samples are
examined in the both blots. A. The presence of PrPC in all of the samples was
confirmed by the western blot with mAb 6H4. B. The same samples examined in
the above western blot (A) were also determined on another western blot with
mAb PRC5. The western blot with PRC5 was able to recognize both PrPC and
PrPSc of Tg(OvPrP-A136)3533+/- samples. Molecular markers indicate 50, 40, 30
and 20 kDa from top to bottom.
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Tg(OvPrP-V136)4166
ID
BspHI

V2

V1

V0

V4

V5

+/-

V6

Tg(OvPrP-A136)3533
V3

V7

A1

A2

A5

A3

+/-

A4
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Figure 4.4. Restriction Fragmented Length Polymorphism (RFLP) validated
that the genotype was corresponding to the expressed 136 polymorphism
of PrP. The genotypes of the previously analyzed mouse samples including both
Tg(OvPrP-A136)3533+/- and Tg(OvPrP-V136)4166+/- were validated by RFLP
analysis. Restriction endonuclease enzyme BspHI recognizes the DNA sequence
at V136 in OvPrP and digests into two fragments of 279 and 251 bp, whereas,
OvPrP-A136 remains undigested (530 bp). All of eight Tg(OvPrP-V136)4166+/mouse samples (ID numbers V0-V7) show digested fragments at 279 and 251
bp. Five samples from Tg(OvPrP-A136)3533+/- mice (ID numbers A1-A5) show
only undigested bands at 530 bp. The above RFLP data confirmed that the
genotype of the samples matched with the expressed 136 polymorphism of PrP
(Figure 4.2. and 4.3.). Molecular markers indicate 1000, 850, 650, 500, 400 and
300 bp from top to bottom.
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B

PK -

76/12/22

76/12/14

48x35

CH1641

SSBP/1

OvPrP-V136

OvPrP-A136

Non-diseased

76/12/22

76/12/14

48x35

CH1641

SSBP/1

OvPrP-V136

OvPrP-A136

KO
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A

+

Figure 4.5. Natural sheep and goat scrapie prions were recognized by mAb
PRC5. Brain homogenates of sheep brains with SSBP/1, CH1641 or 48x35
sheep scrapie prions and of goat brains with 76/12/14 or 76/12/22 goat prions
were examined whether mAb PRC5 was able to recognize those sheep and goat
samples on western blots. Prnp knockout FVB mouse brains (KO) were used as
a negative control. Non-diseased indicates a brain homogenate of healthy sheep,
and it was used as a non-diseased control for the absence of PrPSc. OvPrP-A136
and OvPrP-V136 includes brain homogenates from SSBP/1-inoculated
Tg(OvPrP-ARQ)3533+/- and Tg(OvPrP-VRQ)4166+/- mice, respectively.
Proteinase K (PK) digested (+) samples were examined along with undigested (-)
samples. A. Western blot probed with mAb 6H4 presents that all brain samples
contain PrP. B. The same samples presented in the above western blot (A) were
also examined on another western blot probed with mAb PRC5. Molecular
markers indicate 50, 40, 30 and 20 kDa from top to bottom.
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Figure 4.6. Anti-PrP mAb PRC5 was able to recognize an A136 allele in
sheep brain samples with or without US sheep scrapie. Different genotypes
of sheep samples from a US sheep scrapie affected flock were examined on
western blots with mAb PRC5. Proteinase K (PK) digested (+) and undigested
samples (-) are determined on the bots. A. The western blot probed with mAb
6H4 presents all brain samples contain PrP. B. The western blot including the
same samples examined on the above blot (A) was analyzed with mAb PRC5.
The blot with PRC5 recognized only an A136 allele in homozygous or
heterozygous samples, corresponding to the genotype indicated above. Three
OvPrP polymorphisms at codons 136, 154 and 171 are indicated, and a blank
box indicates a genotype at the position was not reported. Molecular markers
indicate 40, 30 and 20 kDa from top to bottom.
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Figure 4.7. Tg(OvPrP) mice expressing A136, V136 or A and V136 showed
different susceptibilities to SSBP/1 and CH1641. A. Survival curves of
SSBP/1-inoculated
Tg(OvPrP-A136)3533+/-,
Tg(OvPrP-V136)4166+/and
Tg(OvPrP-A/V136) mice were shown. The mean incubation time for Tg(OvPrPA136)3533+/- and Tg(OvPrP-V136) 4166+/- are 412 ± 49 days post inoculation
(dpi) (attack rate, 6/6) and 132 ± 2 dpi (attack rate, 8/8), respectively. SSBP/1inoculated Tg(OvPrP-A/V136) mice heterozygous for A and V at codon 136
developed disease with a shorter incubation time at 105 ± 5 dpi (attack rate, 7/7).
The Log-rank test analysis showed that each incubation time was statistically
different (p<0.0001). B. Survival curves of CH1641-inoculated Tg(OvPrPA136)3533+/-and Tg(OvPrP-V136)4166+/- mice are presented. Unlike SSBP/1,
CH1641-inoculated Tg(OvPrP-V136)4166+/- mice (n = 5) failed to develop
disease at > 450 dpi. CH1641-inoculated Tg(OvPrP-A136)3533+/- mice
developed disease at 310
21 dpi (attack rate, 6/6). The above data shows the
susceptibility of SSBP/1 and CH1641 to Tg(OvPrP) mice is associated with the
136 polymorphism. C. The expression levels of PrP in Tg(OvPrP-A136)3533+/-,
Tg(OvPrP-V136)4166+/- and Tg(OvPrP-A/V136) mouse brains were examined
through comparison with wild-type FVB mice on western blotting using mAb 6H4.
Tg(OvPrP-A136)3533+/- mice express 30% higher levels of PrP, and Tg(OvPrPV136)4166+/- mice express 35% lower levels of PrP. The levels of PrP were 23%
higher in heterozygous Tg(OvPrP-A/V136) mice compared to FVB mice. The
concentrations of total protein were standardized to 60, 30 and 15 µg per lane. A
FVB Prnp0/0 (KO) was used as a negative control. Molecular markers indicate 36,
28 and 19 kDa from top to bottom.
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Figure 4.8. Ample signals of PrPSc-A136 were observed in SSBP/1inoculated Tg(OvPrP-A/V136) heterozygous mouse brains. Western blotting
analyses show that protease-resistant OvPrPSc was accumulated in the SSBP/1inoculated brains from Tg(OvPrP-A136)3533+/-, Tg(OvPrP-V136)4166+/- and
Tg(OvPrP-A/V136) mice. A. Both OvPrP-A136 and OvPrP-V136 alleles were
shown on the blot with mAb 6H4. Three samples from each group are shown and
all included PrPSc in the brains. B. OvPrP-A136 but not OvPrP-V136 alleles was
shown on the blot with mAb PRC5. Interestingly, OvPrPSc-A136 was
accumulated in SSBP/1-inoculated Tg(OvPrP-A/V136) mouse brains (lane 1012), indicating that OvPrP-A136 was already converted to PrPSc at 105 ± 5 dpi. It
is important to note that SSBP/1-inoculated Tg(OvPrP-A136)3533+/- mice
required much longer incubation time to develop disease at 412 ± 49 dpi (Figure
4.7.A.). Proteinase K (PK) digested (+) and undigested (-) samples were
analyzed. Lane1, PK(-) Prnp knockout FVB (KO); lane 2, PK(-) Tg(OvPrPA136)3533+/-; lane 3, PK(-) Tg(OvPrP-V136)4166+/-; lane 4-6, PK(+) Tg(OvPrPA136)3533+/-; lane 7-9, PK(+) Tg(OvPrP-V136)4166+/-; lane 10-12, PK(+)
Tg(OvPrP-AV136). Molecular marker indicates 53, 36, 28 and 19 kDa from top to
bottom.
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Figure 4.9. OvPrPSc-A136 acquires properties of OvPrPSc-V136 in SSBP/1
diseased Tg(OvPrP-A/V136) mice. Histoblots were treated with proteinase K
(PK) and determined with either mAb 6H4 or PRC5. Punctate deposition of
OvPrPSc-A136 was observed in SSBP/1-inoculated Tg(OvPrP-A136)3533+/mouse brains at the levels of the mid-brain, pons and oblongata (left images). On
the other hand, diffused deposition patterns were observed in SSBP/1-inoculated
Tg(OvPrP-V136)4166+/- mouse brains (second from right images). As shown in
the previous western blots (Figure 4.8.), the conversion of OvPrPSc-A136 allele in
SSBP/1-inoculated Tg(OvPrP-A/V136) heterozygous mouse brains was
observed in histoblots as well. The histoblot data revealed that deposition
patterns of OvPrPSc-A136 were diffused and identical to OvPrPSc-V136 under the
state of co-expression of A136 and V136 (right images), indicating the
recruitment of PrPC-A136 by PrPSc-V136.
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Figure 4.10. OvPrP-A136 allele was converted to PrPSc only in the presence
of OvPrP-V136 allele by PMCA with SSBP/1-V136 seed. SSBP/1 diseased
Tg(OvPrP-V136)4166+/- mouse brains were used as SSBP/1-V136 seed. Brain
homogenates from healthy Tg(OvPrP-A136)3533+/- (A, D) and Tg(OvPrPV136)4166+/- (B, E) mice were mixed with the SSBP/1-V136 seed. A mixture of
brain homogenates from Tg(OvPrP-A136)3533+/- and Tg(OvPrP-V136)4166+/mice at the ratio corresponding to equal PrP expression levels was prepared and
mixed with the SSBP/1-V136 seed (C, F). Amplified (A) and 37°C incubated
control (C) samples were collected every 2 hours in the total of 12 hours of
PMCA (48 cycles). The samples were digested with PK and analyzed for PrPSc
conversion on western blots along with controls including undigested (-)
substrates (lane 1), digested (+, lane 2) and undigested (lane 3) seed. In addition
to those controls, PMCA reactions without seed were also prepared, and those
samples were digested with PK (lanes 4, 5). Western blots A, B and C were
probed with mAb 6H4 showing a total PrPSc, and blots D, E and F were probed
with mAb PRC5 presenting only OvPrPSc-A136. Unsuccessful amplification of
OvPrPSc-A136 was observed in OvPrP-A136 substrate alone (A, D). On the other
hand, OvPrP-V136 allele was efficiently converted to PrPSc (B). The mixture of
OvPrP-A136 and OvPrP-V136 showed amplification of PrPSc (C, F). Those data
showed that amplification of OvPrPSc-A136 was observed only in the presence of
OvPrP-V136 alleles with SSBP/1-V136 (F), indicating that the recruitment of
OvPrPC-A136 by OvPrPSc-V136 promotes the OvPrPSc-A136 conversion.
Molecular marker indicates 53, 36, 28 and 19 kDa from top to bottom.
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Figure 4.11. Conversion of OvPrPSc-V136 appears to take place followed by
conversion of OvPrPSc-A136 in PMCA with SSBP/1-V136 seed. Three
independent experiments of PMCA with SSBP/1-V136 were performed, and
three experimental data were plotted in the graph. Amplified PrPSc signals were
1 to signals of 37°C incubated controls at the same time points.
normalized
Normalized PrPSc signals on western blots with mAb 6H4 presenting a total PrPSc
Sc
were shown
on western
0 in solid
2 lines. 4Normalized
6 PrP 8signals 10
12 blots with PRC5
presenting only OvPrP-A136 are plotted in dashed lines. The gradual increase of
amplified OvPrPSc-V136 is evidenced
Hoursin PMCA reactions with OvPrP-V136
substrate alone (blue solid line). Unsuccessful amplification of OvPrPSc-A136 is
observed in reactions with OvPrP-A136 substrate alone (pink solid and dashed
lines). However, amplification of OvPrPSc-A136 was observed only when
OvPrPSc-V136 was co-existed in PMCA reactions, indicating that the recruitment
of OvPrPC-A136 by OvPrPSc-V136 promotes the OvPrPSc-A136 conversion. Error
bars indicate standard errors of the mean. Statistical analyses were performed at
fixed time points (2, 4, 6, 8, 10 or 12 hours separately) using a one-way ANOVA,
and asterisks at 10 hours (**p<0.0016) and 12 hours (*p<0.01) indicate
significant difference. A Newman-Keuls multiple comparison post-hoc test
showed the following groups are statistically significant at 10 hours: A/V136PRC5 vs. A/V136-6H4. Moreover, the Newman-Keuls reported that the following
groups are also statistically significant at 12 hours: A/V136-PRC5 vs. V136-6H4.
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Figure 4.12. PMCA of SSBP/1-A136 produced successful conversion of
PrPSc only with OvPrPC-A136 substrate. PMCA of SSBP/1-A136 was
performed in serial dilutions of seed to substrate to see whether PrPSc could be
amplified after 98 cycles (48 hours). The amplification of SSBP/1-A136 seed to
OvPrPC-A136 substrate at 1:30, 1:90, 1:270 and 1:810 dilutions was able to
produce PrPSc (A. and D). However, inefficient amplification of PrPSc-V136 was
observed at 1:90 and 1:270 dilutions (B). PrPSc signals at 1:30 dilution (B and E)
were most likely coming from the seed SSBP/1-A136. Since OvPrPSc-V136
would not be recognized by mAb PRC5, the amplified signal on the western blot
probed with mAb PRC5 indicated that PrPSc signals at 1:30 dilution were from the
seed. Under the co-presence of OvPrP-A136 and OvPrP-V136 alleles, the PrPSc
conversion was not as efficient as the amplification with OvPrPC-A136 alone.
Some amplification of PrPSc was observed at 1:30 and 1:90 dilutions, but no
amplification of PrPSc was detected at 1:270 and 1:810 dilutions (C and F). These
data indicated that PMCA of SSBP/1-A136 was able to amplify PrPSc with
OvPrPC-A136 compared to OvPrPC-V136 or the mixture of both. Lanes 1:
undigested substrate, 2: undigested seed, 3: PK-digested seed, 4: PMCA
reaction without seed (No seed) incubated at 37°C without sonication, 5: No seed
incubated at 37°C with sonication, 6-13: PMCA samples at multiple dilutions.
PMCA samples (lanes 4 to 13) were digested with PK. Molecular marker
indicates 53, 36, 28 and 19 KDa from top to bottom.
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Figure 4.13. PrPSc conversion models of SSBP/1 in Tg(OvPrP) expressing
both A and V 136 polymorphism: a dominant OvPrPSc-V136 conformation
leading to forced templating of OvPrPC-A136. The above-proposed models
are based on the heterodimer template-associated model. In the models, PrPC is
in equilibrium with an intermediate form of PrP*, and the formation of PrP* is
thought to be facilitated by a hypothetical protein X. The conversion of PrP* to
PrPSc is a catalytic step, and the operative catalyst might be protein X or other
molecules. It is important to note that natural sheep scrapie isolate SSBP/1
consists of mainly a VRQ genotype, however, it is a pool of multiple combinations
of genotypes, suggesting that different conformations of PrPSc are available in
the isolate (a box on the top right corner). The first model indicates that the
conversion of OvPrPSc-V136 is efficient with the genotype matched SSBP/1V136, therefore, the survival time of SSBP/1-inoculated Tg(OvPrP-V136) mice is
relatively shorter than Tg(OvPrP-A136) mice. The second model describes that
the propagation of SSBP/1-A136 with OvPrPC-A136 is not as efficient a process
as the propagation of SSBP/1-V136 with OvPrPC-V136 even though the
genotypes between PrPSc and PrPC are identical. Therefore, the survival time of
SSBP/1-inoculated Tg(OvPrP-A136) mice is much longer due to the slow
conversion rate of OvPrPSc-A136. In those proposed models, the conformations
of PrPSc are different between OvPrPSc-V136 (pentagon) and OvPrPSc-A136
(triangle), inasmuch as the histoblotting data showed diffused vs. punctate
deposition patterns of PrPSc in SSBP/1-inoculated Tg(OvPrP-V136)4166+/- and
Tg(OvPrP-A136)3533+/- mice, respectively (Figure 4.9.). The last model explains
when OvPrPC-A136 and OvPrPC-V136 are co-expressed, the conversion of
OvPrPSc-V136 occurs followed by the conversion of OvPrPSc-A136. The
intermediate forms of OvPrP*-V136 and OvPrP*-A136 interact together to
transform the conformation of OvPrP*-A136 into the conformation of OvPrP*V136, and the adaptation of OvPrP*-V136 conformation in PrP*-A136 allows
SSBP/1-V136 to become a template for the conversion to PrPSc. Therefore, the
conformation of OvPrPSc-A136 is identical to OvPrPSc-V136. In the last proposed
model, the conversion of OvPrPSc-A136 is promoted by the presence of other
allele V136, and the conversion of both alleles can promote quicker development
of disease in SSBP/1-inoculated Tg(OvPrP-A/V136) mice as compared to
Tg(OvPrP-V136) mice.
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Figure 4.14. Presence of OvPrPC-V136 inhibits the amplification of OvPrPScA136 in PMCA with CH1641-A136 seed. PMCA of CH1641-A136 seed with
OvPrP-A136, OvPrP-V136 and the mixture of both was performed. Brain
homogenates from CH1641-inoculated Tg(OvPrP-A136)3533+/- mice was used
as CH1641-A136 seed and mixed with brain homogenates from healthy
Tg(OvPrP-A136)3533+/- (A, D) and Tg(OvPrP-V136)4166+/- (B, E) mice. A mixture
of brain homogenates from Tg(OvPrP-A136)3533+/- and Tg(OvPrP-V136)4166+/mice at the ratio corresponding to equal PrP expression levels was prepared and
amplified with CH1641-A136 (C, F). The amplified samples were collected every
12 hours in a total of 48 hours amplification to study the rate of PrPSc conversion.
The genotyped matched reaction of CH1641-A136 seed and OvPrPC-A136
substrate produced OvPrPSc-A136 efficiently (A and D). However, inefficient
amplification of OvPrPSc-V136 was observed with PMCA of CH1641-A136 (B).
When two substrates were mixed, reduced amplification of OvPrPSc in PMCA of
CH1641-A136 was observed (C and F). The western blot with mAb PRC5
showing only OvPrPSc-A136 allele displayed that the efficiency of OvPrPSc-A136
conversion was reduced remarkably (F). Samples incubated at 37°C without
sonication was used as control (C), and letter A indicates PMCA amplified
samples at 37°C with sonication. Lane 1, PK undigested (-) substrate OvPrPA136 (A, D), OvPrP-V136 (B, E) and mixture of OvPrP-A136 and OvPrP-V136 at
1:2 dilution (C, F); lane 2 and 3, PK (-) and digested (+) CH1641-A136 seed,
respectively; lane 4 and 5, digested PMCA reaction sample without seed (No
seed); lane 6-13, PK(-) and PK(+) PMCA samples. Molecular marker indicates
53, 36, 28 and 19 KDa from top to bottom.
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Figure 4.15. The OvPrPC-V136 allele suppressed
the conversion of PrPScA136-PRP5
A136 in the presence of the both alleles in PMCA with CH1641 seed. PMCA
V136-PRP5
of CH1641-A136 seed with OvPrP-A136, OvPrP-V136 and the mixture of both
was performed independently, twice, to examine A/V136-PRP5
the compatibility of the seed and
substrates for the conversion of PrPSc. Two independent experiments were
plotted in the graph. The signals of amplified PrPSc was normalized to the signals
1
of 37°C incubated
control in the same time points. The X-axis indicated a
duration of PMCA cycles in a total of 48 hours. Samples were collected every 12
Sc
hours. The Y-axis
the4 value of6 normalized
0 Sc indicates
2
8 PrP10signals.
12Solid lines are
normalized PrP signals from western blots with mAb 6H4 showing a total signal
Hours
of PrPSc. Dashed lines are normalized
PrPSc signals from western blots with mAb
Sc
PRC5 showing only OvPrP -A136. The efficient amplification of OvPrPSc-A136
(pink solid and dashed lines) and inefficient amplification of OvPrPSc-V136 (blue
solid line) were observed. The green dashed line shows inefficient amplification
of PrPSc-A136 in the presence of OvPrP-V136. Statistical analyses were
performed at fixed time points (12, 24, 36 or 48 hours separately) using a oneway ANOVA and showed significant difference indicating with an asterisk at 24
hours (*p<0.013). A Newman-Keuls multiple comparison post-hoc test showed
the following groups are statistically significant at 24 hours: A/V136-PRC5 vs.
A136-PRC5 and A/V136-6H4 vs. A136-PRC5.
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Figure 4.16. PrPSc conversion models of CH1641 in Tg(OvPrP) expressing
A136V polymorphism: an inhibitory effect of OvPrPC-V136 on the
propagation of OvPrPSc-A136. The above-proposed models are based on the
heterodimer template-associated model. In the models, PrPC is in equilibrium
with an intermediate form of PrP*, and the formation of PrP* is thought to be
facilitated by a hypothetical protein X. The conversion of PrP* to PrPSc is a
catalytic step, and the operative catalyst might be protein X or other molecules. It
is important to note that natural sheep scrapie isolate CH1641 consists of mainly
a A136 genotype, however, it is a pool of multiple combinations of genotypes,
suggesting that different conformations of PrPSc are available in the isolate (a box
on the right bottom corner). The first model describes that CH1641-A136 is able
to propagate OvPrPSc-A136 from OvPrP*-A136. The second model shows that
the conversion of OvPrPSc-V136 can happen but the process is inefficient.
OvPrPSc-V136 might be cleared by a cellular mechanism as soon as PrPSc is
produced. In addition, the rate of PrPSc conversion is slow enough that the
cellular mechanism is able to remove PrPSc before produce more PrPSc or
aggregates. Thus, CH1641-inoculated Tg(OvPrP-V136) mice did not develop
disease, and the accumulation of PK-resistant OvPrPSc was not observed in their
brains. The conformation of OvPrPSc is unknown. The last model explains the
propagation of CH1641-A136 under co-expressions of OvPrPC-A136 and
OvPrPC-V136. The presence of OvPrPC-V136 prevents the conversion of
OvPrPSc-A136; however, what isoforms of OvPrP-V136 among PrPC, PrP* or
PrPSc play a role in an inhibitory effect on the conversion of PrPSc is not clear.
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Figure 4.17. 3D structures of ovine PrP expressing either A or V 136
polymorphism. The structures of OvPrPA-136 and OvPrP-V136 corresponding
to amino acid residues 114-228 were visualized in VMD. Each of the structures
includes the disordered N-terminal structure and three α-helices (H1-3)
shown in red ribbons. The top molecule is ovine PrP (residues 114-228)
expressing alanine at codon 136. The bottom molecule is ovine PrP (residues
114-228) expressing valine at codon 136. OvPrP 136 polymorphism either
alanine (top) or valine (bottom) are shown in green.
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Figure 4.18. Composed 3D structures of ovine PrP expressing 136
polymorphism either alanine or valine. When the structures of OvPrPA-136
and OvPrP-V136 (residues 114-228) were superimposed, the composed image
showed that the two structures were not aligned exactly the same. The most
apparent difference between two OvPrP structures was the orientation of Y at
codon 228 in the C-terminal region (indicated in a yellow circle). Tyrosine at
codon 228 in the C-terminal region is facing down to locate in close proximity to
the β2-α2 loop in OvPrP-V136 but not OvPrP-A136. In OvPrP-V136, the ring
structure of Y228 at the C-terminal region faced down and was positioned in
close proximity to the loop between the β2-sheet and α2-helix, suggesting the
long-range interaction of the Y at codon 228 and β2-α2 loop. On the other hand,
the ring structure of Y228 flipped away from the β2-α2 loop in OvPrP-A136.
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Figure 4.19. Ribbon diagrams of the C-terminal domain of OvPrP (residues
114-228). A green circle indicates the location of codon 136. Blue dashed lines
indicate intramolecular hydrogen bonds. A. OvPrP-A136. B. OvPrP-V136. C.
Superimposed images of OvPrP-A136 and OvPrP-V136 are enlarged at the αhelix 1 (H-1). The subtle differences between OvPrP-A136 and OvPrP-V136
were found in the structures of three α-helices (H-1, H-2 and H-3), and most
conformational changes were concentrated in H-1. The N-terminal of H-1 was
relaxed and C-terminal of H-1 opened up in OvPrP-A136; therefore, the diameter
of H-1 in OvPrP-V136 was relatively smaller than OvPrP-A136. In addition, the
N-terminal of H-1 had less twist in OvPrP-A136. The difference in H-2 was that
the C-terminus had an additional twist in OvPrP-V136 but not OvPrP-A136
(Figure 4.19.A and B.). In more detail, the conformational differences were found
in the orientation of the following amino acid residues: asparagine at codon 147
and glutamic acid at codon 155 in H-1, asparagine at codon 176 and lysine at
codon 188 in H-2, glutamic acid at codon 203 in H-3 and Y at codon 228.
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Figure 4.20. Comparison of intramolecular hydrogen bonding in ovine PrP
(residues 114-228) with 136 polymorphism either alanine or valine. Blue
dashed lines indicate intramolecular hydrogen bonding. A. OvPrP-A136. B.
OvPrP-V136. Differences are found especially in the N- or C-terminal of three αhelices. The diagram was generated using VMD.
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Chapter 5

Unaltered prion protein expression in Alzheimer disease patients
Published in Prion, 5:2, 109-116; April/May/June 2011

Introduction
For many years, the overlapping clinical, pathological and biochemical
characteristics of Alzheimer’s and prion diseases suggested a shared pathogenic
mechanism. The prion protein (PrP) and the amyloid β (Aβ) peptide, derived from
the amyloid precursor protein (APP), both undergo structural transitions
associated with a gain of toxic function leading to neurodegeneration (Prusiner,
1998). APP and PrP are directly or indirectly associated on the cell surface
(Schmitt-Ulms et al., 2004), and there are similarities in the post-translational
processing of both proteins. Analogous to the α-secretase cleavage of APP, PrPC
undergoes proteolytic cleavage at amino acids 110/111 to produce a 17-kDa
carboxyl-terminal fragment referred to as C1 (Chen et al., 1995) by the possible
action of TNFα-converting enzyme (TACE) or members of the ADAM (α
disintegrin and metalloprotease) family. PrP cleavage following residue 89 results
in the formation of an approximately 21 kDa carboxy-terminal C2 fragment,
which, in infected brains, is resistant to protease digestion and appears to be
facilitated by calpain (Yadavalli et al., 2004). These two cleavage sites flank the
amino acid charge cluster in the central domain where oligomeric Aβ has been
proposed to bind PrPC (Lauren et al., 2009). Both proteins contain conserved
histidine metal-binding domains, GxxxG transmembrane recognition motifs and
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histidine-based high-affinity metal-binding sites, which favor the binding of
transition metals. Related to this, oxidative stress has been implicated in AD
(Martins et al., 1986) and prion disease (Brazier et al., 2006).
There is now convincing evidence that amplification of Aβ aggregates
occurs by a prion-like mechanism (Eisele et al., 2010; Eisele et al., 2009; MeyerLuehmann et al., 2006). Moreover, prion infection is associated and formic acidextractable Aβ1-42 peptide levels are higher, in transgenic mice expressing
mutant APP (Tg2576 mice) compared to non-transgenic controls (Baier et al.,
2008), suggesting that cross-seeding of the two abnormally conformed proteins
may occur. In line which this observation, the brains of diseased scrapie-infected
wild-type mice also contain increase levels of the Aβ1-41 peptide (Parkin et al.,
2007). Conformational templating also appears to occur in other protein
misfolding diseases (Brundin et al., 2010) involving tau (Frost et al., 2009), αsynuclein (Desplats et al., 2009) and polyglutamine proteins (Ren et al., 2009).
Although soluble oligomeric forms of the Aβ peptide, derived from APP,
are proposed as key mediators of synaptic and cognitive dysfunction in AD, the
mechanisms by which these events occur remain unclear. Several recent studies
suggest a direct mechanistic link between PrP and the Aβ peptide in AD
pathogenesis. The studies of Strittmatter and co-workers implicated PrPC as a
major receptor for synthetic soluble Aβ1-42 oligomers, and indicated that PrPC
mediates the deleterious effects of oligomeric Aβ1-42 on synaptic function
(Lauren et al., 2009). Soluble Aβ1-42 oligomer binding was shown to occur at
amino-acid

residues

95–110

of

PrP,
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a

region

close

to

the

PRNP

methionine/valine codon 129 polymorphism, which has numerous important
influences on human prion diseases, and is also implicated as a risk factor for
early-onset AD (Del Bo et al., 2006; Riemenschneider et al., 2004). In
subsequent studies, this group demonstrated a requirement for PrP expression
for axonal degeneration, loss of synaptic markers, early death, and learning and
memory deficits in AD transgenic mice (Gimbel et al., 2010).
While the foregoing findings implicate PrP as a potential therapeutic target
in AD, other studies have been less supportive of this concept. In independent
transgenic mouse studies, ablation or overexpression of PrPC had no effect on
impairment of hippocampal synaptic plasticity (Calella et al., 2010). Moreover,
while the interaction of Aβ1–42 oligomers with PrPC was confirmed in separate
studies, both PrP-expressing and PrP knockout mice were equally impaired in
hippocampal

dependent

behavioral

tests

following

intracerebroventricular

injections of synthetic Aβ1–42 oligomers (Balducci et al.). Finally, other studies in
which overexpression of PrP in vitro was shown to negatively regulate βsecretase (Parkin et al., 2007) would appear to be consistent with a model in
which high levels of PrP result in low levels of Aβ1-42 oligomers.
Here we performed an extensive analysis of PrP levels in AD and pre-AD
patients to address the hypothesis that variable PrPC expression is involved in
AD pathogenesis.
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Materials and Methods
Patients. Frozen samples of hippocampus, superior frontal cortex (BA9) and
superior-middle temporal cortex (BA21-22) were obtained from the University of
Kentucky Rapid Autopsy Program of the Alzheimer's Disease Clinical Center
(UKADC). Tissue was examined from 37 individuals with a mean age of 86.7 ±
7.6 years (Table 5.1.) were examined. These individuals were part of a
longitudinal clinical-pathologic study of aging and AD at the UKADC (Davis et al.,
1999; Schmitt et al., 2000). The Human Investigations Committee at the
University of Kentucky College of Medicine approved the studies. Individuals
included in these studies agreed to annual clinical evaluation and brain donation
at the time of death. For all subjects, cognitive test scores were available within
the last year of life; the average interval from last evaluation to time of death was
7.0 ±3.6 months, with no differences among the three diagnostic groups (p <
0.1). Subjects were categorized as no cognitive impairment (NCI; n = 13),
amnestic mild cognitive impairment (aMCI; n = 7), mild Alzheimer disease (mAD;
n=6), or AD (n = 11) (Petersen, 2004), based on cognitive testing prior to death.
The NCI subjects were without a history of dementia or other neurological
disorders. Standard criteria for exclusion were the presence of (1) significant
cerebral stroke regardless of antemortem date, (2) large cortical infarcts
identified in the postmortem neuropathologic evaluation, (3) significant trauma
within 12 months before autopsy, (4) individuals on a respirator longer than 12
hours before death, (5) individuals in coma longer than 12 hours immediately
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before death, (6) individuals currently undergoing radiation therapy for CNS
tumor, or (7) individuals with Lewy bodies.
Details of the UKADC have been published elsewhere in reference
(Schmitt et al., 2000). All subjects have detailed mental status testing annually,
and have neurologic and physical examinations annually. Subjects had been
followed for 1-14 years (median 8.2 years). Once a subject transitioned to having
aMCI or mAD, they received the mental status test battery and neurologic
evaluation every 6-9 months. The 7 subjects with aMCI, 6 with mAD, and 11 with
AD were initially normal on enrollment into the longitudinal study and later
developed aMCI and AD during follow-up. All aMCI subjects were amnestic
without multi domain involvement. The diagnosis of aMCI, mAD, AD and NCI
were defined by consensus conference. Histological examination of NCI subjects
showed only age-related changes and Braak stage score of 0-II, meeting the
NIA-RI low-likelihood criteria for the histopathologic diagnosis of AD. The clinical
criteria for diagnosis of aMCI included (1) memory complaints, (2) intact activities
of daily living, (3) objective memory impairment for age and education, (4) failure
to meet criteria for dementia, and (5) a clinical dementia rating (CDR) scale score
of 0.5. The Braak stage scores had a range of I-V. Clinical progression to AD
was diagnostically characterized by (1) a decline in cognitive functions from a
previous higher level, (2) decline in one or more areas of cognition in addition to
memory, (3) impaired activities of daily living, (4) a CDR score between 0.5-1,
and (5) a clinical evaluation that excludes other causes of dementia. The criteria
for mAD subjects included the above clinical progression plus a histopathologic
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diagnosis that included a Braak stage score of II-VI. For an AD categorization,
subjects demonstrated a more progressive intellectual decline as described
above, a MMSE less than that of the mAD cohort, and Braak scores of II-VI.
None of the mAD subjects were considered to be at the end-stage of the disease
progression.

Transgenic mice. Tg(HuPrP-M129)6812+/- mice and Tg(HuPrP-V129)7823+/mice express human PrP encoding either M or V at codon 129, referred as
HuPrP-M129 and HuPrP-V129, respectively (Kurt et al., 2009). Transgenic lines
were maintained by breeding with Prnp0/0 mice maintained on an FVB
background (FVB/Prnp0/0) and transgenic offspring were identified by tail biopsy
and extraction of genomic DNA using a Beckman Biomek FX robotic station
followed by PCR screening for the presence of the transgene. Approximately, 1
cm of tail tissue was digested overnight at 55°C with proteinase K (0.5 mg/ml
final concentration) in 50 mM Tris pH 8.0, 100 mM EDTA, 0.5% SDS, the DNA
extracted with phenol and chloroform and concentrated by ethanol precipitation.

Analysis of the PRNP codon 129 polymorphism. Genomic DNA was extracted
from brain homogenates of the 37 individuals. The sense primer (5’ATGGCGAACCTTGGCTGCTGGATGC-3‘)

and

antisense

primer

(5’-

GTGGTTGTGGTGACCGTGTGCTGCTTGAT-3') were used to amplify the PRNP
cording sequence using PCR. The PRNP codon 129 polymorphism was
assessed by digestion of the amplicons with endonucleases NspI (New England
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Biolabs. Inc.) and MaeII (HpyCH4IV, New England Biolabs. Inc.), and the
digested products were analyzed on 1.2% agarose gels.

Western Blotting. 10% brain homogenates were prepared in sterile phosphate
buffered saline (PBS) lacking Ca2+ and Mg2+ ions. The concentration of a total
protein in each sample was determined by bicinchoninic acid assay and
standardized for each lane (5 µg per lane). Proteins were resolved by sodium
dodecyl

sulfate–polyacrylamide

gel

electrophoresis

and

transferred

to

polyvinylidene difluoride Immobilon-FL membranes (Millipore). The transferred
membrane was blocked with 5% non-fat milk in 0.5% Tween-20 in Tris-buffered
saline (TBST) and immunoprobed with mouse monoclonal antibody anti-PrP 6H4
(Prionics) and 3F4 (Covance) followed by horseradish peroxidase–conjugated
anti-mouse secondary antibody. Proteins were visualized using ECL Plus (GE
Healthcare) in an FLA-5000 scanner (Fujifilm Life Science). Anti-actin (Pan) Ab-5
monoclonal antibody (NeoMarkers) was used as an internal control.

Statistical analysis. Statistical analysis of western blot data from the frontal and
temporal cortices and hippocampus of NCI, aMCI, mAD and AD was performed
using a one-way ANOVA for each region separately. When appropriate,
differences between groups were probed using a Newman-Keuls post hoc test.
Each histogram of PrPC in western blots was read by MultiGauge (Fujifilm Life
Science) and the values were standardized against the histogram value of actin.
All data were analyzed with GraphPad Prism 4 and values were expressed as
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mean standard deviation. Differences with P < 0.05 was considered to be a
significant and indicated with asterisks.

Results and Discussion
Table 5.1. summarizes patient characteristics by diagnostic group. Included in
our studies were 13 individuals with NCI, 7 patients with aMCI, 6 with mAD, and
11 with AD. Braak and CERAD scores were determined for all samples (Tables
5.2. and Table 5.3.). Age, post-mortem interval (PMI), and brain weight were
similar among the various groups (Table 5.1.). Differences in mini-mental state
examination (MMSE) scores were highly significant between groups [F(3,33) =
88.853, p < 0.0001]. Post hoc comparisons using the student Newman-Keuls test
showed statistically significant differences between NCI and aMCI (p < 0.05),
between aMCI and mAD (p < 0.05), and between mAD and AD groups (p <
0.05). All dementia groups showed lower MMSE scores than NCI. Both AD
groups showed lower scores than aMCI patients, while the AD group showed
lower scores than mAD (Table 5.1.).
In addition to its important influence on human prion diseases (Wadsworth
et al., 2004), the methionine (M)/valine (V) polymorphism at codon 129 of the
human PrP gene (PRNP) has also been implicated as a risk factor for early-onset
AD (Del Bo et al., 2006; Riemenschneider et al., 2004), although its influence as
a risk factor for AD has been challenged (Li et al., 2005). Analysis of this
polymorphism is also important given its close proximity to the proposed region
of Aβ1-42 oligomer binding (Lauren et al., 2009). We analyzed codon 129
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genotypes by treating PCR amplified patient genomic DNA samples with NspI or
MaeII restriction endonucleases (Figure 5.1.A and B) to distinguish PRNP coding
sequence restriction fragment length polymorphisms (RFLPs) produced by the M
and V codons. The PRNP M129 and V129 allele frequencies were approximately
77% and 23% respectively in the NCI group compared to 71% and 29% in the
cognitively impaired groups. Valine homozygosity was not observed in the NCI
group (Table 5.4.). A previous association of 129V homozygosity and increased
risk of early-onset AD was reported in a Dutch population (Dermaut et al., 2003).
The mean age in each AD group in the current study is over 80 (Table 5.1.). The
period of follow up for patients was up to 14 years with a mean of 8 years
approximately, raising the possibility that some case may have been younger
onset. Nonetheless, patient numbers in our study are too small to draw definitive
conclusions.
To examine a possible relationship between cognitive decline and PrPC
expression, brain homogenates were prepared from frozen samples of
hippocampus, superior frontal cortex (BA9) and superior-middle temporal cortex
(BA21-22) of NCI, aMCI, mAD and AD patients, and immunoblots of samples
containing equivalent total protein levels were probed with either anti-PrP
monoclonal antibodies (mAb) 6H4 or 3F4. Levels of PrP in these preparations
were determined by densitometric analysis of western blots using actin levels as
an internal control in each sample. While we observed a tendency of diminished
PrP levels in rostral compared to caudal areas when immunoblots were probed
with mAb 6H4, regional differences were not significant, and rostrocaudal
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decreases in PrPC were not confirmed when the experiment was repeated using
mAb 3F4 (Figure 5. 2.).
Western blot analysis using both mAb 6H4 and 3F4 showed that
expression of PrPC was not significantly altered among NCI compared to aMCI,
mAD or AD in either the frontal and temporal cortices or hippocampus (Figure 5.
3.). Levels of unglycosylated PrP were not higher in AD compared to control
cases, although there was a tendency for higher levels of aglycosyl PrPC levels in
the temporal cortex of aMCI patients compared to other study groups, and when
measured with mAb 3F4 levels were significantly higher in temporal cortex of
aMCI compared to NCI and AD patients (Figure 5.4.). PrPC expression levels
were also independent of PRNP codon 129 genotype (Figure 5.5.).
Our results appeared to be in general disagreement with the central topic
of recently published studies by Velayos and coworkers (Velayos et al., 2009)
which indicated a tendency for lower steady state PrPC levels in the brains of AD
patents compared to controls (Velayos et al., 2009), especially in the
hippocampus, an outcome apparently inconsistent with previous reports of
increased PrPC immunereactivity in the temporal cortex, hippocampus (CA2) and
subiculum in AD patients compared to controls (Voigtlander et al., 2001).
Although not discussed in the context of their data, the report of Valayos and
coworkers was significant in light of recent studies implicating PrPC as a major
receptor that mediates the deleterious effects of oligomeric Aβ1-42 on synaptic
function (Lauren et al., 2009). Here we observed no differences in total PrPC
levels in AD compared to NCI controls, nor did we observe a graded decrease in
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PrP levels with increasing cognitive impairment. The minor observed differences
between PrPC levels probed with mAb 6H4 and mAb 3F4 could be related to the
site of the binding of these mAbs to PrP. The epitope mAb 6H4 has been
mapped to the sequence DYEDRYYRE, corresponding to PrP residues 144-152
(Korth et al., 1997), while the epitope for 3F4 is located in the KTNMKHM,
corresponding to residues 106-112 (Lund et al., 2007; Rubenstein et al., 1999;
Zou et al., 2010a). Thus, while mAb 6H4 can detect the proteolytically processed
sub-fragment of PrPC, referred to as C1 (Chen et al., 1995), mAb 3F4 cannot.
Because diglycosylated C1 fragments overlap with mono- and non-glycosylated
forms of full-length PrPC, this could potentially affect quantification of PrPC levels
and explain the discrepancy between the two mAbs.
What could explain the discrepancies between our studies and previous
report? Velayos and coworkers studied three patients with AD. No clinical
information was provided, except that one AD patients also had Down syndrome.
Western blotting of PrPC was recorded in three control human cases and two AD
patients. In the present study, we analyzed PrPC expression in a larger cohort
comprised of 37 individuals including 11 AD cases, 6 mAD, 7 aMCI patients and
13 non-demented controls. All patients were well characterized by diagnostic
group, and all samples had short post-mortem intervals (Table 5.1-3.). Our
analysis also included actin as an internal loading control for all samples. In
addition to mAb 6H4, which was also used in the previous study, we used a
second thoroughly characterized mAb (3F4) with reactivity against human PrPC.
The high numbers of well-characterized patients, and the rigorous analysis of
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regional PrPC expression allows for meaningful associations (or lack of
association in this case) to be made between levels of PrP and the presence of
AD.
Velayos and coworkers also reported a shift in the profile of PrP
glycosylation, with the unglycosylated form predominating in AD patients
compared to controls. While we were also unable to confirm the finding of
increased levels of aglycosyl PrPC in AD or mAD patients, we did observe
significantly higher levels of unglycosylated PrP in the temporal cortex of aMCI
patients compared to NCI and AD (but not mAD) patients. Whether this change
corresponding to a specific role for PrP expressing cells in this critical brain
region at early stages of the development of AD, prior to the onset of significant
neurodegeneration and neuronal loss, remains to be determined.
In summary, we conclude that, if PrPC is involved in mediating the toxic
effects of oligomeric Aβ, then this occurs by a mechanism that does not involve
modulation of steady state levels of PrP. This would appear to be an important
insight given recent associations of PrP in AD pathogenesis that implicate PrP as
a potential therapeutic target.

Copyright © Eri Saijo 2012
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Table 5.1. General demographics of subjects. ap < 0.05 compared to NCI. bp <
0.05 compared to aMCI. cp <0.05 compared to mAD. Published in Prion, 5:2,
109-116; April/May/June 2011.
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Table 5.2. Braak scores by clinical diagnosis.
Published in Prion, 5:2, 109-116; April/May/June 2011.
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Table 5.3. CERAD classification by clinical diagnosis.
Published in Prion, 5:2, 109-116; April/May/June 2011.
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Table 5.4. Codon 129 PRNP allele frequency and genotype of subjects.
Published in Prion, 5:2, 109-116; April/May/June 2011.
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Figure 5.1. Representative restriction fragment length polymorphism
(RFLP) analyses. Lanes 1 and 2, brain extracts from Tg(HuPrP-M129)6816+/mice expressing human PrP-M129; lanes 3 and 4, brain extracts from Tg(HuPrPV129)7826+/- mice expressing human PrP-V129; lanes 5 and 6, equal mixture of
brain extracts from transgenic mice expressing human PrP-M129 and transgenic
mice expressing human PrP-V129; lanes 7 – 16, five representative human
samples. Odd numbers, undigested PCR samples; even numbers, digested PCR
samples. (A) PCR amplified samples treated with restriction enzyme NspI, which
cleaves PRNP encoding methionine at codon 129. Methionine carriers produce a
363 bp fragment; valine carriers produce a 438 bp fragment. (B) PCR samples
treated with MaeII, which cleaves PRNP encoding valine at codon 129. Valine
carriers produce a 359 bp fragment. Published in Prion, 5:2, 109-116;
April/May/June 2011.
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Figure 5.2. Rostrocaudal analysis of PrPC levels in NCI and AD patients. For
all sample, levels of total PrPC and actin were measured by densitometric
scanning of western blots. Each PrP value was normalized to its actin value.
Normalized PrP values were compared among the frontal (F) and temporal (T)
cortices and hippocampus (H) in NCI and AD groups. Error bars represent
standard deviations from the mean. Published in Prion, 5:2, 109-116;
April/May/June 2011.
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Figure 5.3. Levels of PrPC in different brain regions of patients with
differing levels of cognitive impairment. Representative western blot analyses
of brain homogenates from NCI, aMCI, mAD and AD patients are shown. AntiPrP 6H4 (A-C) and 3F4 (D-F) antibodies were used to compare the levels of
PrPC among the groups. Actin controls are shown below the 6H4 or 3F4
immunoblots. NCI: lanes 1-4. aMCI: 5-8. mAD: 9-12. AD: 13-16. Three brain
regions including the frontal (A, D, G and J), temporal (B, E, H and K) cortices
and hippocampus (C, F, I and L) were analyzed. Molecular markers indicated are
53, 36, 28 and 19 kDa. Graphs in (G – L) include analyses of all samples from
each group. For each sample, levels of total PrPC were measured by
densitometry. For each sample, levels of actin were also assessed. Each PrP
value was normalized to its actin value. Means and standard deviations were
calculated for each patient group and expressed as the percent value relative to
the NCI group. Published in Prion, 5:2, 109-116; April/May/June 2011.
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Figure 5.4. Unaltered levels of unglycosylated PrPC in AD patients
compared to NCI individuals. Levels of unglycosylated PrPC (~ molecular
weight 25-30 kDa) were measured by densitometric analysis of western blots.
Means and standard deviations were calculated for samples from each patient
group. y-axis values are arbitrary densitometric units. * indicates p< 0.05.
Published in Prion, 5:2, 109-116; April/May/June 2011.
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Figure 5.5. Levels of PrPC do not correlate with human PrP 129
polymorphism in AD patients. Levels of PrPC were measured by densitometry.
For each sample, levels of actin were also assessed. Each PrP value was
normalized to its actin value. These values were compared among individuals
with various PRNP genotypes (M/M, M/V, V/V). (A – C) represent the data
analyzed with 6H4; (D – F) represent the data analyzed with 3F4. Three brain
regions including the frontal (A and D) and temporal (B and E) cortices and
hippocampus (C and F) were analyzed. Published in Prion, 5:2, 109-116;
April/May/June 2011.
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Chapter 6

Discussion and future directions

Prion diseases are caused by misfolding of a normal PrPC isoform into a
pathogenic PrPSc isoform, and PrPSc is believed to serve as a template for PrPC
to undergo a profound conformational structural change to become a pathogenic
PrPSc isoform (Prusiner, 1998). Moreover, numerous studies show that the
conversion of PrPC to PrPSc is constrained by transmission or species barriers
between host PrPC and donor PrPSc. In Chapter 2, the species barrier between
CWD (cervid PrPSc) and human PrPC was directly determined by inoculating
CWD prions into Tg mice expressing human PrP encoding either M or V at codon
129. The results showed that the species barrier between human and cervid was
considerably high in CWD prions. To understand the species barrier of prion
disease, the conformational selection model has been hypothesized to explain
how the species barrier in prion disease restricts transmission of prions (Collinge,
1999, 2010). For example, CWD1, CWD2 and CWD mix prions used in Chapter
2, according to the conformational selection model, contain multiple PrPSc
conformations, and each CWD prion includes the same PrPSc conformation as
well as completely different PrPSc conformations (Figure 6.1.). Those different
PrPSc conformations, which are unique to each CWD prion, reflect to different
properties of CWD prions, referred to as ‘strains’. In the conformation selection
model, host PrPC interact donor PrPSc in preference to selected sets of PrPSc
conformations, and each species prefers different sets of PrPSc conformations.
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For instance, HuPrPC-M129, HuPrPC-V129 and cervid PrPC prefer completely
different sets of PrPSc conformations to facilitate conversion of PrPC to PrPSc
(Figure 6.1.). CWD contains the PrPSc conformations, which are preferred by
cervid PrPC, therefore, donor CWD PrPSc could convert cervid PrPC into PrPSc
resulting in accumulation of proteinase-resistant PrPSc and development of
disease. On the other hand, CWD prions do not contain the PrPSc conformations,
which are preferred by HuPrP-M129 or HuPrP-V129 (Figure 6.1.). Thus, no
accumulation of proteinase-resistant PrPSc is detected, and no disease
development is confirmed. If HuPrPC preferred PrPSc conformations present in
CWD prions, concentrations of the preferred PrPSc were too low to facilitate PrPSc
conversion to reach a detectable level. Thus, the rate of PrPSc conversion by
CWD in Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- mice was not be
efficient to accumulate proteinase-resistant PrPSc in the brain. Since some of
CWD-inoculated Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- mice
presented clinical signs without accumulation of proteinase-resistant PrPSc in
their brains, this suggest the great possibility of presence of PrPSc conformations
preferred by HuPrP-M129 and HuPrP-V129 in CWD. This question would be
possible to test by inoculating the brain materials from CWD-inoculated
Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- mice with clinical signs into
genotype matched Tg(HuPrP) mice. If any animals develop disease during the
secondary passage of CWD, it suggests the presence of human PrPC preferred
PrPSc conformations in CWD.
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The conformational selection model proposes that PrPC preferentially
interacts with preferred PrPSc conformations to convert itself into PrPSc,
suggesting that interactions between host PrPC and donor PrPSc at the level of
the tertiary structures play important roles in PrPSc conversion. The tertiary
structure of

proteins is, in general, predominantly assessed by the primary

structure of proteins. The series of cell culture studies in Chapter 3 tested
whether modifying the primary structure of mouse PrPC led to alter susceptibility
to mouse-adapted RML scrapie prion. I particularly asked that introducing
substitutions of amino acids in specific regions of PrP where majority of
differences among mammalian PrPs were clustered, involve in the transmission
barrier of RML and CWD prions by identifying accumulation of proteinaseresistant PrPSc post infection. The present in vitro data suggest that the primary
structure of PrP encodes crucial information to fold itself into a defined tertiary
structure to facilitate conversion of PrPSc.
Most cellular proteins need to be folded into correct conformations to gain
own functions, and numerous studies have reported that molecular chaperones
play an important role in maintaining functional protein conformations (Hartl &
Hayer-Hartl, 2009). There has been increasing numbers of molecular
chaperones reported to serve different functions in protein folding (Hartl & HayerHartl, 2009). Nonetheless, an essential function of molecular chaperones is to
catalyze or mediate a proper folding process of proteins or to recognize
misfolded proteins for degradation. Moreover, chaperons could provide an
adequate space for proteins to be able to unfold and refold into a proper
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conformation in a dynamic and busy cellular environment. It is important to note
that molecular chaperones are defined by any molecules that interact with any
proteins to assist and/or stabilize functional protein folding, and structures of
molecular chaperones are not clearly defined all the time (Hartl, 1996; Hartl &
Hayer-Hartl, 2009).
Protein misfolding in neurodegenerative diseases has been associated
with molecular chaperones, and elevated levels of molecular chaperones, such
as, heat shock proteins (HSPs) have been reported in Alzheimer’s disease,
Parkinson’s disease and prion disease (reviewed in (Brownell et al., 2012)). For
example, increased levels of small heat shock proteins (sHSPs) were reported in
scrapie-affected sheep (Vidal et al., 2009), BSE-inoculated Tg mice (Tortosa et
al., 2008), and CJD-diseased human brains, especially in neurons and glial cells
(Renkawek et al., 1992). sHSPs are distinguished from large heat shock proteins
by molecular weights. sHSPs bind misfolded proteins to prevent from forming
aggregations until large heat shock proteins come to accommodate refolding
process. Increased levels of HSPs in those neurodegenerative diseased brains
suggest cells attempt to clear misfolded proteins or aggregates; however, the
cellular clearance mechanism mediated by HSPs might slowly compromised over
a long period of time, resulting in accumulation of aggregated proteins.
On the contrary, other group of molecular chaperones might mediate a
misfolding process of proteins, such as PrPSc. Unidentified molecular chaperons,
we denote ‘protein X’, might play a role in conversion of PrPSc from PrPC in
neurons. In PrPSc conversion models including the heterodimer template-

190

associated and nucleated-polymerization models (Figure 1.2.), PrPSc is
thermodynamically stable compared to PrPC. Thus, it will be necessary to
overcome the energy barrier for PrPSc conversion to take place (Figure 6.2.).
Moreover, protein X might assist in unfolding, refolding and/or stabilizing proper
conformation of PrPSc (Figure 6.2.). In addition to overcoming the energy barrier
using a catalyst, the spontaneous conversion of PrPC to PrPSc could be induced
by increasing concentration of PrPSc.
The conformational selection model was introduced earlier to explain the
species barrier, which is determined by compatible conformations between host
PrPC and donor PrPSc. In addition to the conformational selection model, an
unidentified catalyst or molecular chaperone, we denote hypothetical ‘protein X’
might paly an important role in the species barrier of prion diseases. ‘Protein X’
could be a species-specific molecular chaperone to facilitate PrPSc conversion.
As a matter of fact, the Tg mouse study using a human-mouse chimera PrP
demonstrated that Tg mice expressing human-mouse chimera PrP were
susceptible to human prions, whereas Tg mice expressing human PrP were
resistant to the same human prions (Telling et al., 1995). Both host PrPC and
donor PrPSc are from humans; however, cellular factors are from mice. This Tg
mouse study suggests that a species-specific molecular interaction is required to
facilitate PrPSc conversion, which might be mediated by ‘protein X’. Therefore,
the susceptibility or resistance to prions might also be determined by ‘protein X’.
Further, ‘protein X’ could be a group of chaperones to mediate in
unfolding, refolding and stabilizing newly synthesized PrPSc. Another possibilities
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are that ‘protein X’ could be co-chaperone to assist a chaperone or could be one
subunit in a functional chaperone. This one piece of subunits in chaperone might
alter a normal function of existing chaperones to facilitate PrPSc conversion. If a
group of molecular chaperones involves in PrPSc conversion, not all molecular
chaperones determine the species barrier of prion diseases. Some of subunits in
molecular chaperones might be well conserved among mammalian species,
whereas other subunits are unique to species. Those species-specific molecular
chaperones might play a key role in the species barrier of prion diseases.
The PrPSc conversion models in Figure 6.3. explain how a species-specific
protein X determines transmission of CWD and RML prions in cervid and CWD
and CJD prions in humans. According to the conformation selection model, host
PrPC

selects

preferred

PrPSc

conformations

to

facilitate

substantial

conformational change using donor PrPSc as a template. Even though host PrPC
finds preferred PrPSc conformation, the conversion of PrPC into PrPSc does not
occur spontaneously without any catalysts because of the high energy barrier
(Figure 6.2.). In order for PrPC to become PrPSc resulting in disease development
within a host lifespan or within a certain period of time, a catalyst or molecular
chaperone becomes essential to facilitate PrPSc conversion by lowering the
energy barrier. An unidentified catalyst or molecular chaperone ‘protein X’ is a
species-specific in the proposed conversion models (Figure 6.3.). For example,
cervid carries a cervid-specific chaperone, and the cervid-specific chaperone
might be completely different from a chaperone found in humans. A cervidspecific chaperone could facilitate the conversion of cervid PrPC with cervid
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preferred PrPSc and stabilize newly synthesized PrPSc (Figure 6.3.A). On the
other hand, mouse adapted RML scrapie prion dose not contain cervid PrPC
preferred PrPSc conformations, and the cervid-specific chaperone could not
mediate PrPSc conversion (Figure 6.3.B). As a result, RML prion could not
produce PrPSc and disease in cervid. CWD prions do not contain human PrPC
(HuPrPC) preferred PrPSc conformations, further, a human-specific protein X
could not facilitate PrPSc conversion (Figure 6.3.C). Thus, CWD prions failed to
develop disease in humans. When HuPrPC find preferred PrPSc conformations,
such as, CJD prions, HuPrPSc conversion occurs (Figure 6.3.D). A humanspecific protein X could facilitate PrPSc conversion, as a result, humans develop
CJD.
The rabbit epithelial kidney (RK13) cell culture system was used to test
whether altering amino acids in specific regions of mouse PrP altered
susceptibility to species matched prion (mouse adapted RML scrapie prion) in
Chapter 3. RK13 cells expressing a wild-type mouse PrPC (RKM cells) are highly
susceptible to mouse adapted scrapie RML prion (Figure 6.4.A). However, RKM
cells are not susceptible to CWD because PrPSc conformations in CWD are not
mouse PrPC preferred PrPSc conformations (Figure 6.4.B). The series of cell
culture studies in Chapter 3 suggest that altering even one amino acid in specific
regions of mouse PrP, where majority of differences among mammalian species
are clustered, could result in loss of susceptibility to RML prion (Figure 6.4.C).
Since wild-type and variant mouse PrP are expressed in rabbit epithelial kidney
(RK13) cells, ‘protein X’ is a rabbit-specific. Therefore, the present in vitro data

193

shows the primary structure of host PrPC primarily determines susceptibility to
RML prion. These results also suggest that properties of mouse-specific and
rabbit-specific chaperones might be functionally identical. To test whether a
rabbit-specific and mouse-specific ‘protein X’ is functionally identical in RML
transmission, Tg mice expressing the same variant mouse PrP used in the cell
culture studies could be inoculated with RML to see whether develop disease. If
results turn out to be consistent with the in vitro data, mice and rabbits have
functionally identical molecular chaperones to facilitate PrPSc conversion. If those
Tg mice expressing variant mouse PrP develop disease with RML, a mousespecific chaperone has more capacity to facilitate PrPSc conversion of variant
mouse PrPC with RML prion. Thus, molecular chaperones in mouse and rabbit
are functionally different in respect to PrPSc conversion.
The intraspecies transmission barrier of prion disease could be explained
by the conformational selection model. In sheep, susceptibility and resistance to
sheep scrapie prions are strongly controlled by ovine PrP polymorphisms
especially at codon 136 encoding either A or V (Goldmann et al., 1991;
Goldmann et al., 1994). According to the conformational selection model,
SSBP/1 sheep scrapie prion include multiple PrPSc conformations, which can be
classified into at least two groups based on the results in Chapter 4 (Figure 6.5.).
One group contains PrPSc conformations with the OvPrPSc-V136 properties (a
blue box in SSBP/1 in Figure 6.5.), while another group consists of completely
different sets of PrPSc conformations, which have the identical properties to
OvPrPSc-A136 (a pink box in SSBBP/1 in Figure 6.5.). CH1641 sheep scrapie
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prion also has multiple PrPSc conformations; however, a further classification of
PrPSc conformations is unclear (Figure 6.5.). OvPrPC-V136 prefers a specific set
of PrPSc conformations (blue boxes in Figure 6.5.), on the other hand, OvPrPCA136 prefers a different sets of PrPSc conformations (pink boxes in Figure 6.6.).
SSBP/1 prion contains OvPrPC-V136 preferred PrPSc conformations, and
CH1641 does not. Thus, OvPrP-V136 is only susceptible to SSBP/1. Both
SSBP/1 and CH1641 prions include OvPrPC-A136 preferred PrPSc conformations,
therefore, OvPrP-A136 is susceptible to both SSBP/1 and CH1641. However,
OvPrPC-A136 preferred PrPSc conformations are not the major conformations in
SSBP/1. Lower concentration of OvPrPC-A136 preferred PrPSc conformations in
SSBP/1 prion are available for OvPrPSc-A136 conversion. The probability of
OvPrPSc-A136 conversion is considerably low, therefore, OvPrPC-A136 requires
a longer period of time to accumulate OvPrPSc-A136 and to develop disease with
SSBP/1.
A hypothetical chaperone ‘protein X’ might involve in the conversion of
OvPrPSc-A136 and OvPrPSc-V136 (Figure 6.6.). In the following OvPrPSc-V136
and OvPrPSc-A136 conversion models, an unidentified molecular chaperone
‘protein X’ might be linked to an ovine PrP 136 polymorphism. An OvPrP-V136specific protein X facilitates the conversion of OvPrPC-V136 into PrPSc using
OvPrPSc-V136 in SSBP/1 as a template and stabilizes newly synthesized
OvPrPSc-V136 (Figure 6.6.A-1). However, the OvPrP-V136-specific protein X is
not most efficient chaperone for OvPrPSc-V136 conversion with OvPrPSc-A136 in
SSBP/1 prion (Figure 6.6.A-2). Therefore, OvPrPSc-V136 conversion requires a
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longer time with SSBP/1-A136 prion. In addition, newly synthesized OvPrPScV136 might never accumulate in cells because a cellular clearance mechanism
could promptly remove OvPrPSc-V136 as slowly synthesized.
Although an OvPrP-A136-specific protein X might facilitate the conversion
of OvPrPC-A136 into PrPSc with SSBP/1-V136 prion, the OvPrP-A136-specific
protein X might not be most efficient chaperone to facilitate OvPrPSc-A136
conversion with SSBP/1-V136 prion (Figure 6.6.B-1). Thus, the rate of PrPSc
conversion will not be fast enough to accumulate PrPSc in the brain and to
develop disease. On the other hand, the OvPrP-A136-specific protein X could
facilitate the conversion of OvPrPC-A136 into PrPSc using OvPrPSc-A136 in
SSBP/1 as a template (Figure 6.6.B-2). Newly synthesized OvPrPSc-A136 could
be stabilized by the OvPrP-A136-specific protein X.
There is also another possibility that ‘protein X’ might not be linked to the
ovine PrP polymorphism at codon 136, rather universal in ovine, referred to as
ovine-specific ‘protein X’. An ovine-specific protein X facilitates PrPSc conversion
in both OvPrP-A136 and OvPrP-V136 sheep (Figure 6.6. C and D).
In a heterozygous state, an unidentified molecular chaperone ‘protein X’
could be an ovine-specific or OvPrP-A136-specific and OvPrP-V136-specific. If
‘protein X’ is linked to the ovine PrP polymorphism at codon 136, both OvPrPA136-specific and OvPrP-V136-specific ‘protein X’ will be available to facilitate
PrPSc conversion in heterozygous for A/V 136. Conversions of both OvPrPCV136 and OvPrPC-A136 into PrPSc are taken place in the heterozygous state,
even though rates of PrPSc conversion differ between OvPrPSc-V136 and
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OvPrPSc-A136 (Figure 6.7.). Either ovine-specific or OvPrP-V136-specific ‘protein
X’ could facilitate OvPrPSc-V136 conversion and stabilize newly synthesized
OvPrPSc-V136 (Figure 6.7.A.). The conversion rate of OvPrPSc-V136 is higher
than OvPrPSc-A136. The conversion of OvPrPC-A136 into PrPSc will be facilitated
by either ovine-specific or OvPrP-A136-specific ‘protein X’, and the ovine-specific
or OvPrP-A136-specific ‘protein X’ could stabilize newly synthesized OvPrPScA136 (Figure 6.7.C). In addition to the above conversion mechanisms of
OvPrPSc-V136 (Figure 6.7.B) or OvPrPSc-A136 (Figure 6.7.C), a ‘dominant’
templating mechanism of OvPrPSc-V136 conformation, which leads to forced
templating of OvPrPC-A136, is also occurring in the heterozygous state. In the
‘dominant’ templating mechanism, OvPrPSc-V136 helps to convert OvPrPC-A136
to PrPSc using an ovine-specific or OvPrP-V136-specific protein X. Therefore, this
newly synthesized OvPrPSc-A136 obtains the identical properties with a template
OvPrPSc-V136.
CH1641 sheep scrapie prion is most susceptible to OvPrP-A136 and most
resistant to OvPrP-V136 (Goldmann et al., 1994). CH1641 sheep scrapie prion
does not include OvPrPC-V136 preferred PrPSc conformations based on the
conformational selection model (Figure 6.5.). OvPrP-V136-specific or ovinespecific ‘protein X’ is available to facilitate PrPSc conversion. Either ovine-specific
or OvPrP-V136-specific ‘protein X’ could not accommodate the OvPrPC-V136CH1641 PrPSc complex to facilitate PrPSc conversion (Figure 6.8.A-(1).). If
‘protein X’ is linked to OvPrP-V136, PrPSc conversion does not take place due to
the OvPrP-V136-specific protein X. Even though those ‘protein X’ could
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accommodate the OvPrPC-V136-CH1641 PrPSc complex, inefficient ‘protein X’
could not mediate PrPSc conversion fast enough to accumulate PrPSc in the brain
(Figure 6.8.A-(2)). A cellular clearance mechanism might remove newly
synthesized PrPSc as slowly synthesized. CH1641 sheep scrapie prion includes
OvPrPC-A136 preferred PrPSc conformations (Figure 6.5.B). Either OvPrP-A136specific protein X or ovine-specific protein X facilitates OvPrPSc-A136 conversion
and stabilizes newly synthesized OvPrPSc-A136.
In the heterozygous state, OvPrPSc-A136 conversion is inhibited by the
presence of OvPrPC-V136 or OvPrP-V136-specific protein X. OvPrPC-V136
inhibits the conversion of OvPrPC-A136 by preventing interactions among OvPrPA136, CH1641-PrPSc and/or ‘protein X’ (Figure 6.8.C-1). Even though an
appropriate ‘protein X’ is available, ‘protein X’ could not mediate OvPrPSc-A136
conversion. The OvPrP-V136-specific ‘protein X’ could not facilitate OvPrPScA136 conversion (Figure 6.8.C-2). In the heterozygous state, the OvPrP-V136specific ‘protein X’ is available and becomes an inhibitor or antagonist by
interacting with the OvPrPC-A136-CH1641 PrPSc complex before an appropriate
OvPrP-A136-specific protein X interact with the PrPC-PrPSc complex.
Up to this point, I have explained the PrPSc conversion models based on
the conformational selection model using ‘hypothetical protein X’. In order to
identify ‘protein X’, it would be helpful to think where the conversion of PrPC into
PrPSc happens in cells. Cell culture studies reported that PrPC was able to
convert to PrPSc at the cholesterol-rich, detergent-soluble microdomains of the
plasma membrane (Goold et al., 2011; Taraboulos et al., 1995) followed by
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trimming the amino terminus of PrPSc in an acidic environment such as lysosome
(Caughey et al., 1991). These studies suggest that PrPSc conversion happens at
the intercellular and intracellular environments (Figure 6.9.). in order to involve in
PrPSc conversion, catalysts or molecular chaperones, ‘protein X’, which could
mediate PrPSc conversion, might be membrane-bound molecules and closely
located to PrPC at the cholesterol-rich microdomains of the plasma membrane.
Molecules in lysosome might mediate PrPSc conversion in vesicles. Therefore,
‘protein X’ should be intracellular molecules usually available in neurons.
During prion infection, infectious, abnormal PrPSc isoform is taken into
lysosomes by fusing phagocytic vesicles with lysosomes or by translocating with
chaperones and transporting through chaperones into lysosomes. Recent studies
in tauopathy in Alzheimer’s disease revealed that unfolded tau is translocated by
a heat-shock chaperone to lysosome and transported into lysosome through a
transporter (reviewed in (Kaushik & Cuervo, 2012)). The chaperon-mediated
autophagy, which degrades proteins in lysosomes, can only degrade unfolded
tau, and aggregated tau could malfunction the transporters on lysosomes
(reviewed in (Kaushik & Cuervo, 2012)). In prion disease, PrPSc could enter the
intracellular space by phagocytosis for degradation or PrPSc in the cytosol could
be transported into lysosomes using a similar mechanism to tau transportation in
lysosome. However, degradation of PrPSc might turn into multiplying truncated
PrPSc templates in lysosomes. Some studies reported that truncated PrPSc could
convert host PrPC into PrPSc and a full-length of PrPSc is not necessary for PrPSc
conversion (Fischer et al., 1996; Rogers et al., 1993).
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Taken together, ‘protein X’ could be present on the microdomains of the
plasma membrane, lysosomes as well as cytosol. Thus, there are increasing
possibilities that ‘protein X’ could be multiple intracellular molecules. Moreover,
the intracellular molecules could be diverged among mammalian species since
the transmission/species barrier is an important factor in developing prion
disease.
‘Protein X’ hypothesis is not necessarily widely accepted in prion field, and
so far ‘protein X’ is still hypothetical possibly molecular chaperone. However,
through the course of the dissertation work, I started thinking more about true
existence of ‘protein X’ and actual functions in prion pathogenesis. Although the
identity of ‘protein X’ and how it involves in prion pathogenesis might be
overlooked, the results of this dissertation work strongly implies the presence of
‘protein X’ to understand the underlying mechanisms of PrPSc conversion,
transmission/species barrier, and propagating new prion strains within the same
species.
In order to support the proposed models of PrPSc conversion with ‘protein
X’, more questions need to be addressed. First, what is conformational
compatibility? Is it only the conformations between PrPC and PrPSc? Or does the
conformation of the PrPC-PrPSc-chaperone ‘protein X’ complex determine the
transmission barrier? How many chaperones involve in PrPSc conversion? Does
‘protein X’ become available only when PrPSc in neurons or all the time? It would
be helpful to further understand the transmission/species barrier of prion disease
if more precise conformations of PrPSc in each prion strain could be available. It
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might be possible to study the interactions between PrPC and molecular
chaperone ‘protein X’ by blocking the potential epitope where is the loop between
β2-sheet and α2-helix in PrPC using antibodies against the epitope. Additionally,
it would be helpful to identify whether known molecular chaperones are up or
down regulated upon infection. Understanding the transmission/species barrier in
prion disease is crucial to develop early detection assays and strain specific
treatments for prion disease.
The potential functions of PrP were suggested by the studies in the
pathogenesis of AD (Gimbel et al., 2010; Lauren et al., 2009), therefore, further
understanding roles of PrPC in the pathogenesis of AD will greatly help to identify
the function of PrPC. In order to study a relationship between expression levels of
PrPC and its functions in AD patient brains, the expression levels of PrP were
determined in the brains of individuals with AD at three different stages of
cognitive impairments. The three brain regions including the frontal and temporal
cortices and hippocampus were examined; however, unaltered expression levels
of PrPC in those brain regions from different stages of AD did not help to identify
the function of PrPC in the present study. It suggests that increased or decreased
levels of PrPC are not associated with PrPC mediated functions in the
pathogenesis of AD. Unaltered expression levels of PrPC and increased level of
Aβ in the brains of AD patients suggest that the interaction between PrPC and Aβ
induces neurotoxic effects, as proposed by Strittmatter (Gimbel et al., 2010;
Lauren et al., 2009). Therefore, the increased level of Aβ is could be driving force
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to bind PrPC to form more Aβ+PrPC complex with neuronal toxicity causing cell
death and ultimately developing AD.
In future studies, it will be useful to determine the affinity of the complex
formation between PrPC and Aβ. In addition, it will be interesting to quantify the
amount of the Aβ+PrPC complexes in the time course of cell death and also to
identify the threshold levels of the Aβ+PrPC complexes or Aβ alone that cells can
manage before inducing neuronal toxicity.

Copyright © Eri Saijo 2012
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Figure 6.1. The species barrier between cervid and human in interspecies
transmission of CWD. This diagram is based on the conformational selection
model, which explains PrPC preferentially interacts with preferred PrPSc
conformations to facilitate PrPSc conversion. Three gray boxes on the top show
that multiple PrPSc conformations include in CWD1, CWD2 and CWD mix.
Different shapes and colors represent different conformations. The bottom three
boxes indicate potential host species including HuPrPC-M129 (blue box),
HuPrPC-V129 (red box) and cervid PrPC (yellow box). Each host PrPC selectively
interacts with preferred PrPSc conformations. Since any CWD prions do not
include HuPrPC-M129 and HuPrPC-V129 preferred PrPSc conformations, PrPSc in
CWD prions could not become a template to convert these HuPrPC into PrPSc.
Therefore, HuPrPC-M129 and HuPrPC-V129 do not develop disease. On the
other hand, CWD prions contain cervid PrPC preferred PrPSc conformations,
showing in different shapes in red color. Thus, PrPSc in CWD converts cervid
PrPC into PrPSc, resulting in the development of disease.
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Figure 6.2. Hypothetical chaperone ‘protein X’ lowers the energy barrier of
the conversion of PrPC into PrPSc and stabilizes newly synthesized PrPSc. In
this model, PrPSc is thermodynamically stable compared to PrPC; furthermore,
the conversion of PrPSc from PrPC does not happen spontaneously without a
catalyst or chaperon, such as, hypothetical ‘protein X’. The conversion of PrPC
into PrPSc without ‘protein X’ (red arrow) requires overcoming the high energy
barrier than the reaction with ‘protein X’ (blue arrow). ‘Protein X’ could reduce the
energy barrier to facilitate the conversion of PrPC into PrPSc. Moreover, newly
synthesized PrPSc is stabilized by ‘protein X’.
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Figure 6.3. Proposed models explain ‘protein X’ plays a key role in
determining the species barrier of prion diseases in addition to the
conformational selection model. According to the conformation selection
model, host PrPC preferentially interacts with preferred PrPSc conformations and
undergoes substantial conformational change using donor PrPSc as a template.
As shown in Figure 6.2., the conversion of PrPC into PrPSc does not occur
spontaneously without any catalysts because of the high energy barrier. In order
for PrPC to convert into PrPSc and accumulate to cause disease within a host
lifespan or within a certain period of time, a catalyst or molecular chaperone
plays an important role in PrPSc conversion. An unidentified catalyst or molecular
chaperon, we denote hypothetical ‘protein X’. In this model, ‘protein X’ is a
species-specific. For example, cervid carries a cervid-specific chaperon, and the
cervid-specific chaperon might be completely different from a chaperon found in
humans. A. Cervid PrPC and cervid preferred PrPSc could interact with a cervidspecific chaperon to mediate PrPSc conversion, and the cervid-specific ‘protein X’
stabilizes newly synthesized PrPSc. B. PrP conformations between cervid (host)
and RML mouse prion (donor) are not compatible. Moreover, the cervid-specific
chaperone could not accommodate the cervid PrPC-mouse PrPSc complex to
facilitate PrPSc conversion, resulting in no disease development. C. PrPSc
conformations in CWD prion are not human PrPC (HuPrPC) preferred PrPSc
conformations, and a human-specific protein X could not facilitate PrPSc
conversion. Thus, no disease is developed. D. When HuPrPC finds preferred
PrPSc conformations, such as, in CJD prions, HuPrPSc conversion occurs. In
addition, a human-specific ‘protein X’ could facilitate PrPSc conversion. As a
result, humans develop CJD.
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Wild-type and variant mouse PrP are expressed in rabbit epithelial
kidney (RK13) cells, and each RK13 cells are infected with RML.
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Figure 6.4. Conformational selection model is used to explain how RML
mouse prion could not convert variant mouse PrP in RK13 cell culture
systems. The rabbit epithelial kidney (RK13) cell culture system was used to test
whether changing amino acids in specific regions of mouse PrP altered
susceptibility to species matched prion (mouse adapted RML scrapie prion) in
Chapter 3. A. RK13 cells expressing a wild-type mouse PrPC (RKM cells) is
highly susceptible to mouse adapted scrapie RML prion. B. However, RKM cells
are not susceptible to CWD because PrPSc conformations in CWD are not mouse
PrPC preferred PrPSc conformations. C. The series of cell culture studies in
Chapter 3 suggest that substituting even one amino acid in the specific regions of
mouse PrP, where majority of differences among mammalian species are
clustered, could result in loss of susceptibility to RML prion. Since wild-type and
variant mouse PrP are expressed in rabbit epithelial kidney (RK13) cells, ‘protein
X’ is a rabbit-specific. Therefore, the present in vitro data shows the primary
structure of host PrPC is a predominant determinant in susceptibility to RML
prion. These results also suggest that properties of mouse-specific and rabbitspecific chaperones might be functionally identical.
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Figure 6.5. Conformational selection model to explain the intraspecies
transmission barrier of SSBP/1 and CH1641 prions in sheep. The
conformational selection model explains PrPC preferentially interacts with
preferred PrPSc conformations to facilitate PrPSc conversion. The top gray box on
left presents multiple PrPSc conformations include in SSBP/1 sheep scrapie
prion, and the blue and pink boxes in SSBP/1 (left gray box) indicate different
PrPSc conformations in SSBP/1 could be classified into at least two groups based
on the findings in histoblot data in Chapter 4. The right gray box on the top
presents different sets of multiple PrPSc conformations are contained in CH1641
sheep scrapie prion. Different shapes represent different conformations. The
bottom four boxes indicate potential host species including OvPrPC-V136 (blue
boxes) and OvPrPC-A136 (pink boxes). Each host OvPrPC selectively interacts
with different sets of preferred PrPSc conformations. SSBP/1 prion contains
OvPrPC-V136 preferred PrPSc conformations, and CH1641 does not. OvPrPCV136 is only susceptible to SSBP/1. Both SSBP/1 and CH1641 prions include
OvPrPC-A136 preferred PrPSc conformations, therefore, OvPrPC-A136 is
susceptible to both SSBP/1 and CH1641. However, OvPrPC-A136 preferred
PrPSc conformations are not major PrPSc conformations in SSBP/1. Lower
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amount of OvPrPC-A136 preferred PrPSc conformations are available for OvPrPCA136 to interact and utilize for PrPSc conversion. Therefore, OvPrPC-A136
requires a longer period of time to develop disease with SSBP/1.
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Figure 6.6. SSBP/1 conversion models of OvPrPSc-A136 and OvPrPSc-V136:
ovine-specific ‘protein X’ catalyzes PrPSc conversion and stabilizes newly
synthesized PrPSc. In the A and B models, an unidentified molecular chaperone
‘protein X’ is link to the ovine PrP 136 polymorphism. A-1. An OvPrP-V136specific ‘protein X’ facilitates the conversion of OvPrPC-V136 into PrPSc using
OvPrPSc-V163 in SSBP/1. Newly synthesized OvPrPSc-V136 is also stabilized
by the OvPrP-V136-specific ‘protein X’. A-2. The OvPrP-V136-specific ‘protein X’
could accommodate the OvPrPC-V136-SSBP/1-A136 PrPSc complex to facilitate
the conversion of OvPrPSc-V136 using OvPrPSc-A136 in SSBP/1; however, the
OvPrP-V136-specific ‘protein X’ is not most efficient chaperone for the OvPrPCV136-SSBP/1-A136 PrPSc complex. Therefore, OvPrPSc-V136 conversion
requires a longer time with OvPrPSc-A136 as a template. Newly synthesized
OvPrPSc-V136 might never accumulate in neurons because a cellular clearance
mechanism could promptly remove PrPSc as slowly synthesized. B-1. An OvPrPA136-specific ‘protein X’ might be able to accommodate the OvPrPC-A136SSBP/1-V136 PrPSc complex to facilitate the conversion of OvPrPSc-A136;
however, the OvPrP-A136-specific ‘protein X’ is not most efficient chaperone for
the conversion of OvPrPC-A136 into PrPSc using OvPrPSc-V136 in SSBP/1. Thus,
OvPrPSc-V136 conversion will take a longer time. In addition, a cellular clearance
mechanism could remove newly synthesized OvPrPSc-A136 as slowly
synthesized. B-2. The OvPrP-A136-specific ‘protein X’ facilitates the conversion
of OvPrPC-A136 into PrPSc using OvPrPSc-A136 in SSBP/1a1. Newly synthesized
OvPrPSc-A136 is also stabilized by the OvPrP-A136-specific ‘protein X’. In the C
and D models, an unidentified molecular chaperone ‘protein X’ is universal
among ovine. An ovine-specific ‘protein X’ facilitates PrPSc conversion in both
OvPrP-A136 and OvPrP-V136 sheep.
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Figure 6.7. SSBP/1 conversion models of OvPrPSc-V136 and OvPrPSc-A136
in the OvPrP 136 A/V heterozygous: OvPrP-V136-specific ‘protein X’
facilitates a dominant ‘templating’ of OvPrPSc-V136 to convert OvPrPC-A136
conversion. In a heterozygous state, an identified molecular chaperone ‘protein
X’ could be an ovine-specific universal protein X or OvPrP-A136-specific and
OvPrP-V136-specific protein X. If ‘protein X’ is linked to the ovine 136
polymorphism, both OvPrP-A136-specific and OvPrP-V136-specific ‘protein X’
will be available to facilitate PrPSc conversion. In the heterozygous state,
conversions of both OvPrPC-V136 and OvPrPC-A136 into PrPSc are taken place
even though rates of PrPSc conversion differ between OvPrPSc-V136 and
OvPrPSc-A136. (A). The conversion of OvPrPC-V136 into PrPSc will be facilitated
by either universal ovine-specific or OvPrP-V136-specific ‘protein X’, and newly
synthesized OvPrPSc-V136 will be stabilized by ‘protein X’. (C). The conversion
rate of OvPrPSc-V136 is higher than OvPrPSc-A136. The conversion of OvPrPCA136 into PrPSc will be facilitated by either ovine-specific universal ‘protein X’ or
OvPrP-A136-specific ‘protein X’, and the ovine-specific or OvPrP-A136-specific
‘protein X’ could stabilize newly synthesized OvPrPSc-A136. (B). In addition to the
above conversion mechanisms of OvPrPSc-V136 or OvPrPSc-A136, a ‘dominant’
templating mechanism of OvPrPSc-V136 conformation, which leads to forced
templating of OvPrPC-A136, is also occurring in the heterozygous state. In the
‘dominant’ templating mechanism, OvPrPSc-V136 helps to convert OvPrPC-A136
to PrPSc using an ovine-specific or OvPrP-V136-specific ‘protein X’. Therefore,
this newly synthesized OvPrPSc-A136 obtains the same properties as a template
OvPrPSc-V136.
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Figure 6.8. CH1641 conversion models of OvPrPSc-V136 and OvPrPSc-A136:
Conversion of OvPrPSc-A136 is inhibited by the presence of OvPrPC-V136
and/or OvPrP-V136-specific ‘protein X’ in the OvPrP 136 A/V heterozygous
state. CH1641 sheep scrapie prion is most susceptible to OvPrP-A136 and most
resistant to OvPrP-V136. A. CH1641 sheep scrapie prion does not include
OvPrPC-V136 preferred PrPSc conformations based on the conformational
selection model (Figure 6.5.). OvPrP-V136-specific or ovine-specific universal
‘protein X’ is available to facilitate PrPSc conversion. A-(1) Neither ovine-specific
nor OvPrP-V136-specific ‘protein X’ could accommodate the OvPrPC-V136CH1641 PrPSc complex to facilitate PrPSc conversion. If ‘protein X’ is linked to
OvPrP-V136, PrPSc conversion does not take place due to the OvPrP-V136specific ‘protein X’. A-(2) Even though those ‘protein X’ could accommodate the
OvPrPC-V136-CH1641 PrPSc complex, inefficient ‘protein X’ could not mediate
PrPSc conversion fast enough to accumulate PrPSc in the brain. A cellular
clearance mechanism could promptly remove newly synthesized PrPSc as slowly
synthesized. B. OvPrPC-A136 preferred PrPSc conformations are included in
CH1641 sheep scrapie prion (Figure 6.5.). Either OvPrP-A136-specific ‘protein X’
or ovine-specific ‘protein X’, could facilitate PrPSc conversion and stabilize newly
synthesized OvPrPSc-A136. C. In the heterozygous state, OvPrPSc-A136
conversion is inhibited by the presence of OvPrPC-V136 or OvPrP-V136-specific
‘protein X’. C-(1). OvPrPC-V136 inhibits the conversion of OvPrPC-A136 by
interacting with OvPrP-A136, CH1641-PrPSc, or protein X to prevent from forming
an OvPrPC-A136-CH1641 PrPSc complex. Even though most efficient ‘protein X’
is available, ‘protein X’ could not mediate PrPSc conversion. C-(2). The OvPrPV136-specific ‘protein X’ could not facilitate OvPrPSc-A136 conversion. In the
heterozygous state, the OvPrP-V-specific ‘protein X’ is available and becomes an
inhibitor or antagonist by interacting with the OvPrPC-A136-CH1641 PrPSc
complex before most efficient OvPrP-A136-specific ‘protein X’ interact with the
PrPC-PrPSc complex.
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Figure 6.9. PrPSc conversion sites in neuron. A. PrPSc conversion occurs at
the cholesterol-rich microdomains in the plasma membrane. B. PrPSc can enter
neurons by phagocytosis. A phagocytic vesicle can fuse to lysosomes.
Proteolytic enzymes and other molecules become available in the fused vesicles.
PrPSc conversion occurs in lysosomes possibly utilizing molecules from
lysosomes. New PrPC could be provided by phagocytosis to continue converting
PrPSc in lysosomes. The vesicles eventually rupture and newly synthesized PrPSc
will be released to the cytosol. Some PrPSc will be captured by molecular
chaperones to translocate into lysosomes for degradation.
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